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Endothelial and neuronal nitric oxide synthase (eNOS and nNOS respectively) are 
constitutively expressed in vivo. Recent data showed that selective local inhibition of 
nNOS reduced basal blood flow without affecting endothelial-mediated vasodilatation 
induced by acetylcholine or increased shear stress - suggesting that eNOS and nNOS 
have distinct roles in vasoregulation. This thesis aimed to investigate the role of 
nNOS-derived nitric oxide (NO) in the regulation of skeletal blood flow during 
exercise and myocardial blood flow during increased cardiac workload. At a systemic 
level, the role of nNOS on blood pressure and haemodynamics was investigated in a 
first-in-man study. We used the non-selective NOS inhibitor, NG-monomethyl-L-
arginine (L-NMMA), and selective nNOS inhibitor, S-methyl-L-thiocitrulline 
(SMTC), to determine the role of eNOS and nNOS in opposing an increase in 
sympathetically mediated increases in arteriolar tone in the human forearm during 
handgrip exercise. We found that despite reducing basal forearm blood flow (FBF), 
intra-brachial L-NMMA or SMTC had no significant effect on the increase in FBF or 
conduit artery diameter induced by local handgrip exercise, even in the face of 
increased sympathetic stimulation with lower body negative pressure. We investigated 
the relative contribution of eNOS and nNOS in the regulation of coronary vascular 
tone during increasing metabolic demand as achieved through incremental cardiac 
pacing. We found that the pacing induced increase in coronary blood flow and artery 
diameter was blunted by intra-coronary L-NMMA but not so by SMTC. We then 
undertook the first investigation in humans of the effects of systemic nNOS inhibition 
on haemodynamics. We found that intravenous SMTC increased systemic vascular 
resistance and blood pressure, whilst stroke volume, cardiac output and heart rate were 
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reduced. Importantly, there was no effect on flow-mediated dilatation, an effect 
mediated by eNOS. These results suggest that nNOS has a major contribution to basal 
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1.1 PHYSIOLOGICAL REGULATION OF VASCULAR TONE 
 
1.1.1 Vascular tone 
 
Appropriate vascular tone and its dynamic adjustment are important to ensure that 
perfusion mirrors the continuously changing metabolic requirements of tissues 
(Kharbanda and Deanfield, 2001; Li and Forstermann, 2000; Mombouli and 
Vanhoutte, 1999). At a given blood pressure, the blood flow to each organ is 
determined by the peripheral vascular resistance of the organ. This is adjusted by a 
variety of local mechanisms affecting the tone of the smooth muscle in the ‘resistance’ 
vessels – small terminal arteries and arterioles. The endothelium has a major influence 
on overall vascular tone by modulating the balance between endothelium-derived 
relaxing factors and contracting factors.  
 
When the availability of oxygen to the tissues decreases (for example at altitude), the 
blood flow to the tissues increases. This vasodilatation also occurs in response to a 
decrease of other metabolites, such as glucose. In addition to this many humoral 
factors regulate vascular tone. These include vasoconstrictors, such as epinephrine and 
norepinephrine (NE) from the adrenal medullae and the sympathetic nervous system, 




1.1.2 The vascular endothelium 
 
The endothelium is a dynamic organ with paracrine, endocrine and autocrine 
properties (Kharbanda and Deanfield, 2001; Vallance and Chan, 2001; Verma and 
Anderson, 2002). It plays a pivotal role in vascular homeostasis, which is achieved 
through a complex set of interactions between a host of endothelium-derived factors. 
These factors influence a broad range of mechanisms by acting on endothelial cells, as 
well as cells within the vascular lumen (primarily leucocytes and platelets) and in the 
sub-endothelial tissues (primarily vascular smooth muscle cells).  
 
Endothelium-derived factors have three main broad types of action 1: maintaining 
vascular tone, through vasodilatation and vasoconstriction, 2: controlling vascular 
inflammation, by modulation of cell-to-cell interactions between leucocytes, platelets, 
smooth muscle cells and endothelial cells, and 3: regulating the 
coagulation/fibrinolysis axis, through the formation and dissolution of vascular 
thrombotic material (Kharbanda and Deanfield, 2001; Vallance and Chan, 2001; 
Verma and Anderson, 2002). Alterations in the normal function of the endothelium are 
associated with vascular as well as systemic disorders. 
 
Relaxing factors include nitric oxide (NO), prostacyclin (PGI2), bradykinin and 
endothelium-derived hyperpolarizing factors (EDHF); and contracting factors include 
the endothelin group of peptides, angiotensin-II and thromboxane A2 (TXA2) 
(Davignon and Ganz, 2004; Duffy et al., 1999; Feletou and Vanhoutte, 1999; Miyauchi 
and Masaki, 1999; Taddei et al., 1999). Endothelial detection of local changes in 
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metabolism, pressure and flow determines the relative balance between production of 
endothelial relaxing and contracting factors (Kharbanda and Deanfield, 2001). 
 
1.1.3 Autonomic nervous system 
 
The autonomic nervous system is divided into sympathetic and parasympathetic 
systems, the main neurotransmitters being norepinephrine (NE) and acetylcholine 
(ACh). The vasomotor centre is located in the reticular substance of the medulla and 
the lower third of the pons. A large number of areas in the brain can excite or inhibit 
the vasomotor centre. Under normal conditions, the vasoconstrictor area of the 
vasomotor centre transmits signals continuously to the sympathetic vasoconstrictor 
nerve fibres all over the body called ‘sympathetic vasoconstrictor tone’ which 
maintains a partial state of contraction in the blood vessels, called ‘vasomotor tone’ 
(Guyton and Hall, 2011).  
 
The sympathetic nervous system plays a significant role in the regulation of vascular 
tone. NE is the main neurotransmitter of the sympathetic nervous system and is 
released by the sympathetic postganglionic neurons which terminate in the effector 
organs including the vascular smooth muscle cells. Here, α-1 adrenergic receptors are 
activated causing vasoconstriction. NE also has a smaller effect on β-2 adrenergic 
receptors, which cause vasodilatation; however, the net effect of NE on the vasculature 
is that of vasoconstriction (Bennett and Gardiner, 1996). The innervations of the small 
arteries and arterioles (resistance vessels) allows sympathetic stimulation to increase 




1.1.3.1 Non-adrenergic non-cholinergic and nitrergic nerves 
 
ACh and NE are not the only autonomic transmitters. The presence of non-adrenergic 
non-cholinergic (NANC) transmission includes many potential neurotransmitters 
including adenosine triphosphate (ATP), vasoactive intestinal peptide (VIP), 
neuropeptide Y (NPY), substance P, 5-hydroxytryptamine, gamma-aminobutyric acid 
(GABA), dopamine and NO (Lundberg, 1996). The NANC autonomic nerves are 
widely distributed including in the gastrointestinal, respiratory and urogenital tracts, as 
well as vascular smooth muscle.  
 
The discovery of NO as a neurotransmitter was a major breakthrough in understanding 
the mechanisms underlying NANC neurotransmission (Toda and Okamura, 2003). 
Nerves in which the transmission process utilises the L-arginine-NO pathway are 
termed ‘nitrergic’ nerves (Rand, 1992) and vascular smooth muscle is innervated by 
neurons containing neuronal nitric oxide synthase (nNOS) (Bredt et al., 1990; Toda 
and Okamura, 2003). 
 
1.2 NITRIC OXIDE AND VASCULAR TONE 
 
Furchgott and Zawadski showed that vascular endothelial cells must be present for 
acetylcholine to induce relaxation of rabbit aorta (Furchgott and Zawadzki, 1980). The  
endogenous mediator causing endothelium dependant relaxation was initially named 
endothelium derived relaxing factor (EDRF), and was later identified as NO (Ignarro 
et al., 1987; Palmer et al., 1987). NO is a major modulator of vascular tone. Its prime 
function is to counterbalance the vasoconstrictive influence of the sympathetic nervous 
34 
 
and renin-angiotensin systems. In conjunction with other vasodilators such as PGI2 and 
EDHF, NO acts directly on vascular smooth muscle cells to induce muscle relaxation 
(Davignon and Ganz, 2004; Feletou and Vanhoutte, 1999; Jeremy et al., 1999; 
Kharbanda and Deanfield, 2001; Li and Forstermann, 2000; Vallance and Chan, 2001; 
Verma and Anderson, 2002).  
 
The stimulus for a continuous production of NO includes the blood flowing through a 
vessel, which exerts a frictional force on the luminal surface of the endothelium (shear 
stress), and agonists, factors that increase intracellular calcium including local 
mediators and neurotransmitters (Guyton and Hall, 2011). 
 
1.2.1 Nitric oxide synthesis  
 
NO is a highly labile molecule synthesized from L-arginine and molecular oxygen, by 
the nitric oxide synthase (NOS) group of enzymes (Li and Forstermann, 2000; Michel 
and Feron, 1997; Moncada and Higgs, 1993). This process requires a number of co-
factors such as nicotinamide adenine dinucleotide phosphate (NADPH), flavin 
mononucleotide, flavin adenine dinucleotide, tetrahydrobiopterin (BH4) and 
calmodulin. NO diffuses across the endothelial cell membrane into the vascular wall 
and/or vascular lumen where it exerts its physiological effects. 
 
NO acts on its target cells (such as vascular smooth muscle cells and platelets) by 
activating the enzyme guanylate cyclase, and in turn increasing the concentration of 
the intra-cellular messenger cyclic guanosine-3’5-monophosphate (cGMP) (Moncada 
and Higgs, 1993). cGMP mediates many of the effects of NO such as reduction in 
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vascular tone and platelet activation. In addition, NO can directly bind other targets 
such as haem and other iron centred proteins, deoxyribonucleic acid (DNA), thiols and 
enzymes of the mitochondrial chain altering mitochondrial respiration in tissues 
 
1.2.2 Nitric oxide synthases 
 
NO is generated by three different isoforms of NOS. NOS I, or neuronal NOS (nNOS) 
was first identified in central and peripheral neuronal cells, but is also found in other 
tissues such as skeletal (Kobzik et al., 1994) and cardiac (Xu et al., 1999) muscle. It 
plays an important role in controlling neuronal activity. NOS II, or inducible NOS 
(iNOS) can be expressed in many different cells. Inflammation induces production of 
iNOS, which in turn helps to propagate the inflammatory process. NOS III, or 
endothelial NOS (eNOS) was first identified in endothelial cells where it plays a 
pivotal role in the homeostatic function of the endothelium (Fleming and Busse, 1999; 
Li and Forstermann, 2000; Michel and Feron, 1997; Shah et al., 1999) and is also 
expressed in cardiomyocytes, platelets, hippocampus neurons, renal epithelial cells and 
mast cells (Michel and Feron, 1997). In humans, the genes encoding eNOS, nNOS and 
iNOS are located on chromosome 7, 12 and 17 respectively. eNOS and nNOS are 
constituents of healthy cells, however iNOS is generally expressed in response to 
inflammation and infection.  
 
1.2.3 eNOS and vascular tone 
 
A large body of data from animal and human studies indicate that eNOS plays a 
pivotal role in the regulation of vascular tone. The most definitive evidence is derived 
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from eNOS null mice, where vasodilatation elicited by increases in flow or agonists 
such as acetylcholine and substance P is impaired (Moncada and Higgs, 1993; 
Moncada and Higgs, 2006). In humans, local intra-arterial infusion of the non-selective 
NOS inhibitor NG-monomethyl-L-arginine (L-NMMA) inhibits vasodilatation in 
response to acetylcholine infusion or shear stress due to increased blood flow, 
supporting a role of eNOS in regulation of vascular tone (Joannides et al., 1995; 
Moncada and Higgs, 1993; Moncada and Higgs, 2006; Quyyumi et al., 1995a). 
 
1.2.4 NO and basal vascular tone 
 
In addition, there is evidence that continuous release of NO may be responsible for 
basal regulation of vascular tone, known as ‘tonic vasodilatation’. Studies by Vallance 
and colleagues in healthy humans demonstrated that local infusion of L-NMMA into 
the forearm significantly reduced resting blood flow. This effect was abolished by L-
arginine but not D-arginine, thereby confirming that locally generated NO regulates 
basal microvascular tone (Vallance et al., 1989). Similar findings have been 
demonstrated in other vascular beds in vivo, for example, in the coronary circulation 
(Lefroy et al., 1993; Quyyumi et al., 1995a). Further indirect evidence supporting the 
role of NO in tonic vasodilatation is derived from the observation that infusion of L-
NMMA leads to dose-dependent hypertension in animals (Rees et al., 1989) and 
humans (Haynes et al., 1993). The effects of a non-isoform selective NOS inhibitor on 
basal vascular function or blood pressure have generally been attributed to continuous 
release of NO from eNOS. However, they do not conclusively prove its involvement 




1.2.5 Endothelial dysfunction 
 
Endothelial cell dysfunction is a broad term used to describe a state of endothelial 
activation, which is characterised by a reduction in the bioavailability of endothelial 
vasodilators and creation of a pro-inflammatory and pro-coagulant vascular milieu 
(Behrendt and Ganz, 2002; Davignon and Ganz, 2004; Landmesser et al., 2004; Verma 
and Anderson, 2002). Changes in the intricate balance between endothelium-derived 
factors with opposing properties, in particular a reduction in the bioavailability of NO, 
forms the basis of endothelial dysfunction. Endothelial dysfunction is a key step in the 
initiation and progression of atherosclerosis. 
 
Endothelial dysfunction is often assessed indirectly in terms of the extent of 
endothelium-dependent vasodilatation in response to pharmacological, physical and/or 
physiological stimuli, based on the assumption that impaired endothelial vasomotion 
also reflects alterations in other critical properties of the endothelium. The rationale for 
this approach is dependent on the observation that NO, a key determinant of 
endothelial vasomotor function, is also critically involved in the regulation of other 
homeostatic properties of the endothelium. Numerous studies have demonstrated that 
the presence of coronary atherosclerosis is associated with impaired NO-mediated 
vasomotor responses (Cox et al., 1989; Gordon et al., 1989; Ludmer et al., 1986; 
Quyyumi et al., 1995b; Zeiher et al., 1991) and that endothelial dysfunction occurs 
very early in the disease process. Many studies have demonstrated coronary or 
peripheral vasomotor dysfunction in patients with risk factors for atherosclerosis who 
have not yet developed clinically overt disease (Quyyumi et al., 1995b; Quyyumi et 
al., 1997; Vita et al., 1990) and that the degree of impairment relates to the number of 
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risk factors present (Egashira et al., 1993; Vita et al., 1990). Endothelial dysfunction is 
itself independently related to future adverse cardiovascular events (Gonzalez and 
Selwyn, 2003).  
 
1.3 nNOS AND VASCULAR TONE 
 
1.3.1 Introduction to nNOS 
 
nNOS has been found in a variety of sites including brain, spinal cord, sympathetic 
ganglia, adrenal glands, peripheral nitrergic nerves, epithelial cells of various organs, 
kidney macula densa, pancreatic islet cells, vascular smooth muscle cells (Forstermann 
et al., 1994), cardiac myocytes (Xu et al., 1999) and skeletal muscle (Kobzik et al., 
1994). It has been implicated in modulating learning, memory and neurogenesis (Zhou 
and Zhu, 2009). In the central nervous system (CNS), nNOS mediates long-term 
regulation of synaptic transmission (O'Dell et al., 1991; Schuman and Madison, 1994) 
and there is evidence that inhibitors of nNOS impair learning and result in amnesia in 
animals (Bohme et al., 1993; Holscher and Rose, 1992).  
 
There is evidence that nNOS-derived NO in the CNS is involved in the central 
regulation of blood pressure (Toda et al., 2009) and increasingly that peripherally 
nNOS is involved in the local regulation of vascular tone. The conventional view of 
NO-dependent regulation of blood flow in humans has been that this mainly involves 
eNOS in the endothelium of blood vessels. An emerging literature from animal and 




1.3.2 Animal evidence for local nNOS-mediated regulation of vascular tone 
 
nNOS is known to be expressed in the peripheral nervous system (Toda and Okamura, 
2003), primarily in NANC (or nitrergic) nerves, as well as in skeletal (Kobzik et al., 
1994) and cardiac (Xu et al., 1999) muscle and the vessel wall (Kavdia and Popel, 
2004). Animal studies indicate that non-neurological nNOS has important effects on 
the regulation of vascular tone.  
 
Ichihara and colleagues provided direct evidence for nNOS mediated regulation of 
vascular tone in explanted rat kidneys. The nNOS-selective inhibitor, S-methyl-L-
thiocitrulline (SMTC), decreased basal diameter of afferent and efferent arterioles but 
had no effect on vasodilatation to ACh (an eNOS agonist), suggesting that basal tone 
in this bed was regulated by nNOS-derived NO (Ichihara et al., 1998). The cells of the 
macula densa are thought to be the main source of renal nNOS (Wilcox and Welch, 
1998), and when these were removed, the effects of SMTC were abolished (Ichihara et 
al., 1998). Some in vivo studies in rats have reported that acute nNOS inhibition with 
SMTC increases blood pressure (Gozal et al., 1996a; Komers et al., 2000). In nNOS 
knockout mice, the regulatory influence of the macula densa in the kidney was 
significantly attenuated (Vallon et al., 2001). Some in vivo studies in rats have reported 
that acute nNOS inhibition with SMTC increases blood pressure (Gozal et al., 1996a; 
Komers et al., 2000). Another nNOS-selective inhibitor, vinyl-L-N5-(1-imino-3-
butenyl)-L-ornithine (L-VNIO), similarly reduced basal tone in rat mesenteric arteries 
without endothelium  (Hatanaka et al., 2006). L-VNIO increased the vasoconstrictor 
response to perivascular nerve stimulation and local NE concentration, without 
influencing the effect of endogenous NE, suggesting that nNOS-derived NO affects 
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neurotransmitter release from the perivascular nerves (Hatanaka et al., 2006). Selective 
nNOS inhibition with N-(4S)-(4-amino-5-[aminoethyl] aminopentyl)-N-nitroguanidine 
(N4S) also reduced in vivo cerebral arteriolar diameter in rats as well as attenuating 
cerebral hypoxia-induced vasodilatation (Bauser-Heaton and Bohlen, 2007).  
 
1.3.3 Indirect human evidence for local nNOS-mediated regulation of vascular 
tone 
 
It has been well documented that nNOS-derived NO is the predominant vasodilator in 
penile erectile function (Burnett et al., 1993), and a reduction in NO availability is 
thought to contribute to erectile dysfunction. Phosphodiesterase type 5 (PDE5) 
inhibitors, such as sildenafil, are extremely efficacious in restoring the nNOS-cGMP 
mediated vasodilatation in erectile tissue (Ghofrani et al., 2006). There has been an 
association between erectile dysfunction and hypertension, along with other 
cardiovascular risk factors, and these have been attributed to decreased availability of 
NO in both erectile tissue and the vasculature (Solomon et al., 2003). This raises the 
possibility that nNOS-derived NO is reduced in the peripheral vasculature in 
hypertension. It is also worth noting that sildenafil is effective in lowering blood 
pressure (Oliver et al., 2006). 
 
Abundant nNOS has also been demonstrated in the adventitial nerves of saphenous 
vein grafts harvested for coronary bypass surgery (Tsui et al., 2002), as well as the 
human internal mammary artery, where it was predominantly found in the smooth 




1.3.4 Human evidence for local nNOS-mediated regulation of vascular tone 
 
Table 1.1 outlines some of the nNOS-selective inhibitors used in animal studies (Babu 
and Griffith, 1998; Cottyn et al., 2008; Furfine et al., 1994; Handy et al., 1996). Due to 
a lack of safe and clinically validated nNOS-selective inhibitors, more direct 
investigation of the role of nNOS in the regulation of vascular tone in humans in vivo 
has not been possible until recently. Using the nNOS-selective inhibitor SMTC, our 
lab recently undertook a series of first-in-human studies to investigate the possible role 
of nNOS in both the peripheral and coronary circulation (Seddon et al., 2009; Seddon 
et al., 2008). SMTC has a 17-fold selectivity for inhibition of nNOS over eNOS and is 
a more potent inhibitor of nNOS than L-NMMA with relative IC50 values of 0.31 µM 
and 4.1 µM respectively (Furfine et al., 1994). SMTC was chosen because (a) it had 
been extensively used in vivo in animal studies where it was found to be safe 
(Cervenka et al., 2001; Damy et al., 2003; Ichihara et al., 1998; Komers et al., 2000; 
Narayanan et al., 1995; Wakefield et al., 2003), (b) it is water-soluble (Furfine et al., 
1994; Narayanan et al., 1995), (c) it is a reversible inhibitor (Furfine et al., 1994; 
Narayanan et al., 1995), and (d) animal studies had established concentrations at which 










Table 1.1 Neuronal NOS inhibitors used in animal studies. 




Damage to oxygenase domain, loss of the heme 
cofactor (irreversible) 
120 fold selectivity 
for nNOS compared 
to eNOS in vitro 
7-NI 
7-Nitroindazole 
Binding to haem group, disrupting electron flow, 
interfering with the binding of L-arginine and 
BH4 (reversible) 
10 fold selectivity 
over iNOS in vivo. 




Binding to haem group, disrupting electron flow, 
interfering with the binding of L-arginine and 
BH4 (reversible) 
37 fold selectivity for 
nNOS compared to 




Binding to heme moiety, preventing subsequent 
oxygen activation (reversible) 
17 fold selectivity for 
nNOS compared to 
eNOS in vivo 
 
 
1.3.4.1 Forearm vasomotor tone 
 
Local infusion of SMTC into the brachial artery of healthy subjects resulted in a 
significant dose-dependent reduction in basal forearm blood flow (FBF).The effect 
was abolished in the presence of excess L-arginine but not D-arginine, indicating that 
the effects were mediated by stereospecific inhibition of the L-arginine/ NO pathway 
(Seddon et al., 2008). SMTC reduced basal FBF at substantially lower (over 10-fold) 









Figure 1.1: Effects of SMTC and L-NMMA on basal blood flow. Comparative dose 








SMTC had no effect on increases in FBF elicited by infusion of acetylcholine or on 
FMD induced by reactive hyperaemia, which were however inhibited by L-NMMA 
(Seddon et al., 2009; Seddon et al., 2008). Taken together, these results indicate that 
basal microvascular tone and blood flow in the human forearm vascular bed is 
regulated mainly via local nNOS-derived NO whereas increases in flow stimulated by 
acetylcholine and FMD are eNOS-mediated. Since L-NMMA is non-selective for 
nNOS and eNOS, it is able to reduce both basal FBF and the stimulated response to 




1.3.4.2 Coronary vasomotor tone 
 
This data was significantly extended in further studies in which the effects of SMTC in 
the human coronary circulation were investigated (Seddon et al., 2009). Peripheral and 
myocardial circulations differ in terms of microvascular architecture, the pattern of 
blood flow and vascular resistance, metabolic regulation and the pathways that are 
activated to induce hyperaemia (Komaru et al., 2000). Despite this, peripheral artery 
vasomotor function of individuals has been shown to be closely related to vasomotor 
function in their coronary arteries (Anderson et al., 1995). In patients with 
angiographically normal coronary arteries, the intra-coronary infusion of SMTC 
significantly reduced basal blood flow but had no effect on increases in flow induced 
by infusion of substance P (an eNOS agonist). In contrast, substance P-induced 
increases in coronary flow were inhibited by L-NMMA (Seddon et al., 2009). These 
data indicate that local nNOS-derived NO is also a regulator of basal blood flow in the 
human coronary circulation. 
 
1.3.4.3 Mental stress response 
 
NO has been shown to play a role in the increase in FBF induced by mental stress. 
Intra-brachial non-selective NOS inhibition with L-NMMA attenuated the increase in 
FBF produced by standardised mental stress protocols (Cardillo et al., 1997; Dietz et 
al., 1994). Seddon and colleagues found that this vasodilator response was attenuated 
by both L-NMMA and SMTC, but not by norepinephrine, which reduced basal FBF to 
a similar extent to both NOS inhibitors (Seddon et al., 2008). These results suggest a 
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role for local nNOS-derived NO in the regulation of mental-stress induced 
vasodilatation.  
 
1.3.4.4 Skin vasculature 
 
Further evidence for a role of nNOS in regulating human vascular tone comes from 
Kellogg and colleagues. These authors have shown in a series of studies that nNOS 
and eNOS have distinct roles in the regulation of human cutaneous vasculature in vivo. 
Cutaneous vasodilation in the forearm of healthy volunteers in response to local skin 
warming was attenuated by intra-dermal administration of the eNOS-selective 
inhibitor NG-amino-L-arginine (L-NAA), but not the nNOS-selective inhibitor NW-
propyl-L-arginine (N-PLA). Combined inhibition of both isoforms with LNAA and 
NPLA had the same effect as with L-NAA alone. In contrast, cutaneous vasodilatation 
in response to whole body heat stress was attenuated by N-PLA but not L-NAA, with 
combined inhibition having similar effect as N-PLA alone (Kellogg et al., 2009). This 
was in keeping with their previous experiments in which cutaneous vasodilation 
caused by local skin warming was inhibited by the non-selective NOS inhibitor, N-
nitro-L-arginine methyl ester (L-NAME) (Kellogg et al., 1999), and also by L-NAA 
(Kellogg et al., 2008a), and cutaneous vasodilation due to whole body heat was 
attenuated in the presence of the nNOS-selective inhibitor 7-nitroindazole (7-NI), but 
not during local skin warming (Kellogg et al., 2008b). They concluded that local 
nNOS is responsible for centrally mediated, reflex cutaneous active vasodilatation in 
whole body heat stress, whereas eNOS mediates the increase in skin blood flow in 




1.4 PHYSIOLOGICAL ROLES OF LOCAL nNOS IN VASCULAR 
REGULATION 
 
Short-term adjustments in vessel tone mediated through an interplay between 
autonomic activity and local regulatory factors are essential in ensuring that blood flow 
distribution among different vascular beds occurs in line with varying metabolic 
demands to achieve optimal perfusion and function (Harris and Matthews, 2004; 
Joyner and Dietz, 2003). This interaction is especially important during situations 
where vascular regulation is important, such as exercise, when an increase in blood 
flow to the exercising skeletal muscle as well as to myocardium is essential for normal 
function. It is of interest to consider whether nNOS-derived NO may be involved. 
 
1.4.1 Blood flow regulation in exercising skeletal muscle 
 
An important mechanism that contributes to the increase in blood flow in exercising 
skeletal muscle is the local attenuation of sympathetic vasoconstriction – a 
phenomenon known as ‘functional sympatholysis’ (Remensnyder et al., 1962). There 
is increasing evidence from experimental animal studies and some indirect human data 
that nNOS-derived NO may contribute to this process. 
 
1.4.1.1 Animal evidence suggesting a role for nNOS-derived NO in functional 
sympatholysis 
 
Many animal studies suggest a potential role for NO, and more specifically nNOS-
derived NO in regulating blood flow by blunting the vasoconstrictor response to α-
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adrenergic activation during dynamic exercise (functional sympatholysis) and/or 
contributing to exercise induced vasodilation. In the rat hind limb, non-selective NOS 
inhibition with L-NAME substantially increased muscle vasoconstriction in response 
to lumbar sympathetic nerve stimulation (Thomas and Victor, 1998), suggesting that 
sympathetic nerve activity may stimulate NO release from nNOS and/or eNOS A 
similar response has been shown in a dog hind limb model of exercise (Buckwalter et 
al., 2004) and contracting mouse muscle in which nNOS was absent (Fadel et al., 
2003; Grange et al., 2001). Moreover, in nNOS null mice and in the mdx mouse, an 
animal model of Duchenne Muscular Dystrophy (DMD) where dystrophin deficiency 
results in greatly reduced nNOS expression in skeletal muscle, the normal ability of 
muscle contraction to attenuate α-adrenergic vasoconstriction was defective and led to 
abnormal flow regulation (Thomas et al., 1998). Lai and colleagues also showed that 
skeletal muscle perfusion was compromised in the mdx mouse. They used transgenic 
mdx mice (a model of DMD with transplanted nNOS anchoring proteins) and showed 
that they have greater active locomotor muscle blood flow and exercise performance 
compared to the non-transgenic mdx counterparts in which nNOS is absent (Lai et al., 
2009). 
 
Kobayashi and colleagues have suggested that nNOS in skeletal muscle contributes to 
increased blood flow after mild exercise in mouse models (Kobayashi et al., 2008). 
They showed that nNOS null mice have an exaggerated fatigue response to mild 
exercise. In mouse models of nNOS mislocalization from the sarcolemma (such as the 
mdx mouse), prolonged inactivity was only relieved by pharmacologically enhancing 
the cGMP signal that results from muscle nNOS activation during the NO-signalling 
response to mild exercise (Kobayashi et al., 2008). Percival and colleagues reported 
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moderate contraction-induced fatigue and reduced post exercise strength in nNOSµ-
deficient muscle. They reported that they have demonstrated 2 functionally distinct 
nNOS micro-domains in skeletal muscle. Sarcolemmal nNOSµ matches blood supply 
to the metabolic demands of the active muscle and that nNOSβ simultaneously 
modulates the ability of skeletal muscle to maintain force production during and after 
exercise (Percival et al., 2008; Percival et al., 2010)  
 
Taken together, the experimental data above suggests that nNOS-derived NO plays a 
major role in flow regulation during exercise, at least in part through functional 
sympatholysis.  
 
1.4.1.2 Animal evidence which does not suggest a major role for nNOS-derived NO in 
functional sympatholysis 
 
Copp and colleagues used nNOS-selective inhibiton with SMTC at rest and sub-
maximal exercise in healthy rats. This experiment was the first of its kind to 
investigate systematically the effects of selective nNOS inhibition on muscle blood 
flow at rest and exercise in the conscious rat. They found a reduction in baseline 
hindlimb muscle blood flow, but total hindlimb muscle blood flow during exercise was 
not different between control and SMTC (Copp et al., 2010).  
 
1.4.1.3 Human studies suggesting a major role for NO in functional sympatholysis 
 
Kneale and colleagues locally infused the β2-adrenergic agonist, albuterol, into healthy 
humans, which produced an increase in FBF. This effect was attenuated with co-
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infusion of L-NMMA (Kneale et al., 2000), suggesting that sympathetic nerve activity 
may stimulate NO release from nNOS and/or eNOS in humans. However, the role of 
NO in the regulation of flow in skeletal muscle during exercise in humans remains 
conflicting. In healthy humans, a number of studies have shown a reduction in forearm 
blood flow during or immediately after exercise in response to non-selective NOS 
inhibition with L-NMMA or L-NAME. Gilligan and colleagues found that L-NMMA 
reduced FBF at rest and during hand-grip exercise in healthy volunteers (Gilligan et 
al., 1994). Chavoshan and colleagues demonstrated that systemic NOS inhibition with 
L-NAME completely abolished the blunting of vasoconstrictor responses in 
contracting forearm muscle during increased sympathetic activity induced by lower 
body negative pressure (LBNP), as measured by changes in muscle oxygenation by 
near infra-red spectroscopy (NIRS) (Chavoshan et al., 2002). In a recent study, Wray 
and colleagues used Doppler ultrasound to examine FBF at rest and during hand-grip 
exercise in healthy volunteers, and found that L-NMMA attenuated FBF as well as 
brachial artery vasodilatation during exercise (Wray et al., 2011).  
 
1.4.1.4 Human studies not suggesting a major role for NO in functional sympatholysis 
 
Some studies in healthy humans have not been consistent in demonstrating a role for 
NO in functional sympatholysis. Wilson and Kapoor (Wilson and Kapoor, 1993) used 
venous occlusion plethysmography to measure FBF during wrist flexion exercise with 
or without concurrent infusions of NE to provide α-adrenergic vasoconstriction, and 
the effect of locally infused L-NMMA (infused prior to exercise) on these responses 
was determined. L-NMMA significantly reduced resting FBF and blunted the response 
to ACh, but had no effect on blood flow responses during exercise. Endo and 
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colleagues found that L-NMMA reduced FBF (measured by venous occlusion 
plethysmography) at rest and immediately after hand-grip exercise, however the 
percentage increase of FBF from rest were similar before and after L-NMMA, and the 
effect of L-NMMA was comparable to a control vasoconstrictor, angiotensin II (Endo 
et al., 1994). Gordon and colleagues also used L-NMMA in healthy volunteers and 
found that wrist-flexion induced increase in FBF was attenuated. However, 
stabilization of resting vasodilator tone by nitroprusside eliminated the effects of L-
NMMA on peak flow after exercise (Gordon et al., 2002). 
 
Dinenno and Joyner examined the effects of local NOS inhibition with L-NMMA or 
L-NAME on FBF responses (using Doppler ultrasound) during handgrip exercise and 
whilst stimulating release of endogenous norepinephrine (by intra-arterial infusion of 
tyramine). Neither NOS inhibitor restored the vasoconstrictor response to local 
tyramine-stimulated norepinephrine release during exercise, arguing against a role for 
NO in functional sympatholysis (Dinenno and Joyner, 2003). Consistent with these 
findings, the same group have demonstrated that local infusion of sodium nitroprusside 
(SNP) (a NO donor) into the brachial artery at doses sufficient to increase FBF to 
levels observed during exercise does not blunt sympathetic vasoconstriction, induced 
again via local infusion of tyramine (Tschakovsky et al., 2002).  
 
1.4.1.5 Indirect human studies suggesting a major role for nNOS-derived NO in 
functional sympatholysis 
 
Direct studies specifically investigating the role of nNOS in the regulation of skeletal 
muscle blood flow during exercise have not been possible due to the lack of nNOS-
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selective inhibitors for human use. However, a study in children with Duchenne 
Muscular Dystrophy (DMD) who have impaired nNOS-dependent signalling in the 
skeletal muscle, provides indirect evidence to support a possible role of nNOS in 
mediating “functional sympatholysis” in humans. In this study, the vasoconstrictor 
response to LBNP (measured as a decrease in both resting forearm vascular resistance 
measured by venous occlusion plethysmography, and tissue oxygenation measured by 
NIRS was blunted during hand-grip isometric handgrip exercise in healthy subjects 
and in children with limb girdle dystrophy (a muscle disorder with plentiful nNOS), 
but not in those with DMD (Sander et al., 2000). The authors attributed these effects to 
the loss of skeletal muscle nNOS-derived NO in children with DMD.  
 
Taken together, the experimental and clinical studies to date potentially suggest an 
important role for increased NO production in ensuring appropriate perfusion to 
skeletal muscle during exercise. The recent data on local nNOS-mediated effects on 
resting blood flow in humans (Seddon et al., 2009; Seddon et al., 2008) together with 
the aforementioned studies in nNOS deficient mice and children with DMD suggest 
nNOS-derived NO may be important in mediating the regulation of blood flow to 
exercising muscle. Human studies using non-selective NOS inhibitors have had 
conflicting results, but have not been performed in the presence of the increased 
sympathetic activation expected during systemic exercise. 
 
1.4.2 Coronary vasomotor tone and increased myocardial demand 
 
Now to consider myocardial as opposed to skeletal blood flow. Exercise is the most 
important physiological stimulus for increased myocardial oxygen demand. The 
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requirement of exercising muscle for increased blood flow necessitates an increase in 
cardiac output that results in increases in the three main determinants of myocardial 
oxygen demand: heart rate, myocardial contractility, and ventricular work. The 
contribution of the increase in heart rate to the increase in myocardial oxygen 
consumption may account for 50-70% of the increase in myocardial oxygen 
consumption during exercise (Gorman et al., 2000; Heiss et al., 1976; Merkus et al., 
2004). Increased myocardial oxygen demands during dynamic exercise are met 
principally by augmenting coronary blood flow (CBF), which increases in proportion 
to heart rate (Duncker et al., 2012). The strong correlation between coronary flow and 
heart rate occurs because heart rate is a common multiplier for the other determinants 
of myocardial oxygen demand (i.e. contractility and cardiac work), which are 
computed per beat (Duncker and Bache, 2008). 
 
One way to study the relationship between heart rate and coronary blood flow (CBF) is 
by the use of incremental pacing protocols. It is well established that during cardiac 
pacing, angiographically normal human coronary arteries dilate and CBF increases, 
indicating epicardial and microvascular dilatation with increase in myocardial oxygen 
requirements (Gaglione et al., 1987; Gordon et al., 1989; Nabel et al., 1990a; Quyyumi 
et al., 1995a). L-NMMA reduces CBF at rest and attenuates ACh-induced increase in 
CBF (Lefroy et al., 1993; Quyyumi et al., 1995a). Quyyumi and colleagues found in 
patients with angiographically normal coronary arteries that intra-coronary L-NMMA 
produced significant basal increase in coronary vascular resistance and a small 
significant reduction in epicardial coronary artery diameter. Pacing-induced increases 
in CBF and coronary artery diameter were also attenuated in the presence of L-NMMA 
(Quyyumi et al., 1995a). Tousoulis and colleagues also found no increase in coronary 
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artery diameter and significantly attenuated CBF whilst pacing during L-NMMA in 
angiographically normal arteries (Tousoulis et al., 1997). These data confirm the role 
of NO in this process. Our lab has previously found that nNOS-derived NO tonically 
regulates basal CBF whereas eNOS mediates increases in flow in response to the 
eNOS agonist, substance P (Seddon et al., 2009). However, there is no data on the 
relative contribution of different NOS isoforms on pacing-induced increases in blood 
flow in the human coronary circulation.  
 
1.5 nNOS AND BLOOD PRESSURE 
 
The hallmark of primary hypertension is an increase in peripheral vascular resistance, 
therefore dysfunction of the NO pathway within the peripheral vasculature is an 
attractive hypothesis as a mechanism contributing to essential hypertension. However 
there are multiple mechanisms through which NO may regulate blood pressure 
including central, renal and cardiac, in addition to vascular. 
 
Systemic nNOS inhibition with SMTC has previously been shown to increase blood 
pressure in rats in vivo (Gozal et al., 1996b; Komers et al., 2000; Wakefield et al., 
2003), as has the nNOS-selective inhibitor 7-NI (Ollerstam et al., 1997; Xu et al., 








1.5.1 Human studies using L-NMMA  
 
There are many studies in humans using acute systemic NOS inhibiton with L-NMMA 
which have consistently found an increase in systemic vascular resistance and blood 
pressure, with a reduction in heart rate and cardiac output (Brett et al., 1998; Hansen et 
al., 1994b; Haynes et al., 1993; Stamler et al., 1994). Brett and colleagues infused L-
NMMA intravenously in healthy men over 5 minutes. At the maximum dose used of 6 
mg/mL there was an increase (when compared with effect of saline placebo) in systolic 
and diastolic blood pressures of 4.1±1.1 and 12.6±3.5 %, respectively, with a marked 
increase in systemic vascular resistance index (SVRI) of 39.2±5.2 %. Cardiac index 
and heart rate were 22.0±3.3 and 17.0±4.4 % lower after administration of L-NMMA 
(Brett et al., 1998). Stamler and colleagues used invasive measurement of blood 
pressure and cardiac output (Fick method) in response to 3 mg/Kg of intravenous L-
NMMA over 3 min. They found a 15.5±1.3 % increase in mean arterial pressure 
(MAP) and a 63.4±8.2% in systemic vascular resistance (SVR) (Stamler et al., 1994). 
The increase in blood pressure is often thought to be a direct effect on vascular tone of 
basal release of NO, but may involve the central nervous system and renal 
mechanisms. It has previously been considered that eNOS is the isoform responsible 
for these effects, but there is increasing evidence that nNOS is also involved in the 








1.5.2 nNOS and the kidney 
 
1.5.2.1 Renin-angiotensin-aldosterone system 
 
The renin-angiotensin-aldosterone system synergises with the sympathetic nervous 
system, for example by increasing the release of NE from sympathetic nerve terminals. 
It also stimulates aldosterone secretion and plays a central role in the control of sodium 
excretion and fluid volume, as well as vascular tone. Renin secretion occurs in 
response to various physiological stimuli including reduced renal perfusion pressure or 
reduced sodium concentration. It acts on angiotensinogen to form angiotensin I, which 
is then converted to angiotensin II by angiotensin converting enzyme (ACE). The main 
effects of angiotensin II are mediated by acting on AT1 receptors, which belong to the 
family of G-protein-coupled receptors. Effects mediated by AT1 receptors include 
generalised vasoconstriction, increased NE release (reinforcing sympathetic effects), 
proximal tubular reabsorption of sodium, secretion of aldosterone from the adrenal 
cortex (Guyton and Hall, 2011).  
 
1.5.2.2 NO and the kidney 
 
In the kidney, NO regulates sodium and water homeostasis (Lahera et al., 1991) via 
numerous mechanisms, and impaired renal NO synthesis is implicated in the 
pathogenesis of hypertension (Pallone and Mattson, 2002). These mechanisms include 
regulation of renal and glomerular haemeodynamics (Majid and Navar, 2001), 
mediation of pressure natriuresis (Majid et al., 1993), maintenance of medullary 
perfusion (Mattson et al., 1992), inhibition of tubular sodium reabsorption (Ortiz and 
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Garvin, 2002) and modulation of sympathetic nerve activity (Eppel et al., 2003). There 
have been a number of reports demonstrating decreased renal blood flow, increased 
renal vascular resistance and elevated systemic blood pressure after treatment with 
non-selective NOS inhibitors in rats (Gabbai, 2001; Tost et al., 2000) and dogs (Majid 
and Navar, 2001). eNOS-derived NO has been recognised to play important roles in 
controlling renal haemodynamics, including increases in the renal plasma flow and pre 
and post glomerular arteriolar dilatation (Toda and Okamura, 2011). Impairment of 
this system leads to kidney dysfunction and systemic hypertension (Zoccali, 2007). In 
healthy humans, Bech and colleagues found that systemic L-NMMA induced a 
decrease in renal plasma flow, glomerular filtration rate (GFR) and reduction in 
tubular reabsorption of sodium (Bech et al., 1996). In another study with healthy 
volunteers, the use of positron emission tomography (PET) to determine renal blood 
flow showed that this flow was reduced after systemic infusion of L-NMMA 
(Damkjaer et al., 2010). 
 
1.5.2.3 nNOS in the kidneys 
 
nNOS has also been found in the kidney, and may also contribute to the regulation of 
renal blood flow and kidney function (Mount and Power, 2006).  The cells of the 
macula densa are thought to be the main source of renal nNOS (Wilcox and Welch, 
1998), and when these were removed, the effects of SMTC were abolished (Ichihara et 
al., 1998). Ichihara and colleagues delivered intra-arterial SMTC at increasing local 
doses into the isolated afferent and efferent arterioles of rat kidneys and demonstrated 
a clear dose-dependent effect of SMTC on basal tone of both afferent and efferent 
arterioles (Ichihara et al., 1998). Renal flow was decreased with intra-aortic SMTC in 
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control and diabetic rats at a dose which did not affect blood pressure (Komers et al., 
2000). Intra-renal SMTC caused a decrease in the renal plasma flow, GFR and 
absolute sodium excretion in anaesthetized rats, with no effect on blood pressure 
(Cervenka et al., 2001). In human tissue, nNOS has been found in the arteriole 
endothelium and renal nerves containing nNOS were found in perivascular connective 
tissue and near the pelvic epithelium (Bachmann et al., 1995). 
 
1.5.3 nNOS and the nervous system 
 
NO from nNOS is known to play important roles in the brain, mainly as a neuro-
modulator (Kiss and Vizi, 2001; Toda et al., 2009). In the peripheral nerves, NO 
transmits information from the nerves to the smooth muscle (Toda and Okamura, 
1996, 2003). The presence of NANC nerves were discovered in various smooth muscle 
but it was the revelation that NO acts as a neuro-transmitter that was seen as a great 
step forward, and this hypothesis is now widely accepted as an important control 
mechanism in functions of autonomically innervated organs and tissues (Toda and 
Okamura, 2003). The nerves which depend on the release of NO are called ‘nitrergic’ 
(Rand, 1992).  
 
In animal models, NO appears to restrain sympathetic drive in the brain and increased 
nNOS gene expression in hypertensive animals would counterbalance the increased 
sympathetic drive responsible for systemic hypertension (Toda et al., 2009). In a 
variety of mammals, peripheral arteries are innervated by nitrergic nerves that 
contribute to counteracting vasoconstrictor sympathetic nerve activity (Okamura et al., 
1995; Toda and Okamura, 1990). Toda and colleagues found that inhibition with the 
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non-selective NOS inhibitor NG-nitro-L-arginine (L-NA) in isolated mesenteric 
arteries in dogs augmented the constrictor response to nicotine (which stimulates 
neurotransmitters from nitrergic nerves), without any effect on the response to 
exogenous norepinephrine, despite the absence of the endothelium (Toda and 
Okamura, 1990). Similar findings were also found in rat mesenteric arteries (Ferrer et 
al., 2000). SMTC was also found to produce hypertension in conscious rats (Wakefield 
et al., 2003), however knockout mice deficient in nNOS were not hypertensive (Huang 
et al., 1994) but showed behavioural abnormalities suggestive of increased sympathetic 
drive (Nelson et al., 1995) 
 
The brainstem is the major region responsible for sympathetic regulation of blood 
pressure. In rats microinjection of the NO donor SNP into the periventricular nucleus 
decreases blood pressure and heart rate, whereas microinjections of L-NMMA or an 
nNOS antisense oligonucleotide increased blood pressure (Wang et al., 2005). 
Reduced nNOS expression in brainstem nuclei appears to be responsible for the 
enhanced sympathetic drive in heart failure. Expression of nNOS protein and mRNA 
were reduced in rats with heart failure compared with control (Hirooka et al., 2003). 
There was also increased nNOS gene expression in the brain of hypertensive rats 
suggesting an important role of central NO in the modulation of sympathetic activity 
(Plochocka-Zulinska and Krukoff, 1997). Hypertensive rats also had increased nNOS 
activity in the hypothalamus and brainstem (Qadri et al., 2003). NO appears to inhibit 
sympathetic drive in the brain, with an increase in nNOS gene expression in 





1.6 HYPOTHESIS AND AIMS 
 
The role of NO is central to the local regulation of vascular tone and is also involved in 
the regulation of blood pressure. Our entire understanding of the role of NO in 
vascular function in humans in vivo came from the use of L-NMMA, a non-selective 
NOS inhibitor. Recent studies have directly addressed the role of local nNOS in human 
vascular function in vivo using, and importantly, validating the nNOS-selective 
inhibitor SMTC.  The availability of a nNOS-selective inhibitor suitable for human use 
has given us a platform to further evaluate the role of nNOS in cardiovascular 
regulation, not only at rest, but during physiological stimuli, none more important than 
exercise. This is particularly relevant since an increasing volume of animal literature 
suggests that nNOS also has important effects on vascular function and blood pressure. 
SMTC to date has only been administered locally, and whilst its effects suggest that 
local nNOS-derived NO regulates basal vascular tone, there is no evidence available 





The hypotheses underlying this work are that (a) local nNOS-derived NO plays an 
important physiological role in the regulation of myocardial and skeletal blood flow 
during exercise, and (b) at a systemic level, nNOS plays an important role in the 





1.6.2 Aims of thesis 
 
1. To investigate the role of nNOS on forearm vasomotor tone during exercise +/- 
reflex sympathetic activation, using local intra-brachial infusion of SMTC. 
 
2. To investigate the role of nNOS on coronary vasomotor tone during increased 
cardiac workload induced by atrial pacing, using local intra-coronary infusion of 
SMTC. 
 
3. To investigate the role of nNOS on systemic haemodynamics in a first-in-man study 

























SMTC is a selective inhibitor of nNOS which has been used safely in a large number 
of animal studies (Cervenka et al., 2001; Damy et al., 2003; Ichihara et al., 1998; 
Komers et al., 2000; Narayanan et al., 1995; Wakefield et al., 2003), and it is soluble 
in both water and blood (Furfine et al., 1994; Narayanann et al., 1995). SMTC is a 
competitive inhibitor with L-arginine, and inhibition of NOS has been demonstrated to 
be fully reversible. The structure of SMTC is based on the amino acids L-arginine and 
L-citrulline, and is very similar in structure and function to L-NMMA, which has been 
used extensively and safely in human studies in vivo. There is no published evidence 
of nNOS-dependent adverse effects on local vessel thrombosis, platelets, or red blood 
cells.  
 
Our group had previously obtained ethical approval for first-time-use-in-man for 
SMTC, granted by both St Thomas’ Hospital and King’s College Hospital Research 
Ethics Committees following submission of a comprehensive report to an independent 
toxicologist incorporating a full review of the literature relating to previous use of 
SMTC in addition to its pharmaceutical and toxicological profiles (Seddon et al., 
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2008). Further ethical approval for current research studies was again granted by St 
Thomas’ Hospital and King’s College Hospital Research Ethics Committees. 
 
The raw material was purchased from Calbiochem, a subsidiary of Merck Biosciences, 
UK. SMTC was packaged by the pharmacy department at Guy’s & St. Thomas’ 
Hospitals, in 5 ml vials, at the concentration requested for each study. Every batch of 
frozen SMTC was made up specifically for each pre-designed study and was given a 
precautionary one-month expiry date. On each study day, vials of frozen SMTC were 





L-NMMA was obtained from Bachem, Switzerland and was stored in the fridge at 
4°C. On each study day, appropriate concentrations were prepared using serial 
dilutions under sterile conditions.  
 
2.2 FOREARM STUDIES 
 
2.2.1 Subject participation 
 
All studies were performed in accordance with the Helsinki guidelines. Healthy male 
volunteers were recruited for the FBF and radial artery diameter studies from a list of 
suitable subjects who had participated in previous departmental studies. Potential 
volunteers expressed their interest via email, after which they were given a more 
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detailed description of the study over the telephone, and this information was 
subsequently emailed to them as a formal patient information sheet, which had been 
approved by the local research ethics committee. They were informed of the 
procedures, the drugs used and their associated risks. Following this, interested 
subjects were given the opportunity to ask questions and were invited to the 
department to give written informed consent to participate in the studies. All forearm 
studies were carried out in healthy volunteers rather than in patients, and some 
subjects participated in more than one of the study protocols, which were performed 
on different days at least one week apart. 
 
A brief clinical history was taken to allow documentation of age, sex, smoking and 
alcohol habits, and confirmation of healthy volunteer status i.e. no medical conditions. 
Cardiovascular and respiratory examinations were carried out in all subjects. Blood 
pressure and heart rate were measured using an oscillometric method (Omron 705CP) 
and according to established guidelines (O'Brien et al., 2003). Mean systolic blood 
pressure (SBP) and diastolic blood pressure (DBP) values were calculated and used in 
data analysis (mean of 3 measurements). Readings were taken in a quiet, calm 
environment in the supine position, after 20 minutes rest. An appropriately sized cuff 
was used, with the lower end placed approximately 2.5 cm above the ante-cubital 
fossa. Blood samples for baseline blood parameters were taken well in advance of the 
study day to ensure that each subject had “normal” blood tests prior to administration 
of drugs, including lipid profile, full blood count, urea and electrolytes, liver function 





2.2.2 Brachial artery cannulation 
 
Drugs were infused locally via the brachial artery. Drug doses required to provide 
local effects are usually much smaller than what is required for a systemic dose. 
Systemic administration of vaso-active drugs may also lead to activation of central 
effects including changes in sympathetic output and hormonal responses (Collier and 
Robinson, 1974). To study the effects of local infusion of drug on FBF and radial 
artery diameter, a 27 gauge steel needle (Coopers Needle Works, Birmingham, UK) 
was sealed with dental wax to an epidural catheter (Portex, Hythe, UK). This was 
connected to a constant rate infusion pump (Baxter Healthcare Ltd, Thetford, UK). 
The cannula is inserted into the brachial artery and advanced 2-3mm to ensure a stable 
position, and then secured in place with adhesive dressing tape. Saline vehicle and all 
vasoactive drugs were infused at 1 ml/min. After completion of the experimental 
protocol, the needle was removed from the brachial artery and pressure applied over 
the puncture site. No complications due to arterial cannulation arose during any of the 
studies. 
 
2.2.3 Venous occlusion plethysmography 
 
Bilateral strain gauge venous occlusion plethysmography was used to assess FBF. This 
technique has been used widely for over 80 years and works on the principle that by 
occluding venous outflow from a limb whilst allowing arterial inflow to continue, limb 
volume increases proportionately to total limb arterial blood flow (Whitney, 1953). 





Under resting conditions, flow through the forearm is predominantly through skeletal 
muscle (50-70% of total), the remainder being flow through the skin (Cooper et al., 
1955). In contrast, within the hand, which has relatively little skeletal muscle, most 
blood flows through the skin circulation where blood flow has different physiology 
and pharmacology to the forearm (Whitney, 1953). In view of this, during 
measurement of FBF, the wrist cuffs were inflated to suprasystolic pressure 
(180mmHg) to exclude the hands from the circulation. A second cuff was placed 
around the upper arm to achieve venous occlusion. This cuff was inflated rapidly to a 
pressure above venous pressure but below arterial pressure so as to allow arterial 
inflow to continue (i.e. 40-50mmHg) in repeated cycles, with inflation periods of 5 to 
10 seconds followed by 5 seconds of cuff deflation.  During inflation, forearm volume 
increases linearly. The deflation is essential to allow emptying of the forearm veins 
before the next measurement period as the relationship between rate of increase in 
forearm volume and arterial flow will not remain consistent if veins become fully 
distended (Wilkins and Bradley, 1946). Once venous capacitance is exceeded, the limb 
pressure increases and blood escapes the limb. The forearms were positioned above 
the level of the heart with supportive foam pads, to allow adequate venous emptying 
during this deflation period.  
 
The strain gauge is a flexible elastic silicon tube containing mercury. The gauge is 
fastened under slight tension around the forearm at maximal circumference, at a 
distance approximately one third the length of the forearm from the ante-cubital fossa 
(Hokanson et al., 1975). As blood flow into the arm increases, the gauge is stretched 
leading to a change in the length of the enclosed mercury column and hence the 
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electrical resistance. The change in output voltage is recorded using computer software 
(MacLab 400, AD instruments, Australia) and displayed graphically. Venous 
occlusion leads to radial expansion of the forearm and the rate of change in forearm 
circumference is proportional to change in arterial blood flow -  this is represented in 
the formula below (Whitney, 1953): 
 
Increase in forearm circumference 
(mm/min) 
FBF  (ml/min/100ml forearm) = K x      
Forearm circumference (mm) 
(K = proportionality constant) 
 
FBF measurements were made after subjects had rested in a temperature controlled 
room (between 24-26 C) to allow arterial pressure to stabilise. Blood flow is also 
dependant on arterial pressure and therefore studies take place in a relaxed, quiet 
environment so not to affect arterial blood pressure. During the infusion of vasoactive 
drugs, blood flow was measured during the final minute of each infusion period. The 
mean of five measurements was used for analysis. The measurement of FBF by 
venous occlusion plethysmography requires the arms to be motionless, hence FBF 
measurements were also made for 1min immediately after the cessation of handgrip 
exercise with the mean of 5 measurements used for analysis. The within-subject 
coefficient of variation (WCV) for forearm blood flow responses to exercise is similar 
to that to vasodilator drugs and is in the range 10 to 15% for measures repeated over 1 




2.2.4 Radial artery ultrasound 
 
High resolution vascular ultrasound was used to measure the diameter of the radial 
artery. The system incorporates vascular software for 2 dimensional (2D) imaging 
including edge detection software, colour and spectral Doppler, high frequency 
vascular transducer and an ECG monitor (each image is captured at the same point in 
the cardiac cycle). A continuous 3 lead electrocardiogram (ECG) recording is made 
throughout. Images of the radial artery were acquired every 3 seconds using high 
resolution B-mode ultrasound with a 7-MHz linear array transducer (Acuson Aspen 
Advanced Imagegate), attached to a computer. Image quality is optimised by adjusting 
the depth and gain settings so that the longest possible section of artery is visualised, 
longitudinally. The subjects right arm radial artery was imaged in these studies. The 
transducer was held in position using a stereotactic clamp which allows minute 
adjustments in position to be made during acquisition, and the diameter is measured 
when the clearest picture of anterior and posterior intimal layers is obtained. Once the 
protocol is started, the machine settings and the patient’s arm position must remain 
fixed. Images were recorded for 1 min for each measurement of diameter. Scans were 
analysed offline using Vascular research Tools Analyzer for research software 
programme (Medical Imaging Applications LLC, Iowa USA). This programme uses 
automated edge detection algorithms to measure the distance between the anterior and 
posterior walls of the artery throughout the entire acquisition period. This method 
gives a highly reproducible measure of radial artery diameter with a WCV in the range 





2.3 CORONARY STUDIES 
 
2.3.1 Subject participation 
 
Coronary blood flow studies were carried out in patients attending the Department of 
Cardiology, King’s College Hospital, London, for elective cardiac catheterisation. 
Only patients with angiographically normal coronary arteries were to be included in 
the study. The patients were attending for clinical reasons, usually referred for the 
investigation of atypical chest pain, but it was only at the time of cardiac 
catheterisation that would reveal whether the coronary arteries were angiographically 
normal or not. Potential patients were found by searching through referral letters and 
then details of the study were given to the patients well in advance of the procedure 
including a formal patient information sheet approved by the local research ethics 
committee. Patients were informed of the procedure, drugs used and the associated 
risks, and that the study would only be carried out if the diagnostic coronary 
angiogram confirmed angiographically normal arteries, and then written consent was 
obtained for the study. Patients with valvular heart disease, left ventricular 
hypertrophy and left ventricular dysfunction were excluded, as were patients with 
renal or liver failure, or any other significant concurrent disease or condition which in 
the opinion of the investigators would make the patient inappropriate for participation 
in the study. All medications were withheld and all patients abstained from food at 






2.4 SYSTEMIC EFFECTS OF SMTC 
 
In these studies, SMTC was administered systemically for the first time in humans in 
vivo and the effects on systemic haemodynamics were measured. 
 
2.4.1 Subject participation 
 
The studies were approved by the local research ethics committee (St.Thomas’ 
Hospital). Healthy male volunteers were recruited from a list of suitable subjects who 
had participated in previous departmental studies. The study was also advertised on 
the King’s College London University intranet. Medical students were specifically not 
recruited. Potential volunteers expressed their interest via email, after which they were 
given a more detailed description of the study over the telephone, and a formal patient 
information sheet was emailed to them, which had already been approved by the local 
research ethics committee. They were informed of the procedures and their associated 
risks, and the drugs used. Following this, interested subjects were given the 
opportunity to ask questions and then invited to the department to give written 
informed consent to participate in the studies. At this point the subjects were screened 
using the following inclusion and exclusion criteria: 
 
Initial inclusion criteria: 
1. Male 
2. Aged 18-45 years 





1. Participation in a research study within the last month in which a systemically active 
drug has been administered 
2. BMI > 28 kg/m2 (calculated at screening visit) 
3. Alcohol intake > 28 U /week 
4. Smoking within last 3 months 
5. Recreational drug use within last 3 months 
6. Regular use of prescription or ‘over the counter’ medicines which in the opinion of the 
investigator would make the volunteer inappropriate for participation in the study. 
7. Hyperlipidaemia (total cholesterol  > 6 mmol/L on blood sample taken at screening 
visit) 
8. Hypertension (SBP > 140, DBP > 90 on ≥ 2 occasions taken at screening visit)  
9. Diabetes mellitus (blood sample on day of screening visit) 
10. Any history of cardiovascular disease. 
11. Any significant concurrent disease or condition which in the opinion of the 
investigator would make the volunteer inappropriate for participation in the study. 
12. Any significant cardiovascular abnormality or other abnormality detected on 
examination at screening visit. 
13. Any significant abnormality of the ECG carried out at screening visit. 
14. Any significant abnormality of the full blood count (FBC), renal or liver profiles 
(performed at screening visit). 
 





2.4.2 Methods overview 
 
SMTC was first infused intravenously in a dose-escalation safety study. The second 
study was a randomised crossover study with blinded haemodynamic assessment in 
which either the highest dose of SMTC or saline vehicle were infused on separate 
occasions. Blood pressure (BP) and heart rate (HR) were measured by an oscillometric 
method whereas stroke volume (SV) was measured using echocardiography. SVR was 
calculated from the mean MAP and cardiac output (CO). Brachial FMD was measured 





In the first study, left ventricular (LV) stroke volume was measured using 2D trans-
thoracic echocardiography, and in the second study using 3-dimensional (3D) trans-
thoracic echocardiography.  
 
2.4.3.1 2D echocardiography 
 
When using 2D echocardiography the SV was calculated as cross-sectional area (CSA) 
of the left-ventricular outflow tract (LVOT) multiplied by the velocity-time integral 
(VTI) (Otto 2009): 
 




This is based on the concept that the left ventricle of the heart pumps blood into the 
aorta which is cylindrical. The base of the aorta is the systolic CSA of the outflow 
tract, while its height is the distance blood travels during ejection for each beat. The 
distance is expressed as the integral of the Doppler systolic velocity-time curve 
(velocity is the first derivative of distance). The accuracy of this technique depends on 
accurate CSA measurement. We measured the stroke volume at the LVOT using a 
para-sternal long-axis view of the heart, diameter (D) being measured parallel and 
immediately adjacent to the aortic valve, in mid-systole. Area was then calculated 
using the following equation:  
 
Area = π(D/2)2 
 
This is based on the assumption of a circular geometry. Small errors in calculating 
diameter can lead to larger errors on CSA, and hence these measurements were made 
twice at baseline and the mean area calculated. The pattern of flow is assumed to be 
laminar with a spatially flat flow velocity profile. The Doppler signal was recorded at 
a parallel intercept angle to flow, resulting in an accurate velocity measurement. The 
Doppler beam can be aligned to obtain the highest velocity signal, which indicates the 
most parallel alignment with flow. The flow-velocity curve was recorded from an 
apical 5 chamber view using pulsed wave Doppler ultrasound, using the closing click 
of the aortic valve to ensure that the sample volume was located at the same site as the 












2.4.3.2 3D Echocardiography 
 
Under controlled study settings in patients with adequate image quality, 3D 
echocardiography offers better accuracy and precision in measuring LV volumes and 
therefore better precision in measuring LV SV and ejection fraction (EF) compared 
with 2D echocardiography (Dorosz et al., 2012; Jacobs et al., 2006). 
 
3D echocardiography used to rely upon the acquisition of multiple 2D cross-sectional 
images, with the spatial and temporal relationship of each image registered and gated 
to the cardiac and respiratory cycle and then reconstructed to a 3D dataset, which was 
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time-consuming. This methodology is subject to technical limitations during image 
acquisition and requires significant offline data processing. The development of real-
time 3D echocardiography has eradicated the need for image acquisition protocols and 
protracted off-line reconstruction. 3D echocardiography uses recently developed 
matrix array echocardiography probes to image the entire heart and provide improved 
image quality. LV volume assessment has been demonstrated to be rapid, accurate, 
reproducible, and superior to conventional 2D methods (Jacobs et al., 2006). A direct 
volumetric assessment of LV size is preferable to calculations made from 2D because 
it can guard against image foreshortening and does not require any geometric 
assumptions. 3D echo assessment of LV volumes and EF also has been shown to 
compare favourably to the current gold standard of magnetic resonance imaging (MRI) 
(Jacobs et al., 2006; Jenkins et al., 2004; Sugeng et al., 2006).  
 
Software programs calculate 3D volumes by using semi-automated border tracking 
techniques to create a mathematical cast of the whole of the LV throughout the cardiac 
cycle. From this cast the LV volumes (end-diastolic volume, end-systolic volune and 
SV) and EF are derived. Data analysis was performed offline with dedicated 3D 
software by experienced operators, Dr Sitara Khan and Dr Benyu Jiang, who were 
both blinded to all interventions. 
 
2.4.4 Ultrasound for measurement of flow-mediated dilatation 
 
This method is a non-invasive ultrasound-based test to assess conduit artery vascular 
function and has been used for over 20 years (Celermajer et al., 1992). Conduit artery 
diameter was measured before and after an increase in shear stress that was induced by 
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reactive hyperaemia, i.e. FMD, which occurs predominantly as a result of local 
endothelial release of NO (Joannides et al., 1995). The results are reproducible 
(Sorensen et al., 1995), especially when carried out by an experienced operator, and 
correlate with coronary vascular endothelial function (Anderson et al., 1995; Corretti 
et al., 2002). 
 
Images of the radial or brachial artery are acquired by ultrasound as decribed earlier in 
this chapter. Subjects right arm radial/brachial artery was imaged longitudinally. A 
blood pressure cuff was positioned 5-10 cm distal to the transducer on the forearm. 
The transducer is held in position using a stereotactic clamp which allows minute 
adjustments in position to be made during acquisition. A baseline image was recorded 
for 1 min and then the cuff was inflated to at least 50 mmHg above systolic pressure 
for 5 min inducing ischaemia by restricting blood flow. Release of the cuff leads to a 
significant increase in conduit arterial flow to accommodate the dilated resistance 
vessels and this in turn leads to conduit arterial dilatation. Upon cuff deflation the 
resulting reactive hyperaemia was recorded continuously for 3 min. FMD is taken as 
the maximal change in dilatation from baseline. Scans are analysed offline as 
described earlier in this chapter. All artery scanning and FMD analysis was carried out 
by an experienced operator, Dr Benyu Jiang, who was blinded to all interventions. The 








2.5 STATISTICAL ANALYSIS 
 
Data are summarised as mean ± standard error of the mean (s.e.m.) throughout this 
thesis. Effects of NOS inhibitors on forearm and coronary blood flow and conduit 
artery diameter, and on haemodynamic responses were analysed by One-way analysis 
of variance (ANOVA) or by ANOVA for repeated measures as appropriate. All tests 
were two-tailed and differences were considered significant when P<0.05.  
 
Sample sizes for the forearm and coronary protocols are based on the changes in blood 
flow observed in first-in-man studies using SMTC (Seddon et al., 2009; Seddon et al., 
2008). Forearm studies: The within-subject standard deviation of the blood flow 
responses to exercise is approximately 15%. Therefore, we estimate 16 subjects will 
give a > 90% power (P < 0.05) to detect a change in blood flow response of > 10-15%. 
Coronary studies: As for the forearm studies, blood flow response within a single 
study are reproducible (SD < 15%). Therefore, we estimate 16 subjects will give a > 














THE ROLE OF nNOS AND eNOS IN THE 
REGULATION OF VASOMOTOR TONE 
DURING FOREARM EXERCISE AND 




NO plays an important role in regulating arteriolar tone, peripheral resistance and 
blood flow, acting as a tonic dilator opposing sympathetically mediated 
vasoconstriction (Vallance et al., 1989). In humans, brachial artery infusion of the 
selective nNOS inhibitor, SMTC, reduces basal FBF but does not block the eNOS-
mediated vasodilator response to ACh or increased shear stress (Seddon et al., 2009; 
Seddon et al., 2008). Animal studies and indirect observations in humans suggest that 
sympathetic nerve activity may stimulate NO release from eNOS and/or nNOS 
(Kneale et al., 2000; Thomas and Victor, 1998) implying that local NO release may 
counteract reflex sympathetic vasoconstriction or contribute to “functional 
sympatholysis”, i.e., the local attenuation of sympathetic vasoconstriction in the 
exercising muscle. A role for NOS and particularly nNOS in functional sympatholysis 
is supported by some (Buckwalter et al., 2004; Kobayashi et al., 2008; Thomas et al., 
1998) but not all (Copp et al., 2010) animal studies. Human studies using non-specific 
inhibitors of NOS have not been consistent, but have not been performed in the 
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presence of the increased sympathetic activation expected during systemic exercise. 
The recent data on local nNOS-mediated effects on blood flow in humans together 
with previous studies in nNOS deficient mice and in DMD suggest nNOS- derived NO 
may be important in mediating the regulation of blood flow to exercising muscle in 
humans. 
 
We tested the hypothesis that NO release from nNOS and/or eNOS regulated local 
FBF during reflex sympathetic activation at rest and during exercise. The rationale for 
the design of the following study was based on Sander and colleagues’ study in 
children with DMD (Sander et al., 2000) in which both the lower body negative 
pressure (LBNP)-induced decrease in resting forearm vascular conductance and the 
decrease in tissue oxygenation during hand grip exercise were attenuated in controls, 
but not in DMD. The authors attributed these effects to the loss of skeletal muscle 
nNOS-derived NO in children with DMD.  
 
3.1.1 Study aims 
 
The aim of the present study was to use non-selective and selective NOS inhibitors to 
determine the role of eNOS-derived and nNOS-derived NO in opposing an increase in 
sympathetically mediated increases in arteriolar tone in the human forearm during 
handgrip exercise +/- LBNP. The hypothesis underlying this work is that local nNOS-
derived NO plays an important physiological role in matching the amount of muscle 
blood flow to the level of exercise. It is further postulated that this effect may at least 






The studies were approved by the local research ethics committee (St.Thomas’ 
Hospital), and all participants provided written informed consent. Healthy male 
volunteers were recruited by local advertisement. Subjects on regular medication, with 
hypertension, hyperlipidaemia or any significant abnormality on haematological or 
biochemical screening were excluded. Participants were asked to abstain from caffeine 
for at least 12 hours before the studies. The doses of SMTC (0.2µmol/min) and L-
NMMA (2µmol/min) used have been shown to inhibit nNOS and both nNOS and 
eNOS respectively, both at rest and in conditions of increased flow (caused by mental 
stress and by ACh infusion) (Seddon et al., 2008). 
 
FBF studies were undertaken in a quiet temperature-controlled vascular laboratory 
(23°C to 25°C) after at least 30 min of rest. A 27-gauge needle was inserted into the 
brachial artery under local anaesthesia using less than 0.2 ml 1% lignocaine, and saline 
vehicle or drugs infused at 1ml/min by constant rate infusion pump. FBF was 
measured by venous occlusion plethysmography using electrically calibrated mercury-
in-silastic strain gauges (Hokanson et al., 1975). Radial artery diameter was measured 
using a high-precision ultrasound scanner. Drugs were infused for at least 5 min and 
blood flow was measured over the final 1min of infusion, with the mean of 5 
measurements used for analysis.  The protocols described below were used to assess 
the effects of non-selective NOS inhibition with L-NMMA and nNOS specific 
inhibition with SMTC on handgrip exercise +/- reflex sympathetic activation induced 




3.2.1 LBNP to generate upper limb sympathetic vasoconstriction 
 
LBNP is the application of subatmospheric pressure to the lower half of the body from 
the waistline to the feet, in order to retain blood in the veins, reducing venous return 
and therefore cardiac filling pressures. This process, which mimics hypovolaemia, 
leads to a global increase in peripheral sympathetic output (and therefore a global 
increase in peripheral resistance vessel tone) as a mechanism to conserve blood 
volume centrally (Zoller et al., 1972). This increase in resistance vessel tone is 
measured as a reduction in FBF. 
 
The LBNP chamber can be made of any substance that will withstand the generated 
pressure difference, and at the top end there must be a mechanism for ensuring a tight 
seal around the subject’s waist. The LBNP chamber we used was constructed from a 
wooden base and semi-circular wood/fibreglass tube sealed with rubber tubing. The 
subject wore a neoprene canoe spray deck around their waist (tightened with a strap), 
and this was fastened with perspex and clamps to the top end of the chamber to secure 
a tight seal. 
 
Subatmospheric pressure was generated by an electrically powered rotary vacuum 
pump connected through a sealed hole at the foot of the chamber, and the chamber 
pressure was measured using a manometer connected to the inside of the chamber via 
oxygen tubing. The magnitude of the vacuum stimulus was tightly controlled at -
20mmHg using a rheostat connected to the vacuum pump. This was essential, since 
LBNP greater than -20mmHg leads to reduction in systemic arterial pressure in 
addition to decreased cardiac filling pressure, suggesting that higher levels of LBNP 
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affect both arterial baroreceptors and cardiopulmonary receptors (Johnson et al., 1974; 
Zoller et al., 1972). In contrast, when LBNP is -20mmHg or less, cardiac filling 
pressure decreases and forearm vascular resistance increases without any changes in 
arterial parameters including mean pressure or heart rate. This suggests that mild 
LBNP decreases the stimulus to low-pressure receptors in the cardiopulmonary region 
without significantly affecting arterial baroreceptor activity (Johnson et al., 1974; 
Zoller et al., 1972) and that low-pressure cardiopulmonary baroreceptors exert an 
important influence on forearm vascular resistance during situations of reduced 
cardiac filling. Meanwhile, LBNP less than -20mmHg increases sympathetic output in 
muscle branches of the median nerve, again in the absence of any change in arterial 
parameters (Sundlof and Wallin, 1978).  
 
Taken together, these studies suggest that low-pressure baroreceptors exert an 
important influence on forearm vascular resistance in response to the decreased 
cardiac filling pressures induced by mild LBNP, and it is this response that is thought 




3.2.2.1 Effects of L-NMMA on FBF during handgrip exercise 
 
After brachial artery cannulation, saline was infused and baseline FBF was established 
after 7 min of infusion. Subjects then performed handgrip exercise using a modified 
Grip dynamometer (U.S. Gauge, USA) for 3 min at 30pulls/min at low intensity (30% 
maximal voluntary contraction, MVC) and for 3 min during high intensity (80% 
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MVC) handgrip exercise (Longhurst et al., 1974).  MVC is established by asking the 
subject to squeeze the dynanometer as tightly as possible.  The measurement of FBF 
by venous occlusion plethysmography requires the arms to be motionless, and 
therefore FBF measurements were made for 1 min immediately after the cessation of 
handgrip exercise with the mean of 5 measurements used for analysis. This was done 
after low intensity handgrip exercise, immediately after which high intensity handgrip 
exercise was commenced. FBF was again measured as soon as exercise ceased. After a 
~25 min recovery period, L-NMMA (2 µmol/min, n=11) was infused for 7 min at rest 
and during a repeat of the protocol, i.e. further 3 min periods of low and high intensity 
handgrip exercise. To control for a carry-over effect of the first period of exercise, this 
protocol was repeated in a separate group of subjects (n=11) with the infusion of saline 















Figure 3.1: Schematic of study protocol. FBF was measured using venous occlusion 
plethysmography. The effect of low and high intensity hand-grip exercise on FBF was 
measured in the presence of (A) L-NMMA (2 µmol/min) and vehicle and also with (B) 




















































3.2.2.2 Effects of SMTC and L-NMMA on FBF during exercise and LBNP 
 
FBF remained persistently elevated after exercise despite a prolonged period of 
recovery. This protocol was, therefore, performed on separate days. In summary, on 
each day, after baseline FBF was established subjects had an infusion of either saline 
(n=10), SMTC (0.2 µmol/min, n=10) or L-NMMA (2 µmol/min, n=10) at rest and 
during low and high intensity handgrip exercise in the presence of simultaneous – 20 
mmHg LBNP.   
 
A neoprene canoe spray deck was pulled up to the subject’s waist before the subject 
was placed in a LBNP chamber set up on a bed. A tight seal at the top end of the 
chamber was secured using clamps and the subject lay quietly for 30 min before 
infusions or measurements were made. 
 
After brachial artery cannulation, saline was infused and baseline FBF established 
after 7 min infusion. The infusion was then changed to either L-NMMA (2 µmol/min) 
or SMTC (0.2 µmol/min), which was infused continuously until the end of the study. 
The same protocol was repeated with saline vehicle throughout as a control, with FBF 
measurements repeated in the absence of a vasoactive substance. Again, FBF was 
recorded after a further 7 min to give basal FBF during the infusion of vasoactive 
substance. MVC was now established and low and high intensity exercise commenced 
as previously described. LBNP was applied at -20mmHg shortly after the start of 
exercise and continued beyond cessation of exercise until FBF measurements were 




Figure 3.2: Schematic of study protocol. FBF was measured using venous occlusion 
plethysmography. The effect of simultaneous LBNP with low and high intensity 
exercise on FBF was measured in the presence of L-NMMA, SMTC and saline control 


































3.2.2.3 Effects of SMTC and L-NMMA on radial artery diameter during exercise 
 
To assess the role of NO in conduit artery vasodilatation rather than flow, radial artery 
diameter was measured in the presence of L-NMMA or SMTC at rest and during 
exercise. Subjects attended twice, once receiving either L-NMMA or SMTC, and on 
the other occasion saline vehicle throughout as control (Figure 3.3). After brachial 
artery cannulation, saline was infused and baseline radial artery diameter was 
established after 7 min infusion. After baseline diameter was established, subjects had 
an infusion of either saline, SMTC (0.2 µmol/min, n=8) or L-NMMA (2 µmol/min, 
n=8) at rest and during high intensity handgrip exercise. Radial artery diameter 















Figure 3.3: Schematic of study protocol. Radial artery diameter was measured using 
an ultrasound scanner. The effect of high intensity exercise on radial artery exercise 



















3.2.3 Statistical analysis 
 
Data were summarized as mean ± standard error of the mean (s.e.m.). Vasoconstrictor 
responses to SMTC and L-NMMA were expressed as the absolute decrease in FBF 
and percent reduction in FBF from baseline. Vasodilator responses to exercise were 
expressed as the absolute FBF. This method of expressing FBF responses has 
previously been shown to be the most reproducible (Walker et al., 2001). Effects of 
the NOS inhibitors on the blood flow diameter responses were analysed by One-way 
analysis of variance (ANOVA) or by ANOVA for repeated measures as appropriate. 




















3.3.1 Pilot study: SMTC dose-response study 
 
Three initial doses were chosen to be used in these preliminary studies in 3 subjects 
aged 36.3±3.9 years (Table 3.1), in order to allow construction of a dose-response 
curve and confirm our labs previous findings of the effect of SMTC on basal FBF 
(Seddon et al., 2009; Seddon et al., 2008). The three doses of SMTC were 0.05; 0.10 
and 0.20 µmol/min, to achieve estimated local concentrations of 2.5; 5 and 10 µmol/L, 
with each dose being infused for 9 minutes.  
 
Table 3.1: Baseline characteristics of the subjects in the SMTC dose-response study. 
 
Healthy male volunteers (n=3)      
 
Age (years)      36.3±3.9         
Systolic blood pressure [SBP], (mmHg)  122±7.0         
Diastolic blood pressure [DBP], (mmHg)  70±2.2         





After cannulating the brachial artery, saline was infused for 9 min, with FBF recorded 
between 7 and 9 min as a measure of baseline FBF. Next, SMTC was infused for 9 
min, at 0.05 µmol/min. Again, FBF was recorded between 7 and 9min. This was 
repeated with two further cumulative doses of SMTC, 0.1 µmol/min and 0.2 
µmol/min, infused sequentially for 9 min each (Figure 3.4). Blood pressure indices and 
heart rate did not change during the infusion of SMTC. 
 
 
Figure 3.4: Schematic of study protocol. Cumulative doses of SMTC were infused 










SMTC reduced basal blood flow in the infused arm in a dose-dependent manner 
(Figure 3.5). During saline infusion, baseline FBF was 3.19±0.24 ml/min/100mls 
tissue. FBF was reduced to 3.03±0.26, 2.65±0.07 and 2.50±0.15 ml/min/100mls tissue 
with SMTC 0.05, 0.10 and 0.20 µmol/min respectively. Vasoconstrictor effects on 
FBF are generally expressed as percentage reductions in FBF, therefore SMTC 0.05, 
0.1 and 0.2 µmol/min induced reductions of 4.96±3.2, 16.1±6.3 and 21.4±3.5 % 
respectively (P<0.05 only for SMTC 0.2 µmol/min vs. baseline). 
 
Figure 3.5: Effect of local intra-arterial infusion of SMTC on basal FBF (n=3; 
*P<0.05 SMTC 0.2µmol/min vs baseline) 
 

























3.3.2 Pilot study: The effect of handgrip exercise on FBF 
 
Pilot studies were performed to investigate the effect of handgrip exercise on FBF and 
the length of time required for FBF to return to baseline after handgrip exercise. This 
was to aid the design of subsequent protocols for studies with NOS inhibitors. FBF 
was measured by venous occlusion plethysmography as described above. Subjects 
were asked to perform rhythmic handgrip exercise at low and high intensity as 
described earlier. Of note, subjects found it simple to complete the period of low 
intensity exercise. High intensity exercise was significantly more difficult and subjects 
found that they had exercised almost to exhaustion at the completion of 3 min. 5 
subjects aged 32.4±4.7 years were studied. FBF increased from a baseline of 
2.72±0.58 to 8.58±1.47 ml/min/100ml during low intensity handgrip exercise (P<0.05) 
and 15.62±3.21 ml/min/100ml during high intensity handgrip exercise (P<0.05 vs. 












Figure 3.6: FBF at rest (baseline) and during low and high intensity handgrip exercise 
(n=5, *P<0.05 for low intensity exercise vs. rest, high intensity exercise vs. rest, and 
low intensity exercise vs. high intensity exercise) 
 























FBF was then measured at different intervals in recovery, up to 30 min after the period 
of high intensity exercise was completed. This was done to establish the length of time 
required for FBF to return to baseline. We had to consider the total length of the study 
as subjects will have an arterial needle in situ, and we intended to minimise the risk of 
causing any extra discomfort to the subject. We felt that given the length of the 
exercise protocol, the longest we could allow for a break before repeating the protocol 
could be 25-30 min. This was from years of experience of arterial cannulation at the 




The FBF decreased from 15.62±3.21 ml/min/100ml during high intensity exercise (i.e. 
0 min into recovery) to 4.78±0.85 after 10 min (P<0.05 vs. baseline), 4.55±1.07 
(P=NS vs. baseline) after 20 min, and 4.00±1.07 ml/min/100ml (P=0.11 vs. baseline) 
30 min into recovery. At 30 min after exercise, the FBF did not appear to return to 
baseline (Figure 3.7).  
 
 
Figure 3.7: FBF after exercise. FBF appears to plateau without quite returning to pre-
exercise baseline FBF (depicted by the solid black line). 


























3.3.3 Effects of L-NMMA on FBF during exercise  
 
Baseline characteristics for the eleven subjects receiving L-NMMA and the eleven 
control subjects are shown below (Table 3.2). Blood pressure indices and heart rate 
did not change during the infusion of L-NMMA. 
 
Table 3.2: Baseline characteristics of study subjects in the L-NMMA group and the 
control group (n=11 both groups). 
 
Healthy male volunteers    Control       L-NMMA 
  
Age (years)      25.9 (± 2.1)        23.9 (± 2.0) 
Systolic blood pressure [SBP], (mmHg)  127 (±2.5)        131 (±2.7) 
Diastolic blood pressure [DBP], (mmHg)  66 (±1.3)        70 (±1.6) 
Heart rate (beats per minute)    68 (±3.7)        64 (± 2.7)  
 
 
During saline infusion, FBF increased from a baseline of 2.86±0.18 to 10.90±0.56 and 
17.61±1.23 ml/min/100ml immediately after low and high intensity handgrip exercise, 
respectively.  A small increase in FBF persisted after exercise despite a 25 min period 
of recovery (2.86±0.18 ml/min/100ml before exercise vs. 6.20±0.45 ml/min/100ml 
after 25 min recovery). Nevertheless, the FBF elicited by a second period of low 
(9.93±0.87, P=NS vs. saline) and high (16.87±1.31, P=NS vs. saline) intensity 
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handgrip exercise in the presence of L-NMMA was similar to that observed during 
saline infusion (Figure 3.8). 
 
Figure 3.8: A comparison of FBF whilst undertaking low and high intensity exercise, 
during saline or L-NMMA infusion. There was no significant difference in FBF during 
L-NMMA infusion when compared to saline during either low intensity exercise 
(n=11, P=NS) or high intensity exercise (n=11, P=NS). 
 



























Due to the small but persistent increase in FBF after the first set of exercise, the study 
was repeated with saline vehicle throughout. Again, a small increase in FBF persisted 
despite a 25 min period of recovery (2.70±0.29 ml/min/100ml before exercise vs. 
4.97±0.51 ml/min/100ml after 25 min recovery). However, the FBF elicited was 
similar during the first and second exercise periods of low (11.06±1.16 vs. 11.24±1.04 
ml/min/100ml respectively, P=NS) and high intensity (17.86±1.06 vs. 17.46±1.14 
ml/min/100ml respectively, P=NS) (Figure 3.8). 
 
Figure 3.9: A comparison of FBF whilst undertaking low and high intensity handgrip 
exercise during saline infusion. The second set of exercise was carried out after a 
25min break/recovery from the first set of exercise and hence FBF had not quite 
returned to baseline. However, there was no significant difference in FBF when 
compared to the first set of handgrip exercise during either low intensity (n=11, P=NS) 
or high intensity (n=11, P=NS). 
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When comparing the second set of exercises for each study (i.e. second set of exercise 
in the presence of L-NMMA vs. second set of exercise in the control study in the 
presence of saline vehicle) there was no difference in the FBF elicited during low 
intensity (9.93±0.87 vs. 11.24±1.04 ml/min/100ml respectively, P=NS) or high 
intensity (16.87±1.31 vs. 17.46±1.14 ml/min/100ml respectively, P=NS) handgrip 
exercise (Figure 3.10). 
 
Figure 3.10: A comparison of FBF whilst undertaking low and high intensity exercise, 
during saline or L-NMMA infusion, carried out in separate studys. There was no 
significant difference in FBF during L-NMMA infusion when compared to saline 
during either low intensity exercise (n=11, P=NS) or high intensity exercise (n=11, 
P=NS). 

























3.3.4 Effect of L-NMMA and SMTC on FBF during exercise and LBNP 
 
15 healthy male volunteers aged 25.9±2.1 years were studied (Table 3.3). On separate 
study days, L-NMMA (2 µmol/min) and SMTC (0.2 µmol/min) reduced resting blood 
flow to a similar degree, by 23.2±2.2 % (from 5.40±0.72 to 4.21± 0.61 ml/min/100ml, 
P<0.001) and 19.6±2.5 % (from 5.46±0.73 to 4.42±0.60 ml/min/100ml, P<0.001), 
respectively (L-NMMA vs. SMTC P=NS) (Figure 3.11).  
 
Table 3.3: Baseline characteristics of the study subjects. 
 
Healthy male volunteers      
 
Age (years)      25.9±2.0         
Systolic blood pressure [SBP], (mmHg)  126±1.7         
Diastolic blood pressure [DBP], (mmHg)  68±2.0         

































During handgrip exercise and simultaneous LBNP, there was no significant effect of 
either L-NMMA or SMTC on FBF induced by exercise at low intensity (11.66±0.62 
vs. 10.57±0.85 vs. 11.84±1.43 ml/min/100ml tissue change during L-NMMA, SMTC 
and saline vehicle respectively; n=10, L-NMMA vs. SMTC P=NS, L-NMMA vs. 
saline P=NS, SMTC vs. saline P=NS) or high intensity (17.74±1.25 vs. 18.47±2.06 vs. 
19.76±2.25 ml/min/100ml tissue change during L-NMMA, SMTC and saline vehicle 
respectively; n=10, L-NMMA vs. SMTC P=NS, L-NMMA vs. saline P=NS, SMTC 
vs. saline P=NS) (Figure 3.12). Results did not differ when data were analysed using a 
one-way ANOVA on all subjects or a repeated-measurements ANOVA restricted to 
subjects that attended all study days and thus had data during infusion of saline, 




Figure 3.12: A comparison of the FBF during low and high intensity exercise and 
LBNP whilst infusing L-NMMA or SMTC. There is no significant difference in FBF 
during L-NMMA or SMTC infusion when compared to saline, for either low intensity 
(n=10, P=NS for both) or high intensity exercise (n=10, P=NS for both). 























3.3.5 Effects of SMTC and L-NMMA on FBF during LBNP alone  
 
This particular study was carried out in our department by Seddon and colleagues but 
the data has been further analysed in this thesis as it is relevant to the work in this 
chapter. Saline vehicle was infused for 15 min to establish baseline FBF, followed by 
infusion of SMTC (0.2 µmol/min for 15 min, n=8) and, in a separate group of subjects, 
L-NMMA (2 µmol/min for 15 min, n=8). During the final 3 min of each infusion 






Figure 3.13: Schematic of study protocol. The effect of LBNP on FBF was measured 












At rest and in the absence of LBNP, both L-NMMA (2 µmol/min) and SMTC (0.2 
µmol/min) significantly reduced FBF by 25.8±3.0 % (from 2.76±0.20 to 2.02±0.12 
ml/min/100ml, P<0.001, figure 3.14a) and 20.6±3.3 % (from 3.42±0.31 to 2.71±0.27 
ml min/100ml, P<0.01, P=NS compared to L-NMMA, figure 3.13b), respectively.  
LBNP (-20mmHg) reduced FBF by 23.4±5.7 % (from 2.75±0.20 to 2.12±0.22 
ml/min/100ml, P<0.01) during saline infusion and by 44.2±3.5 % in the presence of L-
NMMA (from 2.02±0.12 to 1.14±0.11 ml/min/100ml, P<0.01 vs. saline, figure 3.13a).  
By contrast, the reduction in FBF by LBNP during infusion of SMTC did not differ 
significantly from that observed during saline infusion (from 3.42±0.31 to 2.24±0.20 
ml/min/100ml, i.e., a 34.1±3.0 % reduction, P<0.001 during saline and from 2.71±0.27 
to 1.92±0.18 ml/min/100ml, i.e., a 28.5±4.0 % reduction during SMTC, P=NS 
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between interventions, figure 3.14b). Thus, the relative reduction in FBF in response 
to LBNP was significantly greater in the presence of L-NMMA than in the presence of 
SMTC (44.2±3.5 vs. 28.5±4.0 %, P<0.01, figure 3.14c). 
 
 
Figure 3.14: (a) FBF at rest and during LBNP during infusion of saline and L-
NMMA. * P<0.01 vs. saline with no LBNP; ** P<0.001 vs. saline with no LBNP; † 
P<0.001 vs. L-NMMA with no LBNP. (b) FBF at rest and during LBNP during 
infusion of saline and SMTC. * P<0.001 vs. saline with no LBNP; ** P<0.01 vs. 
saline with no LBNP; † P<0.01 vs. SMTC with no LBNP. (c) The % change in FBF 
during L-NMMA and SMTC with LBNP. * P<0.01 vs SMTC. (+ LBNP; - no LBNP). 

















   
   














































3.3.6 Effects of SMTC and L-NMMA on radial artery diameter during exercise  
 
17 healthy male volunteers (3 volunteers took part in both the L-NMMA and the 
SMTC study) were studied. Only high intensity exercise was performed, to ensure a 
large enough vasodilatation response to be detectable. At rest, radial artery diameter 
did not change in the presence of L-NMMA (from 2.49±0.15 before to 2.48±0.13mm 
after L-NMMA; P=NS) nor SMTC (from 2.37±0.07 before to 2.36±0.08mm after 
SMTC; P=NS). 
 
During handgrip exercise, radial artery diameter increased in the saline control study 
in both group of subjects. In the L-NMMA group, radial artery diameter increased 
from 2.50±0.13 to 2.68±0.11 mm (P<0.01), and in the SMTC group radial artery 
diameter increased from 2.49±0.14 to 2.79±0.15 mm (P<0.05). Radial artery diameter 
also increased during exercise in the presence of L-NMMA (from 2.48±0.13 to 
2.62±0.12mm, P<0.01) and SMTC (from 2.36±0.08 to 2.50±0.07 mm, P<0.001), and 
this was not significantly different to the increase seen during saline control (P=NS, L-









Figure 3.15: A comparison of the radial artery diameter during high intensity exercise 
whilst infusing L-NMMA or SMTC. There is no significant difference in radial artery 
diameter during L-NMMA (n=8, P=NS) or SMTC (n=8, P=NS) infusion when 







































Until recently, it had been assumed that the NO that regulates local blood flow under 
physiological conditions in humans derives exclusively from eNOS. However, first-in-
human studies with the nNOS-selective inhibitor SMTC showed that the basal 
regulation of vascular tone in both the forearm and coronary circulations is mediated 
by nNOS whereas eNOS mediates relaxant responses to pharmacological and shear 
stress stimuli (Seddon et al., 2009; Seddon et al., 2008). Cutaneous vasodilatation 
induced by heat stress is also mediated by nNOS in humans (Kellogg et al., 2008b). 
The autonomic nervous system could activate local release of NO from nNOS through 
a neuronal link and/or eNOS through local release of neurotransmitters such as 
norepinephrine. To our knowledge, this is the first study to examine the relative role of 
local nNOS- and eNOS-mediated vasomotor responses to physiological stimuli that 
modulate activity of the sympathetic and possibly other neural pathways within the 
autonomic nervous system. In the study carried out by colleagues in our department 
we found that non-isoform selective NOS inhibition with L-NMMA augmented the 
forearm vasoconstrictor response to LBNP whereas selective nNOS inhibition (despite 
causing a reduction in basal forearm blood flow similar to that observed with L-
NMMA) had no significant effect on the vasoconstrictor response to LBNP. This 
suggests that reflex sympathetic vasoconstriction is partially opposed by local eNOS- 
but not by nNOS-derived NO in the resting muscle. These results are consistent with 
observations in the rat hind limb where non-selective NOS inhibition with N-nitro-L-
arginine methyl ester (L-NAME) increases muscle vasoconstriction in response to 
lumbar sympathetic nerve stimulation (Thomas and Victor, 1998). The simplest 
explanation for the augmented vasoconstriction to sympathetic stimulation after NOS 
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inhibition is that norepinephrine released from sympathetic nerves in response to 
LBNP stimulates eNOS through alpha or beta-adrenergic receptors, actions that have 
previously been described in animals and humans (Kneale et al., 2000).  
 
Increases in blood flow during exercise depend upon short-term adjustments and 
interplay between autonomic influences and local regulatory factors. These results 
enhance our understanding of the role of NO-mediated circulatory control by 
demonstrating that neither nNOS nor eNOS appear to subserve an obligatory role in 
regulating blood flow during exercise or in modulating the sympathetic 
vasoconstrictor response in exercising muscle in humans in vivo.  
 
Previous human and animal studies examining the role of NO during functional 
hyperaemia have yielded conflicting results. Copp and colleagues found that nNOS 
inhibition with SMTC reduced baseline hindlimb muscle blood flow in the rat, but not 
total hindlimb muscle blood flow during exercise (Copp et al., 2010). However, many 
animal models do suggest a potential role for NO, and more specifically nNOS-
derived NO in regulating blood flow and oxygenation in skeletal muscle by blunting 
the vasoconstrictor response to α-adrenergic activation during dynamic exercise 
(functional sympatholysis) and/or contributing to exercise-induced vasodilatation. 
These include a dog hind limb model of exercise (Buckwalter et al., 2004) and nNOS 
deficient mice (Fadel et al., 2003; Grange et al., 2001; Kobayashi et al., 2008; Lai et 
al., 2009; Percival et al., 2008; Percival et al., 2010; Thomas et al., 1998). In the mdx 
mouse, a mouse model of DMD where dystrophin deficiency results in reduced nNOS 
expression in skeletal muscle, the normal ability of muscle contraction to attenuate α-
adrenergic vasoconstriction is defective (Thomas et al., 1998). Kobayashi and 
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colleagues have suggested that nNOS in skeletal muscle contributes to increased blood 
flow after mild exercise in mouse models (Kobayashi et al., 2008).  
 
In humans, a number of studies have shown a reduction in FBF during exercise in 
response to non-selective NOS inhibition with L-NMMA or L-NAME (Endo et al., 
1994; Gilligan et al., 1994; Gordon et al., 2002; Wray et al., 2011). However, the size 
of the effects has been small and, when compared to a vasoconstrictor control with 
similar effects on resting blood flow, L-NMMA has been found to have no significant 
effect on blood flow responses during exercise (Dinenno and Joyner, 2003). 
Chavoshan and colleagues examined the effect of a reflex increase in sympathetic 
efferent activity (induced by LBNP) on muscle perfusion (assessed from measurement 
of muscle oxygenation by NIRS) during exercise (Chavoshan et al., 2002). Systemic 
NOS inhibition with L-NAME completely reversed the blunted vasoconstrictor 
response to LBNP in the exercising forearm. However, such results could be 
influenced by the reflex response to the systemic effects of L-NAME (which include a 
rise in MAP). Dinenno and Joyner examined the effects of local NOS inhibition with 
L-NMMA or L-NAME on FBF responses during handgrip exercise and whilst 
stimulating release of endogenous norepinephrine (by intra-arterial infusion of 
tyramine). Neither NOS inhibitor restored the vasoconstrictor response to local 
tyramine-stimulated norepinephrine release during exercise, arguing against a role for 
NO in functional sympatholysis (Dinenno and Joyner, 2003). As described earlier, 
Sander and colleagues found that both the LBNP-induced decrease in resting forearm 
vascular conductance and the decrease in tissue oxygenation during hand grip exercise 
were attenuated in controls, but not in children with DMD. The authors attributed 
these effects to the loss of skeletal muscle nNOS-derived NO in children with DMD 
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(Sander et al., 2000). However, dystrophic muscle is characterized by changes in the 
expression and function of a number of proteins (Straub and Campbell, 1997), raising 
a question as to whether the impaired response to sympathetic stimulation in DMD 
were specific for nNOS deficiency. 
 
Our results using L-NMMA showed no significant effect of L-NMMA to blunt 
functional hyperaemia. Similarly, even in the face of increased sympathetic 
stimulation with LBNP, we found no significant effect of either L-NMMA or SMTC 
on FBF responses immediately after exercise. These results confirm the findings of 
Dinenno and Joyner using a different sympathetic stimulus and using both non-
selective and selective inhibitors of NOS (Dinenno and Joyner, 2003) measuring blood 
flow and conduit artery diameter using Doppler. It is likely that there are multiple 
mechanisms involved in exercise hyperaemia and functional sympatholysis including 
metabolic mediators such as adenosine, ATP, potassium, hypoxia, and hydrogen ions 
that may link blood flow to metabolic demands (Clifford and Hellsten, 2004). 
Noradrenergic, noncholinergic peptides such as calcitonin gene-related protein may 
also be involved (Hasbak et al., 2002). These results combined with those of other 
investigators showing the lack of effect of inhibition of NOS on exercise-induced 
hyperaemia are consistent with the proposal by Clifford and Hellsten that there is a 
redundancy of vasodilators contributing to exercise-induced hyperaemia where one 
vasoactive compound may take over when the formation of another is inhibited 






3.4.1 Study limitations 
 
These results pertain to healthy men, and we cannot extrapolate our results to women 
or subjects with cardiovascular risk factors. Due to the limited sample size we cannot 
exclude a small effect of eNOS/nNOS on functional sympatholysis. Our study 
involved acute NOS inhibition and results could differ from those of studies involving 
chronic nNOS inhibition or absent nNOS such as in a knock-out murine model. SMTC 
has relatively high specificity for nNOS, and in order to be sure that SMTC was acting 
specifically on nNOS, we used a concentration previously shown not to inhibit eNOS 
mediated responses (Seddon et al., 2009; Seddon et al., 2008) but which reduced basal 
forearm blood flow to a similar degree to concentrations of L-NMMA, that inhibit 
eNOS mediated responses. However, should more specific inhibitors of nNOS become 
available for human use, it would be advisable to use these to confirm our findings.  
 
Measurements were made immediately after the cessation of handgrip exercise and we 
have extrapolated these results to demonstrate the effect during exercise, as many 
researchers have previously (Endo et al., 1994; Gilligan et al., 1994; Gordon et al., 
2002; Wilson and Kapoor, 1993). It is therefore feasible that we are observing the 
effect on recovery post-exercise rather than exercise itself, and that these may differ. 
Measurements during exercise were not feasible as the measurement of FBF with 
venous occlusion plethysmography requires the arms to be motionless,  However, the 
results are similar to some researchers who have used other techniques during the 
actual exercise period, such as Doppler ultrasound (Dinenno and Joyner, 2003; Green 






In these studies, we used intra-arterial infusions of SMTC and L-NMMA in healthy 
male volunteers to investigate for the first time its effects on FBF during exercise and 
reflex sympathetic activation in humans in vivo. We found that neither NOS isoform 
plays an obligatory role in functional sympatholysis during exercise. This suggests that 
animal models suggesting a role for nNOS in functional sympatholysis may not be 

















THE ROLE OF nNOS VERSUS eNOS IN THE 
REGULATION OF CORONARY 




Intricate changes in microvascular tone are responsible for regulation and distribution 
of myocardial blood flow. NO plays a key role in this complex process regulating 
vessel tone at rest as well as during episodes of increased flow in response to shear 
stress or agonist stimulation (Joannides et al., 1995; Moncada and Higgs, 1993; 
Moncada and Higgs, 2006). Previously thought to derive solely from eNOS in the 
endothelium of blood vessels, it is now clear that NO synthesised from nNOS plays an 
equally important role in regulating blood flow. Previous investigations from our 
group have shown that coronary artery infusion of SMTC, a selective inhibitor of 
nNOS, reduces human basal CBF in vivo, but does not block the vasodilator response 
to substance P, an eNOS agonist (Seddon et al., 2009). In contrast, substance P-
induced increases in coronary blood flow were inhibited by the non-selective NOS 
inhibitor L-NMMA. This suggests that regulation of basal vascular tone, and hence 
blood flow at rest, may primarily be dependent upon the action of vascular nNOS as 
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opposed to eNOS as previously thought. These findings concur with evidence from 
other animal species where nNOS-derived NO has similarly been shown to have a 
paracine vasoregulatory influence in different vascular beds (Chi et al., 2003; Ichihara 
et al., 1998; Thomas et al., 1998; Vallon et al., 2001). 
 
In addition, NO is believed to be one of a number of paracrine mediators that regulate 
myocardial blood flow in response to increased metabolic demand such as that 
encountered during exercise (Buckwalter et al., 2004; Endo et al., 1994; Gilligan et al., 
1994; Gordon et al., 2002; Grange et al., 2001; Sander et al., 2000; Thomas et al., 
1998). However, there is no data on the relative contribution of different NOS 
isoforms to this process in the human coronary circulation.  
 
4.1.1 Study aims 
 
The aim of the present study was to investigate the relative contribution of eNOS- and 
nNOS-derived NO in the regulation of epicardial and microvascular tone during 












The studies were approved by the local research ethics committee (King’s College 
Hospital), and all participants provided written informed consent. The studies 
conformed to the standards set by the latest revision of the Declaration of Helsinki. 
 
Patients undergoing diagnostic cardiac catheterization for atypical chest discomfort, 
who had angiographically smooth unobstructed coronary arteries, were recruited to the 
study. Subjects with valvular heart disease, left ventricular hypertrophy or systolic 
dysfunction and significant renal, hepatic or inflammatory disease were excluded. 
Studies were performed in the morning after an overnight fast. Any vasoactive drugs 
were discontinued and subjects refrained from alcohol, caffeinated drinks and smoking 
on the day of the study. Patients were given a formal patient information sheet and all 
procedures and their associated risks were explained. Subjects were randomly 
assigned to receive saline vehicle and then either SMTC (0.0625 µmol/min) or L-
NMMA (25 µmol/min) during a second incremental pacing protocol. The doses of 
these agents have been shown to inhibit nNOS and both nNOS and eNOS, respectively 




The study protocol is summarised in Figure 1. Cardiac catheterization was performed 
via the right femoral arterial and venous routes in a quiet, temperature-controlled, 
cardiac catheterization laboratory with digital cineangiography. After completion of 
diagnostic coronary angiography, a standard temporary pacing wire was positioned in 
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the right atrium and a 0.014-in intra-coronary Doppler wire (FloWire, Volcano 
Therapeutics Inc, Rancho Cordova, CA, USA) advanced through a 6F guiding catheter 
into a straight, non-overlapping and side-branch free segment of the proximal left 
coronary artery. Either the left anterior descending (LAD) or circumflex (LCx) arteries 
were used as detailed in Table 1. The Doppler wire was interfaced with a real-time 
spectral analysis system (ComboMap Pressure and Flow system, Volcano 
Therapeutics Inc, Rancho Cordova, CA, USA) to derive continuous Doppler traces 
and corresponding average peak velocity (APV) values.  
 
Changes in the diameter of the study artery was calculated using an automated Philips 
quantitative coronary angiography (QCA) edge detection system in a 2.5-5mm length 
segment of vessel approximately 2.5 mm distal to the tip of the Doppler wire. 
Angiographic images were obtained with the study artery positioned at the isocentre 
without altering the angle of projection throughout the study. CBF was calculated 
from the product of corresponding APV value and QCA-derived coronary artery 
diameter (1/2 x APV x coronary cross-sectional area) (Doucette et al., 1992) at pre-
specified time points as outlined below and in Figure 4.1. Saline vehicle was infused 
directly into the coronary artery followed by either SMTC (0.0625 µmol/min) or L-
NMMA (25 µmol/min) via the guiding catheter at an infusion rate of 2 ml/min. All 
results were recorded digitally and analysed offline in a blinded fashion at the end of 
the study by the same investigator.  
 
Changes in CBF were measured in response to incremental atrial pacing (to increase 
metabolic demand) before and after intra-coronary infusion of vehicle and SMTC/L-
NMMA. APV was initially measured in the presence of saline vehicle at baseline and 
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after 20 beats per minute (bpm) paced increments in heart rate every 2 min up to a 
maximum heart rate of 150 bpm or the occurrence of rate-related temporary atrio-
ventricular block. APV was then allowed to return to baseline. This was followed by a 
7 min intra-coronary infusion of a NOS inhibitor (STMC or L-NMMA). The pacing 
protocol was then repeated in the presence of the NOS inhibitor. To avoid hyperaemic 
effects of angiographic contrast influencing CBF calculations at each stage of the 
protocol, APV recordings were made immediately prior to obtaining the 
corresponding angiographic image. Furthermore, the protocol progressed to the next 
stage only after the APV value had returned to its pre-contrast reading. Aortic pressure 














Figure 4.1: Schematic diagram of the protocol. Incremental pacing from 70 bpm up to 
150 bpm was carried out with measurements of average peak velocity (APV), blood 
pressure, ECG and coronary angiography after each step. This was in the presence of 
intra-coronary saline and then either L-NMMA or SMTC. 
 
Saline L-NMMA or SMTC
Atrial pacing
Coronary Angiogram,         






















4.2.2 Statistical analysis 
Data was recorded as mean ± SEM. Vasoconstrictor responses to SMTC and L-
NMMA were calculated as percentage decrease in basal blood flow. Effects of the 
NOS inhibitors and pacing on the blood flow responses were analysed by One-way 
analysis of variance (ANOVA) or by ANOVA for repeated measures as appropriate. 
All tests were two-tailed and differences were considered significant when P<0.05. All 
graphs demonstrating results with pacing are plotted against both heart rate (HR) and 
cardiac workload, which was calculated as mean arterial pressure (MAP) x (HR). 





















Twenty patients (11 male, mean age 57±3.2 years) were studied, 10 in each group 
receiving either SMTC or L-NMMA. Baseline characteristics were similar between 
the SMTC and L-NMMA groups (Table 4.1). None of the subjects developed an 
adverse reaction to the study drugs, symptoms of ischaemia or changes in the surface 




















Table 4.1: Baseline characteristics of patients. There was no significant difference in 
the characteristics between the 2 groups of patients. 
 
           SMTC            L-NMMA               
   [n = 10]    [n = 10]                     
  
     Age (years)    58.7±2.9    57.1±3.7     (P=0.73) 
 Male/ Female, n   6 / 4     5 / 5                        
 Cardiovascular risk factors: 
     Smoker, n            4       4            
     Hypertension, n       5       3            
     Diabetes mellitis, n       4       2            
     Hypercholesterolaemia, n       3       7            
     Family history, n       1       1  
 Systolic BP (mmHg)                 128±7.9  139±7.8            (P=0.30)                 
 Diastolic BP (mmHg)   77±4.1    74±2.3            (P=0.79)                
 Study artery, n 
      LAD        5        6                        
          LCx         5        4                                              







4.3.1 Influence of L-NMMA and SMTC on basal CBF 
 
Intra-coronary infusion of L-NMMA or STMC both reduced basal CBF to a similar 
extent (P=NS) (Figure 4.2A). L-NMMA (25 µmol/min) reduced basal flow by 
25.0±2.68 %, from 59.7±9.52 to 43.9±6.47 ml/min (P<0.01) and SMTC (0.625 
µmol/min) by 19.2±3.25%, from 70.0±8.16 to 55.8±6.57 ml/min (P<0.001). As with 
changes in CBF, there was a similar reduction in basal coronary artery diameter in 
response to L-NMMA and SMTC (P=NS) (Figure 4.2B). L-NMMA reduced coronary 
arterial diameter from 2.66±0.22 to 2.54±0.20 mm (P<0.01) and SMTC from 
2.53±0.12 to 2.48±0.11 mm (P<0.01). 
 
There was no change in blood pressure with either intra-coronary L-NMMA (MAP: 
96.7±4.48 to 100.6±5.54 mmHg, P=NS) or SMTC (MAP: 97.8±6.09 to 100.0±7.35 











Figure 4.2: Effect of SMTC and L-NMMA on basal coronary tone. (A) Percentage 
reduction in basal coronary blood flow after SMTC (n=10) and L-NMMA (n=10). 
SMTC and L-NMMA both significantly reduced basal coronary artery blood flow to a 
similar extent (p=NS SMTC vs L-NMMA). (B) Effect of SMTC and L-NMMA on 
epicardial conduit artery tone. SMTC and L-NMMA both significantly reduced basal 







4.3.2 Influence of L-NMMA and SMTC on CBF in response to incremental 
pacing 
 
Incremental pacing did not cause any significant change in blood pressure during 
saline vehicle in either the L-NMMA (MAP: 98.2±4.46 to 93.3±4.96 mmHg, P=NS) 
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or SMTC (MAP: 91.9±5.13 to 96.6±6.26 mmHg, P=NS) groups, or during L-NMMA 
(MAP: 103.6±5.87 to 100.5±6.63 mmHg, P=NS) or SMTC (MAP: 106.6±8.10 to 
99.6±5.83 mmHg, P=NS) infusion. 
 
In the presence of saline vehicle, incremental pacing led to an expected increase in 
CBF in both L-NMMA (from 56.8±9.27 to 83.5±14.2 ml/min; P<0.01) and SMTC 
(from 67.2±8.98 to 98.5±12.87 ml/min; P<0.01) groups (Figure 4.3). During L-
NMMA infusion, although CBF increased in response to incremental pacing (from 
45.5±6.76 to 61.6±9.49 ml/min; P<0.01), the magnitude of increase was significantly 
blunted compared to changes in flow during saline infusion (ΔCBF - L-NMMA: 
16.1±3.91ml/min, saline: 26.8±5.74 ml/min; P<0.05 by 2-way ANOVA) (Figure 4.3A 
and 4.3B). The CBF also increased with pacing during STMC infusion (from 
54.7±7.03ml/min to 102.1±16.57 ml/min; P<0.01), but in contrast to L-NMMA, was 
unchanged from that achieved with saline (102.1±16.6ml/min vs 98.5±12.9 ml/min 
respectively; P=NS) (Figure 4.3C and 4.3D). Representative coronary Doppler traces 










Figure 4.3: Effect of L-NMMA and SMTC on the CBF response to pacing. L-NMMA 
vs saline in the coronary blood flow response to pacing plotted against both (A) heart 
rate and (B) cardiac workload. SMTC vs saline in the coronary blood flow response to 
pacing plotted against both (C) heart rate and (D) cardiac workload. Sequential atrial 
pacing in the presence of saline increased CBF in both groups (*P<0.01 both groups). 
During L-NMMA, CBF increased with pacing (*P<0.01) but was significantly blunted 
compared to that during saline (ΔCBF L-NMMA vs saline †P<0.05). In patients 
receiving SMTC, pacing induced increase in CBF (*P<0.01) was similar to that during 

























Figure 4.4. Representative coronary Doppler spectral displaying APV (A) at baseline 
heart rate during saline vehicle (B) at peak heart rate during saline vehicle (C) at 
baseline heart rate during L-NMMA (D) at peak heart rate during L-NMMA.  
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The effects of pacing on coronary resistance were similar to those on flow. In the 
presence of saline vehicle, incremental pacing led to a decrease in CVR in both L-
NMMA (from 1.98±0.19 to 1.28±0.12 mmHg.ml-1.min; P<0.01) and SMTC (from 
1.64±0.27 to 1.14±0.17 mmHg.ml-1.min; P<0.05) groups (Figure 4.5). During L-
NMMA infusion, CVR decreased in response to incremental pacing (from 2.68±0.42 
to 1.90±0.22 mmHg.ml-1.min; P<0.05) but was significantly greater compared to 
saline (1.90±0.22 vs 1.28±0.12 mmHg.ml-1.min; P<0.01) (Figure 4.5A and 4.5B). 
CVR decreased with pacing during STMC infusion (from 2.25±0.40 to 1.02±0.15 
mmHg.ml-1.min; P<0.05) but was unchanged from that achieved with saline 














Figure 4.5: Effect of L-NMMA and SMTC on the CVR response to pacing. Influence 
of L-NMMA vs saline on CVR in response to pacing plotted against both (A) heart 
rate and (B) cardiac workload. Influence of SMTC vs saline on CVR in response to 
pacing plotted against both (C) heart rate and (D) cardiac workload. Sequential atrial 
pacing in the presence of saline decreased CVR in both groups (L-NMMA group: 
**P<0.01; SMTC group: *P<0.05). During L-NMMA, CVR continued to decrease in 
response to incremental pacing (*P<0.05) but was significantly greater compared to 
saline (†P<0.01). In patients receiving SMTC, pacing induced increase in CVR 




















4.3.3 Influence of L-NMMA and SMTC on coronary arterial diameter in 
response to incremental pacing 
 
Sequential atrial pacing in the presence of saline increased coronary arterial diameter 
in both groups (L-NMMA: 2.64±0.22 to 2.72±0.20 mm; P<0.05, and SMTC: 
2.51±0.11 to 2.64±0.11 mm; P<0.01). This response was blunted with infusion of L-
NMMA, where coronary artery diameter did not increase with pacing (2.53±0.20 to 
2.54±0.20 mm; P=NS) (Figure 4.6A and 4.6B), but not SMTC, where coronary artery 
diameter continued to increase in response to atrial pacing (2.46±0.11 to 2.67±0.13 














Figure 4.6: Effect of L-NMMA and SMTC on the coronary diameter response to 
pacing. Influence of L-NMMA vs saline on coronary artery diameter in response to 
pacing plotted against both (A) heart rate and (B) cardiac workload. Influence of 
SMTC vs saline on coronary artery diameter in response to pacing plotted against both 
(C) heart rate and (D) cardiac workload. Sequential atrial pacing in the presence of 
saline increased coronary arterial diameter in both groups (L-NMMA group: *P<0.05; 
SMTC group: **P<0.01). This response was blunted with infusion of L-NMMA 
(†P<0.001), but not SMTC, where coronary diameter continued to increase in response 






















The conventional view of NO-dependent regulation of blood flow in humans had been 
that this mainly involves eNOS in the endothelium of blood vessels. Previous 
experiments by our group had recently provided evidence that nNOS-derived NO 
plays a key role in the local regulation of basal blood flow in the human forearm and 
coronary circulations (Seddon et al., 2009; Seddon et al., 2008). This investigation is 
the first of its kind to investigate systematically the effects of selective NOS inhibition 
on the regulation of coronary vasomotor tone during increasing cardiac workload. We 
found that local infusion of L-NMMA led to a significant reduction in basal CBF, 
consistent with previous results by our group (Seddon et al., 2009) as well as others 
using similar doses (Duffy et al., 1999; Egashira et al., 1996; Lefroy et al., 1993; 
Quyyumi et al., 1995b). SMTC led to a similar reduction in basal CBF to L-NMMA, 
as previously shown (Seddon et al., 2009), but the novel finding in this study was that 
during atrial pacing the increase in CBF and coronary artery diameter was blunted by 
L-NMMA but not so by SMTC.  
 
In animal models, selective inhibition of nNOS or eNOS gene deletion attenuates 
exercise-induced vasodilatation and increase in blood flow in the skeletal muscle 
(Fadel et al., 2003; Grange et al., 2001; Kobayashi et al., 2008; Thomas et al., 1998). 
As previously discussed, in nNOS knockout mice and the mdx mouse, the ability of 
muscle contraction to attenuate α-adrenergic vasoconstriction has been shown to be 
defective and lead to abnormal flow regulation (Thomas et al., 1998). However, 
similar results have not been replicated in humans. Continuous short-term adjustments 
to CBF are fundamentally important to ensure there is a close match between 
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myocardial tissue perfusion and cardiac workload (Deussen et al., 2012). NO is known 
to be one of a number of paracrine mediators (including adenosine, prostaglandins, 
and EDHF’s), which in conjunction with vascular autonomic input, determine optimal 
CBF (Deussen et al., 2012; Garland et al., 2011; Liu et al., 2011).  
 
However, the relative contribution of different NOS isoforms to regulation of 
epicardial and microvascular tone, and thus blood flow, in response to changes in 
metabolic demand remains unclear. Our results indicate that the vasoregulatory 
influences of eNOS and nNOS are complementary to one another, with nNOS 
primarily influencing CBF at rest, and eNOS contributing to changes in response to 
increasing metabolic demand as induced through incremental cardiac pacing. 
 
NO has been implicated in regulation of vascular tone in response to changes in 
metabolic demand in the coronary circulation (Berdeaux et al., 1994; Chi et al., 2003; 
Duffy et al., 1999; Kuo et al., 1991; Quyyumi et al., 1995a; Tousoulis et al., 1997). 
Quyyumi and colleagues demonstrated that non-selective inhibition of NOS results in 
a significant reduction in both microvascular and epicardial vasodilatation during 
cardiac pacing. In patients with angiographically normal coronary arteries they paced 
at a mean rate of 140 bpm. During pacing in the control study there was a 50 % 
increase in CBF and a 9 % increase in coronary artery diameter. During L-NMMA, 
cardiac pacing produced only a 23 % increase in CBF and the baseline change in 
diameter remained constant (Quyyumi et al., 1995a). Tousoulis and colleagues again 
found no increase in coronary artery diameter during L-NMMA whilst pacing at 140 
bpm in angiographically normal arteries, with significantly reduced change in CBF 




Increased myocardial oxygen demand leads to metabolic dilatation of the small 
resistance coronary arterioles to augment local blood flow and oxygen supply to match 
demands (Macho et al., 1981). As a consequence of this microvascular dilatation, 
dilatation of large epicardial arteries follows due to increased flow and hence shear 
stress. This FMD response can be induced by physiological stimuli (such as dynamic 
exercise or atrial pacing) and is considered an important regulatory mechanism in the 
coronary circulation in humans. During pacing, we confirmed previous findings that 
angiographically normal human coronary arteries dilate and CBF increases (Gaglione 
et al., 1987; Gordon et al., 1989; Nabel et al., 1990a; Quyyumi et al., 1995a). Pacing-
induced FMD in the coronary arteries is abolished by L-NMMA (Duffy et al., 1999; 
Quyyumi et al., 1995a; Tousoulis et al., 1997), confirming the role of NO in this 
process. In addition, atherosclerosis, which is known to reduce local bioavailability of 
NO, blunts CBF and/or epicardial dilatation in response to a host of different 
metabolic stimuli such as bicycle exercise, cold pressor, mental stress as well as 
pacing (Gordon et al., 1989; Nabel et al., 1990a, b; Yeung et al., 1991) 
 
Previous studies have shown that SMTC had no effect on the increase in CBF or 
conduit epicardial artery dilatation induced by intracoronary substance P. In contrast, 
L-NMMA significantly inhibited the response to substance P (Seddon et al., 2009). 
The effect of substance P is likely to represent the combination of a direct effect on the 
epicardial artery (Toda and Okamura, 1989) and a result of FMD. This is similar to the 
response in the forearm vasculature, where SMTC reduced basal tone but had no effect 
on the increase in forearm blood flow induced by the agonist, ACh, or shear stress by 
FMD, whereas these were inhibited by L-NMMA (Seddon et al., 2009; Seddon et al., 
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2008). Peripheral vasomotor function has been shown to be related to vasomotor 
function in the coronary arteries in individuals (Anderson et al., 1995), despite 
peripheral and myocardial circulations differing in terms of microvascular 
architecture, metabolic regulation, patterns of blood flow and vascular resistance, and 
the pathways that are activated to induce hyperaemia (Komaru et al., 2000). 
 
Although previous studies have already established the role of NO in regulation of 
CBF during changes in metabolic demand, none as in our study, has directly examined 
the relative contribution of eNOS- and nNOS-derived NO to this regulatory process. 
Our results further indicate that NOS inhibition significantly attenuates, but does not 
abolish changes in CBF. This confirms the notion that pathways controlling metabolic 
regulation of blood flow have significant redundancy through interdependence on a 
host of metabolites including NO, such as adenosine, prostaglandins, as well as neural 
inputs (Deussen et al., 2012). 
 
Our study did not examine the association between nNOS and autonomic mediated 
changes in metabolic demand in the heart as seen during exercise or mental stress. 
Human studies have shown that mental stress-induced vasodilatation in the forearm is 
significantly attenuated by selective inhibition of nNOS. However, this response is not 
influenced by a vasoconstrictor (norepinephrine) that reduces basal flow to a similar 
extent to the NOS inhibitor. Taken together these findings strongly suggest a role for 
local nNOS-derived NO in regulation of microvascular tone during mental stress 
(Seddon et al., 2008). On the basis of the emerging evidence future studies should also 
examine the role of nNOS in regulation of CBF in response to autonomic stimulation. 
In addition, at a cellular level nNOS has been isolated to both the peri-vascular 
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autonomic fibres as well as the vessel wall (Bachetti et al., 2004; Boulanger et al., 
1998; Schuman and Madison, 1994).  
 
Animal studies have indicated that there may be an inverse functional association 
between different NOS isoforms in the vascular wall where a reduction in eNOS 
expression is compensated for by an increase in nNOS activity (Boulanger et al., 
1998). This is an important association which requires further exploration in humans 
in particular to identify how presence of conventional cardiovascular risk factors 
and/or atherosclerosis may influence simultaneous nNOS / eNOS expression and 
hence CBF during episodes of increased metabolic demand. 
 
4.4.1 Study limitations  
 
Pacing-induced change in CBF is not necessarily a pure model of increased workload 
and may also be influenced by other factors such as cardiac mechanics and the 
duration of diastole. Nevertheless, it is an objective and easy-to-implement 
intervention in the invasive setting of a clinical cardiac catheterization laboratory. 
 
It should also be noted that these studies were not performed in healthy volunteers and 
that most of the patients who took part in these studies had at least 1 risk factor for 
coronary disease, which could have potentially influenced the results. Such patients 
have been demonstrated to have impaired vasomotor responses (Quyyumi et al., 
1995b; Quyyumi et al., 1997; Vita et al., 1990). Consequently, although all the 
patients had angiographically normal coronary arteries, it is unlikely that this 




The baseline characteristics of the two groups given either SMTC or L-NMMA were 
well matched, there were a mixture of males and females, and the total number of 
subjects studied was small. Related to this, and due to the fact that in the SMTC group 
the generally smaller circumflex artery was studied in slightly more subjects, due to 
either difficulty placing the wire in the LAD or due to LAD vessels with unsuitable 
anatomy for precise measurement (e.g. tortuosity), the baseline mean epicardial 




Our study provides the first direct evidence that increases in CBF in response to 
pacing-induced change in metabolic demand is mediated by eNOS- as opposed to 
















FIRST-IN-MAN STUDY OF THE EFFECTS 





It has been well documented in both animal and human studies that non-selective NOS 
inhibition with L-NMMA causes a transient pressor response when infused 
systemically and this has been assumed to be mediated through inhibition of eNOS 
(Gamboa et al., 2007; Hansen et al., 1994a; Haynes et al., 1993; Owlya et al., 1997; 
Stamler et al., 1994). In our own lab, Brett and colleagues infused L-NMMA 
systemically in men and observed modest transient increases (compared with effect of 
saline placebo) in systolic and diastolic blood pressures of 4.1±1.1 % and 12.6±3.5 % 
respectively, suggesting that normal arterial blood pressure is kept down by the 
continuous generation of NO (Brett et al., 1998). This NO could be generated at 
different sites that regulate blood pressure, such as resistance vessels, the brain and the 
kidneys. 
 
As discussed in this thesis, recent evidence suggests that a major source of basal NO 
release regulating local vascular tone in humans is nNOS (Seddon et al., 2009; Seddon 
et al., 2008). Local nNOS-selective inhibition with SMTC reduces basal blood flow in 
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the forearm and coronary circulations without affecting endothelial-mediated 
vasodilatation. These findings suggest that, through regulation of local vascular tone, 
nNOS may influence SVR and hence blood pressure. In addition, nNOS in the brain, 
kidneys and myocardium could also affect blood pressure. This study aimed to 
examine the hypothesis that nNOS systemically regulates blood pressure in man using 
the specific nNOS inhibitor SMTC and measuring changes in CO, blood pressure and 
SVR. This would establish if some or all of the effects previously attributed to eNOS 
are in fact due to nNOS. SMTC had been given locally via the intra-brachial and intra-
coronary routes but not in doses that would have a systemic effect. Hence this would 
be a first-in-man study of the effects of systemic nNOS-specific inhibition on 
haemodynamics.  
 
5.1.1 Study aims 
 
The aim of the proposed study was to establish the effects of acute systemic inhibition 
of nNOS with SMTC on the regulation of systemic haemodynamics, i.e. SVR, CO, 













The studies were approved by the local research ethics committee (St.Thomas’ 
Hospital). Healthy male volunteers were recruited from a list of suitable subjects who 
had participated in previous departmental studies, as described in chapter 2.  
 
5.2.1 SMTC Dosing 
 
SMTC 0.2 µmol/min produces a similar reduction in FBF to that achieved by 
LNMMA 2 µmol/min (Seddon et al 2008) and is therefore approximately 10 times 
more potent than LNMMA to increase forearm resistance. Hence, we assumed that the 
dose of SMTC required to achieve systemic effects would be approximately 10 times 
more potent than L-NMMA. We wanted to establish a dose of SMTC which produces 
a 30 to 40 % increase in SVR as this is what is observed with similar studies using 
systemic L-NMMA. L-NMMA at 12-24 µmol/Kg (3-6 mg/Kg) (bolus dose over 5 
min) gives a 20-40 % increase in SVR, an effect which is maximal within 10 to 15 min 
after the start of the infusion (Brett et al., 1998; Haynes et al., 1993). We therefore 
expected a SMTC dose of 1.2-2.4 µmol/Kg to produce the same increase in SVR. 
 
We calculated the total SMTC dose that we had already given in forearm and coronary 
studies to establish a safe starting point for a rising single dose study. The maximum 
dose administered in forearm studies is 0.2 µmol/min x ~20 min study = 4 µmol. 
Maximum dose in coronary studies is 0.625 µmol/min x ~12 min study = 7.5 µmol. 
We chose a starting dose which would be similar to the dose that we had already 
given, and hence started with 0.1 µmol/Kg to be given as a bolus over 10 min, which 
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for an average 70 Kg man would be a total systemic dose of 7 µmol. Doses were first 
administered in a rising single dose study and the regimen for the study was SMTC 
0.1, 0.3, 1.0, 3.0 µmol/Kg and placebo on separate occasions (a subject would attend 
on five separate occasions), with placebo randomised in relation to the rising dose 
schedule, stopping when we established a dose with a 30-40 % increase in SVR. 
  
5.2.2 Protocol 1: dose response study 
 
Participants were asked to abstain from caffeine for at least 12 hours before the 
studies. Subjects attended study days at least 1 week apart. The subjects also attended 
for safety blood checks (FBC, renal and liver profiles) 3 to 5 days after the study.  
 
Studies were undertaken in a quiet temperature-controlled vascular laboratory (23 °C 
to 25 °C) after at least 30 min of rest. A 16-gauge intravenous cannula was inserted 
into the ante-cubital fossa. An ECG was recorded and then baseline measurements 
were taken. HR and BP were measured using a standard oscillometric method (Omron 
705CP) and according to established guidelines (O'Brien et al., 2003), and left 
ventricular SV was measured using 2D trans-thoracic echocardiography as described 
in chapter 2. CO was calculated as SV multiplied by the HR, and SVR was calculated 
as MAP/CO. SMTC (0.1, 0.3, 1.0, and 3.0 µmol/Kg), in rising doses according to 
visit, was given by intravenous infusion over 5 min. HR and BP was recorded at 0, 5 
and 10 min after completion of SMTC infusion. At 15 min HR, BP and SV were 
measured. All these measurements were repeated at 30 min after infusion, and then 
every 30 min for a total of 3 hours to ensure values had returned to baseline. At the 
end of the study an ECG was recorded (Figure 5.1). 
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Figure 5.1: Schematic of study protocol. Measurement were made at baseline and 
then after infusion of IV SMTC.  
SMTC
HR, BP onlyHR, BP, 
ECHO
0 5 10 15 9060 12030 180 min150Baseline (2) 
 
5.2.3 Protocol 2: randomised crossover study 
 
The protocol was altered to undertake a randomised crossover study with blinded 
haemodynamic assessment in which the highest dose of SMTC achieved from 
protocol 1 or saline vehicle were infused on separate occasions (2 visits per subject) 
(Figure 5.6). The dose of SMTC used was the dose found to produce an increase in 
SVR of about 30-40 %. BP and HR were measured by an oscillometric method as 
before and SV was measured using 3D echocardiography to allow for more accurate 
assessment, as described in chapter 2.  
 
To assess whether this dose of SMTC was affecting eNOS, brachial FMD was 
measured, as described in chapter 2. Again, CO was calculated as the SV multiplied 
by the HR, and SVR as MAP/CO. Measurement of HR, BP and SV were made at 
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baseline and then at 0 min and 30 min after the end of infusion.  FMD was measured 
at baseline and then again after SMTC infusion, immediately after HR, BP and 
echocardiography measurements at 0 min were completed.  
 
Figure 5.2: Schematic of protocol 2. 
SMTC
HR, BPHR, BP, ECHO




5.2.4 Statistical analysis 
 
Data were summarized as mean ± standard error of the mean (s.e.m.). Changes in HR 
and BP were expressed as the absolute changes in bpm and mmHg from baseline 
respectively. Changes in SV, CO and SVR were expressed as percentage changes from 
baseline. Effects of SMTC on the haemodynamic responses were analysed by paired t-
tests or ANOVA for repeated measures as appropriate. All tests were two-tailed and 





5.3.1 Protocol 1: dose response study 
 
Nine healthy male subjects aged 21.1±0.87 years were studied. The baseline 
characteristics are shown in table 5.1. 
 
Table 5.1: Baseline characteristics of the subjects in protocol 1 (dose response study).  
 
Healthy male volunteers (n=9) 
 
Age (years)     21.1±0.87 
Systolic blood pressure (mmHg)  127.3±2.87 
Diastolic blood pressure (mmHg)  74.2±2.98 
Height (m)     1.80±0.02 
Weight (kg)     77.8±4.65 




No subjects had any changes in biochemical or haematological profiles after infusion 
of SMTC. The SMTC had to be infused over ~10 min rather than 5 min due to mild 
irritation felt by a few subjects during infusion, especially at the higher doses (due to 
the pH of the SMTC solution which was lower with each increase in dose). This 
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irritation would cease as soon as the SMTC was stopped. The longer infusion time and 
using a large vein in the ante-cubital fossa resolved this issue. There were no other 
adverse effects. 
 
After the first 3 subjects we analysed the data to assess whether the SMTC was having 
any effect at the doses studied. The first 3 subjects received SMTC 0.1, 0.3, 1.0 and 
3.0 µmol/Kg and placebo. Unfortunately one of the subjects withdrew from the study 
before completion (personal reasons not related to the study) and only received SMTC 
0.1, 0.3, 1.0 µmol/Kg (did not receive SMTC 3.0µmol/Kg or placebo). 
 
The 2 lower doses of SMTC (0.1 and 0.3µmol/Kg) did not appear to affect BP, 
whereas the higher doses (1.0 and 3.0µmol/Kg) did, especially DBP and MAP (Figure 
5.2). This was expected to be the case as the lowest dose of SMTC was equivalent to 
what has been given in the coronary studies and had no effect on BP. For the next 6 
subjects the dosing schedule was changed to SMTC 1.0, 3.0 µmol/Kg and placebo (3 









Figure 5.3: Review after 3 subjects. Change in SBP, DBP and MAP at different doses 
of SMTC (placebo, 0.1, 0.3, 1.0, 3.0 µmol/Kg)  for the first 3 subjects at (A) 0 min (B) 
5 min (C) 10 min (D) 15 min after the end of infusion. There appears to be an increase 
in DBP and MAP at the higher doses of SMTC, which appears greater the earlier it is 
after the completion of SMTC infusion. 
 
 










































































































































A total of 9 subjects therefore had SMTC infused at 1.0 and 3.0 µmol/Kg. No subjects 
had any changes in biochemical or haematological profiles after infusion of SMTC. 
The SMTC was infused over ~10 min through a large vein in the ante-cubital fossa to 
minimise local irritation. There were no other adverse effects. 
 
When compared to placebo, SMTC significantly decreased HR, increased DBP and 
MAP, decreased SV and CO, and increased SVR from baseline in a dose-dependent 
manner. There was no effect on SBP. The maximum effect on HR and BP was 
immediately after the end of SMTC infusion, i.e. 0 min (Figure 5.4). At 0 min, when 
compared to placebo, SMTC 3.0 µmol/Kg significantly decreased HR from baseline 
by 7.72±1.46 bpm (-10.2±1.37 during SMTC vs -2.47±0.94 bpm during placebo; n=8, 
P<0.01), increased DBP by 5.78±1.13 mmHg (6.56±0.44 vs 0.78±1.08 mmHg; n=8, 
P<0.01) and increased MAP by 4.11±1.05 mmHg (4.18±0.61 vs 0.06±1.09 mmHg; 
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Figure 5.4 (next page): The effect of SMTC 1.0 and 3.0 µmol/Kg on HR, SBP, DBP 
and MAP at (A) 0 min (B) 15 min after the end of infusion. SMTC increases HR, 
decreases DBP and decreases MAP in a dose-dependent manner, with greater effect 
earlier after the end of the infusion. *P<0.05 for HR at 0 min SMTC 1.0 µmol/Kg vs 
placebo; and for DBP at 15 min SMTC 3.0 µmol/Kg vs placebo. **P<0.01 for HR at 0 
and 15 min SMTC 3.0 µmol/Kg vs placebo; for DBP at 0min SMTC 3.0 µmol/Kg vs 
placebo; and MAP at 0 min SMTC 3.0 µ mol/Kg vs placebo. 
+P<0.05 for HR at 15 min SMTC 3.0 µmol/Kg vs SMTC 1.0µmol/Kg; for DBP at 
0min SMTC 3.0 µmol/Kg vs SMTC 1.0 µmol/Kg; and for MAP at 0 min SMTC 3.0 


















At 15min post SMTC, the first set of readings were taken of SV using 2D 
echocardiography. This was only carried out on the final 6 subjects in this study. In 
one subject the echocardiogram for the visit in which SMTC 1 µmol/Kg was infused 
could not be analysed due to technical reasons. When compared to placebo, SMTC 3.0 
µmol/Kg significantly decreased SV by 17.2±4.40 % (-13.1±1.85 vs 4.14±3.18 %; 
n=6, P<0.05), decreased CO by 24.7±5.99 % (-21.9±1.70 vs 2.86±5.16 %; n=6, 
P<0.01) and increased SVR by 33.8±6.28 % (30.5±2.65 vs -3.28±5.27 %; n=6, 


















Figure 5.5: The effect of SMTC 1.0 and 3.0 µmol/Kg on SV, CO and SVR at 15 min 
after the end of infusion. SMTC significantly decreased SV, decreased CO, and 
increased SVR in a dose-dependent manner. 
*P<0.05 for SV SMTC 3.0 µmol/Kg vs placebo.  
**P<0.01 CO and SVR SMTC 3.0 µmol/Kg vs placebo. 










The effect of SMTC decreased with time and at 60 min after the end of the infusion, 
SMTC 3.0 µmol/Kg no longer had an effect on any of the haemodynamic parameters 
when compared to placebo (Figure 5.6). 
 
Figure 5.6: The effect of SMTC 3.0 µmol/Kg 0 to 60 min after the end of infusion for 
(A) HR (B) BP (C) SV and CO (D)  SVR. By 60 min SMTC 3.0 µmol/Kg no longer 
had any effect on any of the systemic haemodynamics when compared to placebo. 





















































































































































































































5.3.2 Protocol 2: randomised crossover study 
 
Eight healthy male subjects aged 27.8±2.22 years were studied. The baseline 
characteristics are shown in table 5.2. The above results suggested that the peak action 
of SMTC is at 0 min after the end of infusion rather than at 10-15 min. This likely 
represents the longer infusion time of the SMTC when compared to studies using L-
NMMA, usually given over 3-5 min and producing a maximum effect at ~15 min after 
the start of the infusion (Brett et al., 1998). The protocol was altered for the next 8 
subjects and we undertook a randomised crossover study with blinded haemodynamic 
assessment in which the highest dose of SMTC (3.0 µmol/Kg over 10 min) or saline 
vehicle was infused on separate occasions (2 visits per subject) (Figure 5.2). The dose 
of SMTC used was the dose found in protocol 1 to produce an increase in SVR of 
about 30-40%. FMD was measured at baseline and then again after SMTC infusion, 
immediately after HR, BP and echocardiography measurements at 0 min were 
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completed. This was at about 10-15 min after the end of infusion, which from the 
results in protocol 1 showed that at this point SMTC 3.0 µmol/Kg increased SVR by 
~34% from baseline when compared to placebo. Blood samples for SMTC 
concentration were also collected from the subjects. These were taken at baseline 
(before SMTC infusion), at 20 min after SMTC (immediately after all measurements 
including FMD had been completed), and at 60 min after SMTC. These samples were 
sent to a mass spectrometry facilty for measurement of SMTC concentration. 
 
Table 5.2: Baseline characteristics of the subjects in protocol 2 (randomised crossover 
study).  
 
Healthy male volunteers (n=8) 
 
Age (years)     27.8±2.22 
Systolic blood pressure (mmHg)  128.8±2.40 
Diastolic blood pressure (mmHg)  77.9±2.86 
Height (m)     1.77±0.02 
Weight (kg)     73.1±3.81 
Body Mass Index (kg/m2)   23.3±0.99 
 
 
There were no changes in haematological or biochemical profiles and no adverse 
reactions. All 8 subjects had HR, BP and FMD data (n=8) but for one subject the 
echocardiography data could not be used due to technical reasons (n=7). Left 
ventricular stroke work (SW) was also calculated, as SV multiplied by MAP.  
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5.3.2.1 Time point: 0 min after end of infusion 
 
When compared to placebo, SMTC 3.0 µmol/Kg reduced HR by 6.10±1.38 bpm (-
9.16±1.29 vs -3.06±0.72 bpm; n=8, P<0.01), increased DBP by 9.72±1.78 mmHg 
(9.75±1.52 vs 0.03±0.95 mmHg; n=8, P<0.001), increased MAP by 7.37±1.70 mmHg 
(7.52±1.25mmHg vs 0.15±0.91 mmHg ; n=8, P<0.01), decreased SV by 14.0±3.23% 
(-6.78±5.63 vs 7.19±4.20 %; n=7, P<0.01), reduced CO by 22.8±2.5 % (-21.4±5.94 vs 
1.41±4.34 %; n=7, P<0.001), and increased SVR by 42.2±6.4 % (42.3±10.1 vs 
0.10±4.84 %; n=7, P<0.001). SMTC did not significantly change SBP (3.06±1.79 vs 

















Figure 5.7: The effect of SMTC 3.0 µmol/Kg in study 2 at 0 min after the end of 
infusion, on (A) HR (B) BP (C) SV and CO (D) SVR. SMTC decreased HR, SV and 
CO; and increased DBP, MAP and SVR. SMTC did not affect SBP. *P<0.01, 
























SMTC 3.0 µmol/Kg had no significant affect on FMD (6.24±1.50 to 6.84±1.41 %; 
n=8, P=NS). In the placebo study FMD did not change either (7.03±1.07 to 7.07±0.91 
%; n=8, P=NS) (Figure 5.8). 
 
Figure 5.8: The effect of SMTC 3.0 µmol/Kg on FMD. (A) SMTC did not affect 


























Using 3D echocardiography we also calculated the left ventricular EF. SMTC 3.0 
µmol/Kg had no significant affect on EF, which did not change in the placebo study 
either. There was also no difference in the change in EF when comparing SMTC to 
placebo (SMTC: 56.2±0.31 to 52.7±3.29 %, Placebo: 56.2±1.10 to 55.9±1.16 %, n=7, 
P=NS for both; ΔEF SMTC vs placebo, n=7, P=NS) (Figure 5.9). 
 
Figure 5.9: The effect of SMTC 3.0 µmol/Kg on left ventricular ejection fraction. (A) 











5.3.2.2 Time point: 30 min after end of infusion 
 
At 30 min after SMTC infusion, when compared to placebo, SMTC no longer had an 
effect on HR (-2.84±1.25 vs -2.88±1.40 bpm; n=8, P=NS), SBP (0.50±1.64 vs -
0.88±1.23 mmHg; n=8, P=NS), DBP (2.31±1.85 vs 3.34±1.08 mmHg; n=8, P=NS) or  
MAP (1.71±1.65 vs 1.94±0.88 mmHg; n=8, P=NS). Although not statistically 
significant, there was a trend suggesting that when compared to placebo, SMTC still 
reduced SV by 16.13±10.39 % (0.11±5.94 vs 16.3±6.72 %; n=7, P=NS), reduced CO 
by 16.6±10.6 % (-5.60±6.30 vs 10.9±6.42 %; n=7, P=NS), and increased SVR by 
15.8±10.8 % (10.3±7.82 vs -5.49±5.08 %; n=7, P=NS).  
 
When compared to placebo, SMTC did not significantly change EF (SMTC: 
56.2±0.31 to 57.6±2.79 %, Placebo: 56.2±1.10 to 57.5±2.06 %, n=7, P=NS for both; 
ΔEF SMTC vs placebo, n=7, P=NS). 
 
5.3.2.3 Time point: 60 and 120 min after end of infusion 
 
At 60 min after SMTC infusion, when compared to placebo, SMTC no longer had an 
effect on HR (-3.59±1.20 vs -4.06±1.18 bpm; n=8, P=NS), SBP (4.81±1.94 vs 
4.38±1.63 mmHg; n=8, P=NS), DBP (5.63±1.92 vs 4.41±1.73 mmHg; n=8, P=NS) or  
MAP (5.35±1.69 vs 4.40±1.27 mmHg; n=8, P=NS). At the end of the study, subjects 
were asked to wait in the patient lounge and were reviewed again at 120min after 
infusion, to ensure there were no adverse reactions and to repeat measurements of HR 
and BP. When compared to placebo, SMTC had no effect on HR, SBP, DBP or MAP 
at this stage either (Figure 5.10). 
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Figure 5.10: The effect of SMTC 3.0 µmol/Kg 0 to 120 min after the end of infusion 
for (A) HR (B) BP (C) SV and CO (D) SVR (E) SW. By 30 min SMTC 3.0 µmol/Kg 
no longer had any effect when compared to placebo. **P<0.001, *P<0.01 (SMTC 3.0 















































































































































































































































5.3.2.4 Serum SMTC concentration 
 
SMTC was not detected in the blood of any subjects prior to SMTC infusion. SMTC 
80.5±10.8 ng/mL was detected in the serum at 20 min after SMTC. This is a SMTC 
concentration of 0.29 µM. SMTC concentration of approximately 10 µM is optimal 
for inhibition of nNOS-mediated responses without affecting the eNOS-mediated 
response to ACh, when infused intra-arterially in animals in vivo (Cervenka et al., 
2001; Ichihara et al., 1998), therefore these concentrations of SMTC are unlikely to 
inhibit eNOS.  
 
The concentration decreased to 22.8±3.87 ng/mL at 60 min (p<0.001 SMTC 
concentrations at 20 min vs 60 min) (Figure 5.11). This is consistent with the above 














Figure 5.11: Serum SMTC concentration after the end of infusion. *P<0.001 SMTC 
concentration at 20 min vs 60 min. 

































Previously, first-in-human studies from our group with the nNOS-selective inhibitor 
SMTC showed that the basal regulation of vascular tone in both the forearm and 
coronary circulations is mediated by nNOS whereas eNOS mediates relaxant 
responses to pharmacological and shear stress stimuli (Seddon et al., 2009; Seddon et 
al., 2008). We have now carried out first-in-human studies investigating the effects of 
systemic nNOS-selective inhibition with SMTC. Systemic SMTC has previously been 
shown to increase blood pressure in rats in vivo (Gozal et al., 1996b; Komers et al., 
2000; Wakefield et al., 2003), as has the nNOS-selective inhibitor 7-NI (Ollerstam et 
al., 1997; Xu et al., 2000).  
 
In our study, SMTC increased DBP and SVR in a dose-dependent manner with the 
highest dose used of 3 µmol/Kg increasing SVR by 42.2±6.4 %. SMTC also caused a 
reduction in HR, SV and CO. These results are similar to what has previously been 
shown with systemic non-selective NOS inhibition with L-NMMA (Brett et al., 1998; 
Brillante et al., 2009; Hansen et al., 1994b; Haynes et al., 1993; Kiely et al., 1998; 
Stamler et al., 1994), and imply that the effects that have previously been attributed to 
eNOS are likely to be largely mediated through nNOS. In support of this is our finding 
that there was no effect of SMTC on FMD, which suggests that there was no inhibition 
of eNOS activity at the dose studied. Our maximum dose of SMTC was also up to 8 
times smaller than the dose of L-NMMA causing similar haemodynamic effects (Brett 
et al., 1998), an approximate dose ratio which has been shown to be nNOS-selective in 




Among the first to use systemic L-NMMA in humans were Haynes and colleagues 
(Haynes et al., 1993), who found that 3 mg/kg L-NMMA infused systemically over 5 
min produced an increase in DBP of 7.1 mmHg and in MAP of 6.9 mmHg, with a 
decrease in HR of 14 bpm, when compared to placebo, at about 10-15 min after start 
of infusion. There was no significant increase in SBP in their study. Using a non-
invasive bioimpedance method to calculate CO, they found that cardiac index 
decreased by 25±4 % and SVR increased by 46±12 % (Haynes et al., 1993). Stamler 
and colleagues used invasive measurement of blood pressure and cardiac output (Fick 
method) in response to 3 mg/Kg L-NMMA over 3 min. They found a 15.5±1.3 % 
increase in MAP and a 63.4±8.2 % increase in SVR (Stamler et al., 1994). Both 
groups supported the notion that through regulation of local vascular tone, NO 
influences SVR and hence blood pressure.  
 
It is possible that the increase in blood pressure initiates a baroreceptor reflex resulting 
in withdrawal of sympathetic efferent activity and augmentation of vagal activity, 
causing a decrease in HR and CO (Bredt et al., 1990; Chowdhary et al., 2000; 
Schindler et al., 2004; Zanzinger, 1999) . Stamler and colleagues suggested that the 
effects of L-NMMA on cardiac function cannot be explained solely by the increase in 
blood pressure as similar changes in blood pressure with phenylephrine (a control 
vasoconstrictor) did not cause an equivalent decrease in CO (Stamler et al., 1994). 
Some animal studies have also shown such effects, for example in dogs (Harrison et 
al., 2000). However it must be noted that phenylephrine may have direct cardiac 
effects (as a positive inotrope) in addition to being a vasoconstrictor. Hansen and 
colleagues found that L-NMMA infused systemically increased MAP by 10±2 mmHg 
and found a reduction in HR and sympathetic nerve activity (measured using 
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microneurography), but these reflex changes were not different to those evoked by a 
phenylephrine-induced increase in blood pressure, suggesting that NO is not involved 
in the attenuation of sympathetic outflow (Hansen et al., 1994a). Charkoudian and 
colleagues also had similar findings, including no difference in the reflex changes in 
muscle sympathetic nerve activity with systemic L-NMMA between subjects with 
high or low baseline sympathetic nerve activity, and concluded that differences in 
baroreflex control of the peripheral circulation were not major contributors to the 
different pressor responses between those two groups (Charkoudian et al., 2006). 
These studies along with some others (Brillante et al., 2009; Cui et al., 2003) go 
against a major role for NO in central inhibition of sympathetic efferent activity in 
humans. However others have found a role for NO, with one study showing L-NMMA 
induced sympathetic activation was masked by an inhibitory effect of arterial 
baroreflexes indicating that NO is involved in the central regulation of sympathetic 
outflow in humans (Owlya et al., 1997). Separate from this issue is the question as to 
whether the hypertensive effect of SMTC might be mediated centrally. Since HR fell 
(rather than increase) after SMTC, this appears unlikely. It is theoretically also 
possible that the increase in SVR after SMTC could involve changes in renal renin-
angiotensin-aldosterone activity. This requires further study. 
 
The most straight forward explanation for the decrease in SV and CO with SMTC 
would be that this was due to the increase in SVR (increased afterload). However, it is 
also possible that there might be a direct cardiac effect of SMTC and that the decrease 
in CO with systemic nNOS inhibiton may have a multifactorial basis. nNOS-derived 
NO has a direct effect on the myocardium, it being well established that nNOS is also 
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located in the cardiac myocytes (Xu et al., 1999) as well as the vessel wall (Kavdia 
and Popel, 2004) and the peripheral nerves (Toda and Okamura, 2003).  
 
The effect of NO on cardiac contraction has been extensively studied. In the heart, 
eNOS is mostly found in coronary vascular and endocardial endothelial cells and to a 
lesser extent in the sarcolemma of cardiac myocytes (Carnicer et al., 2013; Feron et 
al., 1996). eNOS found in coronary vascular endothelial cells exert paracrine effects 
on myocardial contraction (Seddon et al., 2007). nNOS is found in the sacroplasmic 
reticulum of cardiac myocytes, as well as in cardiac autonomic nerves and ganglia 
(Danson et al., 2005; Xu et al., 1999). The autocrine effects of nNOS appear to include 
the modulation of basal inotropic state, β-adrenergic responsiveness, and the force-
frequency relationship (reviewed in (Seddon et al., 2007). Stimulation of NO from 
eNOS or nNOS can modulate LV function, particularly diastolic function, and NO has 
been shown to inhibit myocardial sympathetic (β-adrenergic) responses (Shah and 
MacCarthy, 2000). NOS inhibition reduces the positive inotropic effect of NO in 
cardiac muscle (Rassaf et al., 2006) and Prendergast and colleagues found that NO 
augments the Frank-Starling response by increasing LV compliance in the isolated 
heart (Prendergast et al., 1997) which occurs for both human and animal models 
(Paulus and Shah, 1999). It may be that this effect is mediated through nNOS-derived 
NO as nNOS deficient animals have been shown to have impaired ventricular 
relaxation (Ashley et al., 2002; Gyurko et al., 2000; Sears et al., 2003). Some of these 
studies at the same time however found that basal contractility was enhanced, 
consistent with nNOS-derived NO causing an increased calcium content and greater 
contraction (Ashley et al., 2002; Sears et al., 2003). Studies on LV myocytes of nNOS 
deficient mice or with nNOS inhibition showed an enhanced inotropic response to 
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isoproterenol in LV myocytes, suggesting that the myocardial source of NO involved 
in the autocrine regulation of β-adrenergic responses may be nNOS. It is possible that 
the disruption of the nNOS gene is not myocardial-specific, and these mice have been 
shown to have impaired vagal control of heart rate and an elevated basal sympathetic 
nerve activity (Choate et al., 2001; Jumrussirikul et al., 1998) which may contribute to 
the enhanced basal inotropy and the discrepancy between data from in vivo mice 
(Casadei, 2006), which have been shown to produce a smaller inotropic response when 
compared to wild type mice (Barouch et al., 2002; Dawson et al., 2005).  
 
In the current study, we found no significant effect of SMTC on LV EF or SW. 
Although more detailed measurements of cardiac function, for example by pressure-
volume analysis, would be needed to precisely assess whether systemic SMTC had a 
direct effect on cardiac contractility, the lack of change in LV SW argues against this 
possibility. It therefore seems likely that the major driver of the reduction in cardiac 
output may actually be the increase in SVR.  
 
5.4.1 Heart rate 
 
We found that SMTC reduced heart rate. This may have been secondary to the 
hypertensive effects of nNOS inhibiton or may even have been a primary effect. 
Inhibiton of NOS has been shown to have modest bradycardic effects (Pabla and 
Curtis, 1995) and NO donors elicit a positive chronotropic effect in vitro (Musialek et 
al., 1997) and in vivo in animals (Hogan et al., 1999a) and humans (Hogan et al., 
1999b).  NO is thought to have an important role in the autonomic control of heart rate 
and this is likely to be nNOS-mediated. As mentioned, nNOS deficient mice have 
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impaired vagal control of heart rate (Choate et al., 2001; Jumrussirikul et al., 1998). 
Exercise training induced bradycardia in mice is related to upregulation of nNOS 
(Danson and Paterson, 2003) and nNOS buffers the increase in heart rate by 
sympathetic nerve stimulation in rabbits and guinea pigs (Sears et al., 1998). nNOS is 
also localized in intrinsic cardiac vagal neurons and stellate sympathetic ganglia 
innervating the sino-atrial node (Herring et al., 2002; Herring and Paterson, 2009). In 
humans, heart rate increases when systemic L-NMMA is infused with atropine 
(cholinergic blockade), rather than decreases (L-NMMA alone), and this is abolished 
by propranolol suggesting this effect is sympathetically mediated (Lepori et al., 2001; 
Sartori et al., 2005).  
 
5.4.2 Coronary flow 
 
NO also plays a significant role in the regulation of coronary vascular tone. It could 
also well be possible that the reduction in coronary blood flow seen with NOS 
inhibition produces a negative inotropic effect, and that this contributes to the 
reduction in CO. This has been demonstrated in isolated rat hearts (Amrani et al., 
1992), as well as in humans in vivo (Cotton et al., 2001). However, in our study we did 
not find any signs of coronary ischaemia clinically or on the subjects’ ECG, nor did 
SMTC effect cardiac left ventricular EF or SW. It is therefore unlikely that changes in 







5.4.3 Study limitations 
 
Again, our results pertain to healthy men and cannot be extrapolated to women or 
subjects with cardiovascular risk factors. Due to the limited sample size we cannot 
exclude a small effect of nNOS to directly reduce cardiac function. This requires 
further investigation which could be carried out in a cardiac catheterisation suite 
model with pressure-volume analysis of human left ventricular function.  
 
SMTC has relatively high specificity for nNOS and to be sure that SMTC was acting 
specifically on nNOS, we measured FMD, an effect mediated through eNOS. 
However, should more specific inhibitors of nNOS become available for human use it 




In these studies, for the first time in humans we used systemic infusion of SMTC in 
healthy male volunteers to investigate its effects on systemic haemodynamics in vivo. 
We found that nNOS inhibition produces an increase in SVR and DBP, with a 
reduction in HR and CO which was previously noted with systemic non-selective NOS 
inhibition with L-NMMA. This suggests a role for nNOS in the regulation of human 










6.1 GENERAL DISCUSSION 
 
In a series of experiments, this thesis aimed to investigate the role of nNOS-derived 
NO in the regulation of skeletal blood flow during exercise and myocardial blood flow 
during increased cardiac workload. At a systemic level, the role of nNOS-derived NO 
on blood pressure and haemodynamics was investigated. 
 
6.1.1 Skeletal blood flow 
 
In the experiments in chapter 3, I used non-selective and selective NOS inhibitors to 
determine the role of eNOS-derived and nNOS-derived NO in opposing an increase in 
sympathetically mediated increase in arteriolar tone in the human forearm during 
handgrip exercise. In further experiments, I investigated the role of eNOS and nNOS-
derived NO during reflex sympathetic activation using LBNP +/- handgrip exercise. 
Experimental data from animals and indirect human studies had suggested that local 
nNOS-derived NO played an important role in counteracting reflex sympathetic 
vasoconstriction or contributed to “functional sympatholysis” (the local attenuation of 
sympathetic vasoconstriction) in the exercising muscle (Sander et al., 2000; Thomas et 
al., 1998; Thomas and Victor, 1998). We found that despite reducing basal FBF, intra-
brachial L-NMMA or SMTC had no significant effect on the increase in FBF or 
178 
 
conduit artery diameter induced by local handgrip exercise. Furthermore, even in the 
face of increased sympathetic stimulation with LBNP, we found no significant effect 
of either L-NMMA or SMTC on the FBF response to exercise. Human studies with L-
NMMA have not been consistent in demonstrating a role for NO in functional 
sympatholysis (Dinenno and Joyner, 2003) and our results concur with these findings.  
 
These experiments do not exclude a role for nNOS in exercising muscle. It has been 
demonstrated that nNOS is abundant in the skeletal muscle (Nakane et al., 1993). 
Exercise induced reflex sympathetic activation may limit skeletal muscle performance 
by a direct effect on muscle energetics. α and β adrenergic stimulation could adversely 
affect muscle efficiency and impair performance by stimulating glycogenolysis and 
lactate production (Richter et al., 1982). In humans, sympathetic denervation produces 
important changes in the bioenergetics of the working muscle i.e. it attenuates 
exercise-induced muscle acidification and causes significant reduction in PCr 
depletion and ADP concentration. These changes are associated with a significantly 
reduced pressor response to exercise (Kardos et al., 2000). It may well be that nNOS is 
involved in this process. Future studies could involve nNOS-selective inhibition with 
SMTC whilst measuring muscle bioenergetics using magnetic resonance spectroscopy. 
This technique records signals from high-energy phosphate compounds which are 
central to energy metabolism in vivo. In normal exercising muscle, the hydrolysis of 
ATP releases the energy necessary for the sliding between myosin and actin proteins, 
the basis of muscle contraction (Mattei et al., 2004). Different indices are used to 
illustrate energetics and include the rate of PCr decrease, drop of pH, initial rate of 




6.1.2 Myocardial blood flow 
 
In the experiments in chapter 4, I investigated the relative contribution of eNOS- and 
nNOS-derived NO in the regulation of coronary epicardial and microvascular tone in a 
cardiac catheter laboratory model of increasing metabolic demand as achieved through 
incremental cardiac pacing. I found that the pacing induced increase in CBF and 
coronary artery diameter and decrease in CVR was blunted by L-NMMA but not so by 
SMTC. Pacing likely induces a flow mediated dilatation in the coronary arteries which 
is regulated by eNOS rather than nNOS, as is the shear stress response in the forearm 
(Seddon et al., 2009). This effect is consistent with many studies in which L-NMMA 
attenuated the pacing induced coronary vasodilatation in humans (Quyyumi et al., 
1995a). 
 
Our study did not examine the association between nNOS and autonomic mediated 
changes in metabolic demand in the heart as seen during exercise or mental stress. 
Seddon and colleagues showed that mental stress-induced vasodilatation in the 
forearm is significantly attenuated by selective inhibition of nNOS, strongly 
suggesting a role for local nNOS-derived NO in regulation of microvascular tone 
during mental stress (Seddon et al., 2008). Whereas the above study was undertaken in 
the forearm, the effects of mental stress on the coronary circulation may be more 
relevant from a clinical viewpoint.  
 
In healthy individuals and subjects with angiographically normal coronary arteries, 
mental stress increases myocardial blood flow through vasodilatation of resistance 
vessels (Schoder et al., 2000b). This ensures that myocardial blood supply matches the 
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rise in oxygen demand induced by stress-driven increases in heart rate, blood pressure 
and myocardial contractility. Mental stress as encountered in daily life or under 
controlled conditions may contribute to myocardial ischaemia (Krantz et al., 1996). 
This may account for the increased risk of adverse cardiovascular events (such as 
myocardial infarction) associated with mental stress (Jiang et al., 1996; Krantz et al., 
1999). Coronary artery disease is known to reduce the bioavailability of NO by direct 
and indirect action on eNOS, however, the influence on nNOS, which may play an 
important role in regulation of mental stress-induced change in vascular blood flow, 
remains unclear. Schoder and colleagues demonstrated that in comparison to healthy 
volunteers, patients with coronary artery disease had a significantly smaller increase in 
CBF in response to mental stress (Schoder et al., 2000a).  
 
Future studies could examine the role of nNOS in regulation of CBF in response to 
mental stress in normal coronary arteries and in those with cardiovascular risk factors 
or established coronary artery disease. 
 
6.1.3 Systemic haemodynamics 
 
In chapter 5, first-in-man experiments were carried out using systemic infusion of 
SMTC to selectively inhibit nNOS and investigate the effects on systemic 
haemodynamics. Seddon and colleagues had found, using intra-brachial and intra-
coronary infusion of SMTC, that nNOS in involved in the basal regulation of 
peripheral vascular resistance both in the forearm (Seddon et al., 2008) and coronary 
(Seddon et al., 2009) circulations. We found that intravenous SMTC increased SVR 
and blood pressure, whilst SV, CO and heart rate were reduced. Importantly, there was 
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no effect on FMD, an effect mediated by eNOS. The effects of this dose of SMTC, 
which we first established in a rising dose response study, were similar to those seen in 
many previous studies in human’s in vivo using non-selective NOS inhibition (Haynes 
et al., 1993; Stamler et al., 1994), which raises the question of whether the effects of 
NO on basal haemodynamics are attributable to nNOS rather than eNOS.  
 
We raised the question of whether the increase in blood pressure seen with systemic 
SMTC may not be only due to the effect on the resistance vessels. Indeed, nNOS is 
also found in the nervous system, where centrally it affects blood pressure, and the 
kidneys, from which activation of the renin-angiotensin-aldosterone system is 
important in the regulation of blood pressure. The decrease in cardiac output may well 
be multifactorial and not only due to a baroreceptor reflex response to increased 
peripheral vascular resistance, but a primary myocardial effect. NO has both autocrine 
effects on the heart from the myocyte itself, and paracrine effects from the endothelial 
cells and nerves. nNOS may play a role via both of these as it is expressed in the 
myocyte (Xu et al., 1999) and neuronal tissue (Shah and MacCarthy, 2000). However, 
we found no significant effect of SMTC on LV EF or SW. It therefore seems likely 
that the major driver of the reduction in cardiac output may actually be the increase in 
SVR.  
 
6.2 CLINICAL IMPLICATIONS 
 
The results in this thesis may have potential clinical implications. The hallmark of 
essential hypertension is an increase in peripheral vascular resistance. However, eNOS 
stimulated responses have been shown to be relatively preserved in essential 
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hypertension compared to other risk factors for cardiovascular disease, such as 
diabetes and hypercholesterolaemia (Celermajer et al., 1992; Chowienczyk et al., 
1992). Our findings provide a potential explanation for this discrepancy, and raises the 
important question of whether it is indeed nNOS dysfunction that is the primary 
abnormality in hypertension. It may be that this is compensated for by increased 
expression/activity of eNOS, which could explain the relatively preserved eNOS 
responses seen in hypertension. Such compensatory activity of NOS isoforms is well 
recognized in eNOS knock-out mice where nNOS may compensate for absence of 
eNOS (Huang et al., 2002; Meng et al., 1998). Future studies could involve nNOS-
selective inhibition with SMTC in patients with hypertension, with the hypothesis that 
they will reveal a diminished vasoconstrictor response compared to healthy volunteers. 
 
Another clinical scenario where nNOS may be fundamental is heart failure. nNOS is 
widely found in the cardiac myocytes (Xu et al., 1999) and it has been shown to act as 
a major modulator of cardiac function and intracellular calcium fluxes (Ashley et al., 
2002; Sears et al., 2003). In addition to its effects in the myocyte, it also acts as a 
modulator of the autonomic control of the cardiovascular system (Herring and 
Paterson, 2009). Patients with heart failure have a decreased vasomotor response to 
intra-coronary L-NMMA suggesting that basal release of NO in the coronary 
circulation is decreased in patients with heart failure (Mohri et al., 1997), an effect 
which is now believed to be mediated by nNOS (Seddon et al., 2009). Furthermore 
patients with congestive heart failure had enhanced inotropic response to β-adrenergic 
agonists after intra-coronary L-NMMA (Hare et al., 1998). Intracoronary L-NMMA 
also reduced LV contractility in patients with normal LV function, but had no effect in 
cardiomyopathy patients (Cotton et al., 2001). In animals post-infarction, heart nNOS 
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expression increases (Bendall et al., 2004; Damy et al., 2003), which was also found to 
be the case in patients with dilated cardiomyopathy, who furthermore displayed 
reduced eNOS expression (Damy et al., 2004). It may well be that increased nNOS 
activity counteracts a decrease in eNOS expression and activity. In this thesis we did 
not find that any change in the cardiac left ventricular EF or SW with systemic nNOS 
inhibition. However, future studies could involve more detailed assessment of cardiac 
function in a cardiac catheter laboratory model by means of pressure-volume analysis. 
This would investigate the effect that nNOS inhibition had on cardiac contractility, 
shedding further light on how much is attributable to a primary cardiac effect as 
opposed to a secondary effect due to the increase in peripheral vascular resistance. 
 
6.3 FUTURE WORK 
 
In this chapter so far, many ideas for future studies have been raised for the different 
vascular beds being investigated. In this thesis as a whole, forearm and systemic 
studies were undertaken in healthy men, and coronary studies in patients with 
angiographically normal coronary arteries (however, this was a combination of men 
and women, and those with cardiovascular risk factors). It would be interesting to see 
if there are gender differences in the effect of nNOS inhibition. Potential gender 
differences in vascular function may be related to the effects of female sex hormones 
on the vasculature (Orshal and Khalil, 2004), with evidence that sex hormones modify 
the bioavailability of NO, with total NO production greater in premenopausal women 
than men (Forte et al., 1998). Future studies could compare the effects of nNOS 




Carrying out studies in those with cardiovascular risk factors would also be exciting. 
As discussed, this would be particularly interesting in subjects with hypertension, in 
both local vasculature and in systemic nNOS inhibition. Another risk factor which 
would be fascinating to study be would be patients with diabetes mellitus. nNOS is 
abundant in the perivascular nerves, and diabetes mellitus is a disease which readily 
affects the peripheral nervous system. Future studies could investigate the effects of 
mental stress on vascular tone, an effect which is thought to involve the perivascular 
nerves, comparing healthy subjects to those with diabetes. 
 
6.4 STUDY LIMITATIONS 
 
Experiments investigating changes in forearm vasomotor tone and systemic 
haemodynamics were carried out on healthy men only. Further work is required to 
explore the effect of SMTC on women, and those with cardiovascular risk factors. In 
contrast, studies investigating coronary vasomotor tone were not performed in healthy 
volunteers, indeed most of the patients who took part in these studies had at least 1 
risk factor for coronary disease, and hence potentially had impaired vasomotor 
responses (Quyyumi et al., 1995b; Quyyumi et al., 1997; Vita et al., 1990). Further 
work is required to investigate the effects of nNOS inhibition in the context of these 
conditions, particularly in hypertension as described above. 
 
SMTC was used in all the studies in this thesis as a selective nNOS inhibitor. In the 
forearm and coronary studies I used a concentration that was previously shown to 
reduce basal flow to a similar degree as L-NMMA without inhibiting eNOS mediated 
responses (Seddon et al., 2009; Seddon et al., 2008). When giving SMTC systemically 
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I established a dose with similar effects on SVR as previous studies with L-NMMA at 
an approximate dose ratio which has shown to be nNOS-selective in forearm studies 
(Seddon et al., 2008), and in the current study did not inhibit FMD. Currently SMTC 
is the only available nNOS inhibitor available for intra-arterial or intravenous human 
use, however, others have been used intradermally (Kellogg et al., 2009). Should more 
specific inhibitors of nNOS become available it would be advisable to use these to 























In this thesis we have found that despite the considerable animal data, and some data 
in humans, neither NOS isoform plays an obligatory role in functional sympatholysis 
during exercise in the human forearm in vivo. We have also provided the first direct 
evidence that pacing-induced vasodilatation in the coronary arteries is mediated by 
eNOS rather than nNOS. And finally, we have carried out first-in-man studies of the 
effect of nNOS-selective inhibition on systemic haemodynamics. We found an 
increase in SVR and BP, suggesting a significant role for nNOS in the regulation of 
these. Furthermore we have established a dose of SMTC which can be given 
systemically to inhibit nNOS selectively and therefore be used for further studies of 

















1. British Heart Foundation Clinical Research Training Fellowship (no. 
FS/09/062/27958). 
 
2. King’s British Heart Foundation Centre of Research Excellence Clinical 
Research Fellowship (no. RE/08/003). 
 
Publications to date: 
 
1. Shabeeh H, Melikian N, Dworakowski R, Casadei B, Chowienczyk P, Shah 
AM. Differential role of endothelial vs neuronal nitric oxide synthase in the 
regulation of coronary blood flow during pacing-induced increases in cardiac 
workload. Am J Physiol Heart Circ Physiol. 2013 May; 304(9):H1277-82. 
 
2. Shabeeh H, Seddon M, Brett S, Melikian N, Casadei B, Shah AM, 
Chowienczyk P. Sympathetic activation increases NO release from eNOS but 
neither eNOS nor nNOS play an essential role in exercise hyperaemia in the 
human forearm. Am J Physiol Heart Circ Physiol. 2013 May; 304(9):H1225-
30. 
 
3. Seddon M, Melikian N, Dworakowski R, Shabeeh H, Jiang B, Byrne J, 
Casadei B, Chowienczyk P, Shah A. Effects of neuronal NOS (nNOS) on 
188 
 























Amrani, M., O'Shea, J., Allen, N.J., Harding, S.E., Jayakumar, J., Pepper, J.R., 
Moncada, S., and Yacoub, M.H. (1992). Role of basal release of nitric oxide on 
coronary flow and mechanical performance of the isolated rat heart. The Journal of 
physiology 456, 681-687. 
 
Anderson, T.J., Uehata, A., Gerhard, M.D., Meredith, I.T., Knab, S., Delagrange, D., 
Lieberman, E.H., Ganz, P., Creager, M.A., Yeung, A.C., et al. (1995). Close relation 
of endothelial function in the human coronary and peripheral circulations. Journal of 
the American College of Cardiology 26, 1235-1241. 
 
Ashley, E.A., Sears, C.E., Bryant, S.M., Watkins, H.C., and Casadei, B. (2002). 
Cardiac nitric oxide synthase 1 regulates basal and beta-adrenergic contractility in 
murine ventricular myocytes. Circulation 105, 3011-3016. 
 
Babu, B.R., and Griffith, O.W. (1998). N5-(1-Imino-3-butenyl)-L-ornithine. A 
neuronal isoform selective mechanism-based inactivator of nitric oxide synthase. The 
Journal of biological chemistry 273, 8882-8889. 
 
Bachetti, T., Comini, L., Curello, S., Bastianon, D., Palmieri, M., Bresciani, G., 
Callea, F., and Ferrari, R. (2004). Co-expression and modulation of neuronal and 
endothelial nitric oxide synthase in human endothelial cells. Journal of molecular and 




Bachmann, S., Bosse, H.M., and Mundel, P. (1995). Topography of nitric oxide 
synthesis by localizing constitutive NO synthases in mammalian kidney. The 
American journal of physiology 268, F885-898. 
 
Barouch, L.A., Harrison, R.W., Skaf, M.W., Rosas, G.O., Cappola, T.P., Kobeissi, 
Z.A., Hobai, I.A., Lemmon, C.A., Burnett, A.L., O'Rourke, B., et al. (2002). Nitric 
oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. 
Nature 416, 337-339. 
 
Bauser-Heaton, H.D., and Bohlen, H.G. (2007). Cerebral microvascular dilation 
during hypotension and decreased oxygen tension: a role for nNOS. American journal 
of physiology Heart and circulatory physiology 293, H2193-2201. 
 
Bech, J.N., Nielsen, C.B., and Pedersen, E.B. (1996). Effects of systemic NO synthesis 
inhibition on RPF, GFR, UNa, and vasoactive hormones in healthy humans. The 
American journal of physiology 270, F845-851. 
 
Behrendt, D., and Ganz, P. (2002). Endothelial function. From vascular biology to 
clinical applications. The American journal of cardiology 90, 40L-48L. 
 
Bendall, J.K., Damy, T., Ratajczak, P., Loyer, X., Monceau, V., Marty, I., Milliez, P., 
Robidel, E., Marotte, F., Samuel, J.L., et al. (2004). Role of myocardial neuronal nitric 
oxide synthase-derived nitric oxide in beta-adrenergic hyporesponsiveness after 




Bennett, T., and Gardiner, S. (1996). Nervous Control of Blood Vessels (The 
Autonomic Nervous System) (Mosby). 
 
Berdeaux, A., Ghaleh, B., Dubois-Rande, J.L., Vigue, B., Drieu La Rochelle, C., 
Hittinger, L., and Giudicelli, J.F. (1994). Role of vascular endothelium in exercise-
induced dilation of large epicardial coronary arteries in conscious dogs. Circulation 
89, 2799-2808. 
 
Bohme, G.A., Bon, C., Lemaire, M., Reibaud, M., Piot, O., Stutzmann, J.M., Doble, 
A., and Blanchard, J.C. (1993). Altered synaptic plasticity and memory formation in 
nitric oxide synthase inhibitor-treated rats. Proceedings of the National Academy of 
Sciences of the United States of America 90, 9191-9194. 
 
Boulanger, C.M., Heymes, C., Benessiano, J., Geske, R.S., Levy, B.I., and Vanhoutte, 
P.M. (1998). Neuronal nitric oxide synthase is expressed in rat vascular smooth 
muscle cells: activation by angiotensin II in hypertension. Circulation research 83, 
1271-1278. 
 
Bredt, D.S., Hwang, P.M., and Snyder, S.H. (1990). Localization of nitric oxide 
synthase indicating a neural role for nitric oxide. Nature 347, 768-770. 
 
Brett, S.E., Cockcroft, J.R., Mant, T.G., Ritter, J.M., and Chowienczyk, P.J. (1998). 
Haemodynamic effects of inhibition of nitric oxide synthase and of L-arginine at rest 




Brillante, D.G., O'Sullivan, A.J., Johnstone, M.T., and Howes, L.G. (2009). Predictors 
of inotropic and chronotropic effects of NG-monomethyl-L-arginine. European journal 
of clinical investigation 39, 273-279. 
 
Buckwalter, J.B., Taylor, J.C., Hamann, J.J., and Clifford, P.S. (2004). Role of nitric 
oxide in exercise sympatholysis. J Appl Physiol 97, 417-423; discussion 416. 
 
Burnett, A.L., Tillman, S.L., Chang, T.S., Epstein, J.I., Lowenstein, C.J., Bredt, D.S., 
Snyder, S.H., and Walsh, P.C. (1993). Immunohistochemical localization of nitric 
oxide synthase in the autonomic innervation of the human penis. The Journal of 
urology 150, 73-76. 
 
Cardillo, C., Kilcoyne, C.M., Quyyumi, A.A., Cannon, R.O., 3rd, and Panza, J.A. 
(1997). Role of nitric oxide in the vasodilator response to mental stress in normal 
subjects. The American journal of cardiology 80, 1070-1074. 
 
Carnicer, R., Crabtree, M.J., Sivakumaran, V., Casadei, B., and Kass, D.A. (2013). 
Nitric oxide synthases in heart failure. Antioxidants & redox signaling 18, 1078-1099. 
 
Casadei, B. (2006). The emerging role of neuronal nitric oxide synthase in the 
regulation of myocardial function. Experimental physiology 91, 943-955. 
 
Celermajer, D.S., Sorensen, K.E., Gooch, V.M., Spiegelhalter, D.J., Miller, O.I., 
Sullivan, I.D., Lloyd, J.K., and Deanfield, J.E. (1992). Non-invasive detection of 
193 
 
endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340, 
1111-1115. 
 
Cervenka, L., Kramer, H.J., Maly, J., and Heller, J. (2001). Role of nNOS in 
regulation of renal function in angiotensin II-induced hypertension. Hypertension 38, 
280-285. 
 
Chance, B., Eleff, S., Leigh, J.S., Jr., Sokolow, D., and Sapega, A. (1981). 
Mitochondrial regulation of phosphocreatine/inorganic phosphate ratios in exercising 
human muscle: a gated 31P NMR study. Proceedings of the National Academy of 
Sciences of the United States of America 78, 6714-6718. 
 
Charkoudian, N., Joyner, M.J., Barnes, S.A., Johnson, C.P., Eisenach, J.H., Dietz, 
N.M., and Wallin, B.G. (2006). Relationship between muscle sympathetic nerve 
activity and systemic hemodynamics during nitric oxide synthase inhibition in 
humans. American journal of physiology Heart and circulatory physiology 291, 
H1378-1383. 
 
Chavoshan, B., Sander, M., Sybert, T.E., Hansen, J., Victor, R.G., and Thomas, G.D. 
(2002). Nitric oxide-dependent modulation of sympathetic neural control of 
oxygenation in exercising human skeletal muscle. The Journal of physiology 540, 377-
386. 
 
Chi, O.Z., Liu, X., and Weiss, H.R. (2003). Effects of inhibition of neuronal nitric 
oxide synthase on NMDA-induced changes in cerebral blood flow and oxygen 
194 
 
consumption. Experimental brain research Experimentelle Hirnforschung 
Experimentation cerebrale 148, 256-260. 
 
Choate, J.K., Danson, E.J., Morris, J.F., and Paterson, D.J. (2001). Peripheral vagal 
control of heart rate is impaired in neuronal NOS knockout mice. American journal of 
physiology Heart and circulatory physiology 281, H2310-2317. 
 
Chowdhary, S., Vaile, J.C., Fletcher, J., Ross, H.F., Coote, J.H., and Townend, J.N. 
(2000). Nitric oxide and cardiac autonomic control in humans. Hypertension 36, 264-
269. 
 
Chowienczyk, P.J., Watts, G.F., Cockcroft, J.R., and Ritter, J.M. (1992). Impaired 
endothelium-dependent vasodilation of forearm resistance vessels in 
hypercholesterolaemia. Lancet 340, 1430-1432. 
 
Clifford, P.S., and Hellsten, Y. (2004). Vasodilatory mechanisms in contracting 
skeletal muscle. J Appl Physiol 97, 393-403. 
 
Collier, J.G., and Robinson, B.F. (1974). Comparison of effects of locally infused 
angiotensin I and II on hand veins and forearm arteries in man: evidence for 
converting enzyme activity in limb vessels. Clinical science and molecular medicine 
47, 189-192. 
 
Cooper, K.E., Edholm, O.G., and Mottram, R.F. (1955). The blood flow in skin and 




Copp, S.W., Hirai, D.M., Schwagerl, P.J., Musch, T.I., and Poole, D.C. (2010). Effects 
of neuronal nitric oxide synthase inhibition on resting and exercising hindlimb muscle 
blood flow in the rat. The Journal of physiology 588, 1321-1331. 
 
Corretti, M.C., Anderson, T.J., Benjamin, E.J., Celermajer, D., Charbonneau, F., 
Creager, M.A., Deanfield, J., Drexler, H., Gerhard-Herman, M., Herrington, D., et al. 
(2002). Guidelines for the ultrasound assessment of endothelial-dependent flow-
mediated vasodilation of the brachial artery: a report of the International Brachial 
Artery Reactivity Task Force. Journal of the American College of Cardiology 39, 257-
265. 
 
Cotton, J.M., Kearney, M.T., MacCarthy, P.A., Grocott-Mason, R.M., McClean, D.R., 
Heymes, C., Richardson, P.J., and Shah, A.M. (2001). Effects of nitric oxide synthase 
inhibition on Basal function and the force-frequency relationship in the normal and 
failing human heart in vivo. Circulation 104, 2318-2323. 
 
Cottyn, B., Acher, F., Ramassamy, B., Alvey, L., Lepoivre, M., Frapart, Y., Stuehr, 
D., Mansuy, D., Boucher, J.L., and Vichard, D. (2008). Inhibitory effects of a series of 
7-substituted-indazoles toward nitric oxide synthases: particular potency of 1H-
indazole-7-carbonitrile. Bioorganic & medicinal chemistry 16, 5962-5973. 
 
Cox, D.A., Vita, J.A., Treasure, C.B., Fish, R.D., Alexander, R.W., Ganz, P., and 
Selwyn, A.P. (1989). Atherosclerosis impairs flow-mediated dilation of coronary 




Cui, J., Zhang, R., Wilson, T.E., Witkowski, S., Crandall, C.G., and Levine, B.D. 
(2003). Nitric oxide synthase inhibition does not affect regulation of muscle 
sympathetic nerve activity during head-up tilt. American journal of physiology Heart 
and circulatory physiology 285, H2105-2110. 
 
Damkjaer, M., Vafaee, M., Moller, M.L., Braad, P.E., Petersen, H., Hoilund-Carlsen, 
P.F., and Bie, P. (2010). Renal cortical and medullary blood flow responses to altered 
NO availability in humans. American journal of physiology Regulatory, integrative 
and comparative physiology 299, R1449-1455. 
 
Damy, T., Ratajczak, P., Robidel, E., Bendall, J.K., Oliviero, P., Boczkowski, J., 
Ebrahimian, T., Marotte, F., Samuel, J.L., and Heymes, C. (2003). Up-regulation of 
cardiac nitric oxide synthase 1-derived nitric oxide after myocardial infarction in 
senescent rats. FASEB journal : official publication of the Federation of American 
Societies for Experimental Biology 17, 1934-1936. 
 
Danson, E.J., Choate, J.K., and Paterson, D.J. (2005). Cardiac nitric oxide: emerging 
role for nNOS in regulating physiological function. Pharmacology & therapeutics 106, 
57-74. 
 
Danson, E.J., and Paterson, D.J. (2003). Enhanced neuronal nitric oxide synthase 
expression is central to cardiac vagal phenotype in exercise-trained mice. The Journal 




Davignon, J., and Ganz, P. (2004). Role of endothelial dysfunction in atherosclerosis. 
Circulation 109, III27-32. 
 
Dawson, D., Lygate, C.A., Zhang, M.H., Hulbert, K., Neubauer, S., and Casadei, B. 
(2005). nNOS gene deletion exacerbates pathological left ventricular remodeling and 
functional deterioration after myocardial infarction. Circulation 112, 3729-3737. 
 
Deussen, A., Ohanyan, V., Jannasch, A., Yin, L., and Chilian, W. (2012). Mechanisms 
of metabolic coronary flow regulation. Journal of molecular and cellular cardiology 
52, 794-801. 
 
Dietz, N.M., Rivera, J.M., Eggener, S.E., Fix, R.T., Warner, D.O., and Joyner, M.J. 
(1994). Nitric oxide contributes to the rise in forearm blood flow during mental stress 
in humans. The Journal of physiology 480 ( Pt 2), 361-368. 
 
Dinenno, F.A., and Joyner, M.J. (2003). Blunted sympathetic vasoconstriction in 
contracting skeletal muscle of healthy humans: is nitric oxide obligatory? The Journal 
of physiology 553, 281-292. 
 
Donald, A.E., Halcox, J.P., Charakida, M., Storry, C., Wallace, S.M., Cole, T.J., 
Friberg, P., and Deanfield, J.E. (2008). Methodological approaches to optimize 
reproducibility and power in clinical studies of flow-mediated dilation. Journal of the 




Dorosz, J.L., Lezotte, D.C., Weitzenkamp, D.A., Allen, L.A., and Salcedo, E.E. 
(2012). Performance of 3-dimensional echocardiography in measuring left ventricular 
volumes and ejection fraction: a systematic review and meta-analysis. Journal of the 
American College of Cardiology 59, 1799-1808. 
 
Doucette, J.W., Corl, P.D., Payne, H.M., Flynn, A.E., Goto, M., Nassi, M., and Segal, 
J. (1992). Validation of a Doppler guide wire for intravascular measurement of 
coronary artery flow velocity. Circulation 85, 1899-1911. 
 
Duffy, S.J., Castle, S.F., Harper, R.W., and Meredith, I.T. (1999). Contribution of 
vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilation, and 
flow-mediated dilation in human coronary circulation. Circulation 100, 1951-1957. 
 
Duncker, D.J., and Bache, R.J. (2008). Regulation of coronary blood flow during 
exercise. Physiological reviews 88, 1009-1086. 
 
Duncker, D.J., Bache, R.J., and Merkus, D. (2012). Regulation of coronary resistance 
vessel tone in response to exercise. Journal of molecular and cellular cardiology 52, 
802-813. 
 
Egashira, K., Inou, T., Hirooka, Y., Yamada, A., Maruoka, Y., Kai, H., Sugimachi, 
M., Suzuki, S., and Takeshita, A. (1993). Impaired coronary blood flow response to 
acetylcholine in patients with coronary risk factors and proximal atherosclerotic 




Egashira, K., Katsuda, Y., Mohri, M., Kuga, T., Tagawa, T., Kubota, T., Hirakawa, Y., 
and Takeshita, A. (1996). Role of endothelium-derived nitric oxide in coronary 
vasodilatation induced by pacing tachycardia in humans. Circulation research 79, 331-
335. 
 
Endo, T., Imaizumi, T., Tagawa, T., Shiramoto, M., Ando, S., and Takeshita, A. 
(1994). Role of nitric oxide in exercise-induced vasodilation of the forearm. 
Circulation 90, 2886-2890. 
 
Eppel, G.A., Denton, K.M., Malpas, S.C., and Evans, R.G. (2003). Nitric oxide in 
responses of regional kidney perfusion to renal nerve stimulation and renal ischaemia. 
Pflugers Archiv : European journal of physiology 447, 205-213. 
 
Fadel, P.J., Zhao, W., and Thomas, G.D. (2003). Impaired vasomodulation is 
associated with reduced neuronal nitric oxide synthase in skeletal muscle of 
ovariectomized rats. The Journal of physiology 549, 243-253. 
 
Feletou, M., and Vanhoutte, P.M. (1999). The alternative: EDHF. Journal of molecular 
and cellular cardiology 31, 15-22. 
 
Feron, O., Belhassen, L., Kobzik, L., Smith, T.W., Kelly, R.A., and Michel, T. (1996). 
Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with 
caveolin isoforms in cardiac myocytes and endothelial cells. The Journal of biological 




Ferrer, M., Alonso, M.J., Salaices, M., Marin, J., and Balfagon, G. (2000). Increase in 
neurogenic nitric oxide metabolism by endothelin-1 in mesenteric arteries from 
hypertensive rats. Journal of cardiovascular pharmacology 36, 541-547. 
 
Fleming, I., and Busse, R. (1999). Signal transduction of eNOS activation. 
Cardiovascular research 43, 532-541. 
 
Forstermann, U., Closs, E.I., Pollock, J.S., Nakane, M., Schwarz, P., Gath, I., and 
Kleinert, H. (1994). Nitric oxide synthase isozymes. Characterization, purification, 
molecular cloning, and functions. Hypertension 23, 1121-1131. 
 
Forte, P., Kneale, B.J., Milne, E., Chowienczyk, P.J., Johnston, A., Benjamin, N., and 
Ritter, J.M. (1998). Evidence for a difference in nitric oxide biosynthesis between 
healthy women and men. Hypertension 32, 730-734. 
 
Furchgott, R.F., and Zawadzki, J.V. (1980). The obligatory role of endothelial cells in 
the relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373-376. 
 
Furfine, E.S., Harmon, M.F., Paith, J.E., Knowles, R.G., Salter, M., Kiff, R.J., Duffy, 
C., Hazelwood, R., Oplinger, J.A., and Garvey, E.P. (1994). Potent and selective 
inhibition of human nitric oxide synthases. Selective inhibition of neuronal nitric oxide 
synthase by S-methyl-L-thiocitrulline and S-ethyl-L-thiocitrulline. The Journal of 




Gabbai, F.B. (2001). Effects of nitric oxide synthase blockers on renal function. 
Nephrology, dialysis, transplantation : official publication of the European Dialysis 
and Transplant Association - European Renal Association 16 Suppl 1, 10-13. 
 
Gaglione, A., Hess, O.M., Corin, W.J., Ritter, M., Grimm, J., and Krayenbuehl, H.P. 
(1987). Is there coronary vasoconstriction after intracoronary beta-adrenergic blockade 
in patients with coronary artery disease. Journal of the American College of 
Cardiology 10, 299-310. 
 
Gamboa, A., Shibao, C., Diedrich, A., Choi, L., Pohar, B., Jordan, J., Paranjape, S., 
Farley, G., and Biaggioni, I. (2007). Contribution of endothelial nitric oxide to blood 
pressure in humans. Hypertension 49, 170-177. 
 
Garland, C.J., Hiley, C.R., and Dora, K.A. (2011). EDHF: spreading the influence of 
the endothelium. British journal of pharmacology 164, 839-852. 
 
Ghofrani, H.A., Osterloh, I.H., and Grimminger, F. (2006). Sildenafil: from angina to 
erectile dysfunction to pulmonary hypertension and beyond. Nature reviews Drug 
discovery 5, 689-702. 
 
Gilligan, D.M., Panza, J.A., Kilcoyne, C.M., Waclawiw, M.A., Casino, P.R., and 
Quyyumi, A.A. (1994). Contribution of endothelium-derived nitric oxide to exercise-




Gonzalez, M.A., and Selwyn, A.P. (2003). Endothelial function, inflammation, and 
prognosis in cardiovascular disease. The American journal of medicine 115 Suppl 8A, 
99S-106S. 
 
Gordon, J.B., Ganz, P., Nabel, E.G., Fish, R.D., Zebede, J., Mudge, G.H., Alexander, 
R.W., and Selwyn, A.P. (1989). Atherosclerosis influences the vasomotor response of 
epicardial coronary arteries to exercise. The Journal of clinical investigation 83, 1946-
1952. 
 
Gordon, M.B., Jain, R., Beckman, J.A., and Creager, M.A. (2002). The contribution of 
nitric oxide to exercise hyperemia in the human forearm. Vasc Med 7, 163-168. 
 
Gorman, M.W., Tune, J.D., Richmond, K.N., and Feigl, E.O. (2000). Feedforward 
sympathetic coronary vasodilation in exercising dogs. J Appl Physiol 89, 1892-1902. 
 
Gozal, D., Torres, J.E., Gozal, Y.M., and Littwin, S.M. (1996a). Effect of nitric oxide 
synthase inhibition on cardiorespiratory responses in the conscious rat. J Appl Physiol 
(1985) 81, 2068-2077. 
 
Gozal, D., Torres, J.E., Gozal, Y.M., and Littwin, S.M. (1996b). Effect of nitric oxide 
synthase inhibition on cardiorespiratory responses in the conscious rat. Journal of 




Grange, R.W., Isotani, E., Lau, K.S., Kamm, K.E., Huang, P.L., and Stull, J.T. (2001). 
Nitric oxide contributes to vascular smooth muscle relaxation in contracting fast-
twitch muscles. Physiol Genomics 5, 35-44. 
 
Green, D.J., Bilsborough, W., Naylor, L.H., Reed, C., Wright, J., O'Driscoll, G., and 
Walsh, J.H. (2005). Comparison of forearm blood flow responses to incremental 
handgrip and cycle ergometer exercise: relative contribution of nitric oxide. The 
Journal of physiology 562, 617-628. 
 
Gyurko, R., Kuhlencordt, P., Fishman, M.C., and Huang, P.L. (2000). Modulation of 
mouse cardiac function in vivo by eNOS and ANP. American journal of physiology 
Heart and circulatory physiology 278, H971-981. 
 
Handy, R.L., Harb, H.L., Wallace, P., Gaffen, Z., Whitehead, K.J., and Moore, P.K. 
(1996). Inhibition of nitric oxide synthase by 1-(2-trifluoromethylphenyl) imidazole 
(TRIM) in vitro: antinociceptive and cardiovascular effects. British journal of 
pharmacology 119, 423-431. 
 
Hansen, J., Jacobsen, T.N., and Victor, R.G. (1994a). Is nitric oxide involved in the 
tonic inhibition of central sympathetic outflow in humans? Hypertension 24, 439-444. 
 
Hansen, J., Jacobsen, T.N., and Victor, R.G. (1994b). Is nitric oxide involved in the 




Harris, K.F., and Matthews, K.A. (2004). Interactions between autonomic nervous 
system activity and endothelial function: a model for the development of 
cardiovascular disease. Psychosomatic medicine 66, 153-164. 
 
Harrison, R.W., Thakkar, R.N., Senzaki, H., Ekelund, U.E., Cho, E., Kass, D.A., and 
Hare, J.M. (2000). Relative contribution of preload and afterload to the reduction in 
cardiac output caused by nitric oxide synthase inhibition with L-N(G)-methylarginine 
hydrochloride 546C88. Critical care medicine 28, 1263-1268. 
 
Hasbak, P., Lundby, C., Olsen, N.V., Schifter, S., and Kanstrup, I.L. (2002). 
Calcitonin gene-related peptide and adrenomedullin release in humans: effects of 
exercise and hypoxia. Regulatory peptides 108, 89-95. 
 
Hatanaka, Y., Hobara, N., Honghua, J., Akiyama, S., Nawa, H., Kobayashi, Y., 
Takayama, F., Gomita, Y., and Kawasaki, H. (2006). Neuronal nitric-oxide synthase 
inhibition facilitates adrenergic neurotransmission in rat mesenteric resistance arteries. 
The Journal of pharmacology and experimental therapeutics 316, 490-497. 
 
Haynes, W.G., Noon, J.P., Walker, B.R., and Webb, D.J. (1993). Inhibition of nitric 
oxide synthesis increases blood pressure in healthy humans. Journal of hypertension 
11, 1375-1380. 
 
Heiss, H.W., Barmeyer, J., Wink, K., Hell, G., Cerny, F.J., Keul, J., and Reindell, H. 
(1976). Studies on the regulation of myocardial blood flow in man. I.: Training effects 
205 
 
on blood flow and metabolism of the healthy heart at rest and during standardized 
heavy exercise. Basic research in cardiology 71, 658-675. 
 
Herring, N., Danson, E.J., and Paterson, D.J. (2002). Cholinergic control of heart rate 
by nitric oxide is site specific. News in physiological sciences : an international 
journal of physiology produced jointly by the International Union of Physiological 
Sciences and the American Physiological Society 17, 202-206. 
 
Herring, N., and Paterson, D.J. (2009). Neuromodulators of peripheral cardiac 
sympatho-vagal balance. Experimental physiology 94, 46-53. 
 
Hirooka, Y., Shigematsu, H., Kishi, T., Kimura, Y., Ueta, Y., and Takeshita, A. 
(2003). Reduced nitric oxide synthase in the brainstem contributes to enhanced 
sympathetic drive in rats with heart failure. Journal of cardiovascular pharmacology 42 
Suppl 1, S111-115. 
 
Hogan, N., Casadei, B., and Paterson, D.J. (1999a). Nitric oxide donors can increase 
heart rate independent of autonomic activation. J Appl Physiol 87, 97-103. 
 
Hogan, N., Kardos, A., Paterson, D.J., and Casadei, B. (1999b). Effect of exogenous 





Hokanson, D.E., Sumner, D.S., and Strandness, D.E., Jr. (1975). An electrically 
calibrated plethysmograph for direct measurement of limb blood flow. IEEE Trans 
Biomed Eng 22, 25-29. 
 
Holscher, C., and Rose, S.P. (1992). An inhibitor of nitric oxide synthesis prevents 
memory formation in the chick. Neuroscience letters 145, 165-167. 
 
Huang, A., Sun, D., Shesely, E.G., Levee, E.M., Koller, A., and Kaley, G. (2002). 
Neuronal NOS-dependent dilation to flow in coronary arteries of male eNOS-KO 
mice. American journal of physiology Heart and circulatory physiology 282, H429-
436. 
 
Huang, Z., Huang, P.L., Panahian, N., Dalkara, T., Fishman, M.C., and Moskowitz, 
M.A. (1994). Effects of cerebral ischemia in mice deficient in neuronal nitric oxide 
synthase. Science 265, 1883-1885. 
 
Ichihara, A., Inscho, E.W., Imig, J.D., and Navar, L.G. (1998). Neuronal nitric oxide 
synthase modulates rat renal microvascular function. The American journal of 
physiology 274, F516-524. 
 
Ignarro, L.J., Buga, G.M., Wood, K.S., Byrns, R.E., and Chaudhuri, G. (1987). 
Endothelium-derived relaxing factor produced and released from artery and vein is 




Jacobs, L.D., Salgo, I.S., Goonewardena, S., Weinert, L., Coon, P., Bardo, D., Gerard, 
O., Allain, P., Zamorano, J.L., de Isla, L.P., et al. (2006). Rapid online quantification 
of left ventricular volume from real-time three-dimensional echocardiographic data. 
European heart journal 27, 460-468. 
 
Jenkins, C., Bricknell, K., Hanekom, L., and Marwick, T.H. (2004). Reproducibility 
and accuracy of echocardiographic measurements of left ventricular parameters using 
real-time three-dimensional echocardiography. Journal of the American College of 
Cardiology 44, 878-886. 
 
Jeremy, J.Y., Rowe, D., Emsley, A.M., and Newby, A.C. (1999). Nitric oxide and the 
proliferation of vascular smooth muscle cells. Cardiovascular research 43, 580-594. 
 
Jiang, W., Babyak, M., Krantz, D.S., Waugh, R.A., Coleman, R.E., Hanson, M.M., 
Frid, D.J., McNulty, S., Morris, J.J., O'Connor, C.M., et al. (1996). Mental stress--
induced myocardial ischemia and cardiac events. JAMA : the journal of the American 
Medical Association 275, 1651-1656. 
 
Joannides, R., Haefeli, W.E., Linder, L., Richard, V., Bakkali, E.H., Thuillez, C., and 
Luscher, T.F. (1995). Nitric oxide is responsible for flow-dependent dilatation of 
human peripheral conduit arteries in vivo. Circulation 91, 1314-1319. 
 
Johnson, J.M., Rowell, L.B., Niederberger, M., and Eisman, M.M. (1974). Human 
splanchnic and forearm vasoconstrictor responses to reductions of right atrial and 




Joyner, M.J., and Dietz, N.M. (2003). Sympathetic vasodilation in human muscle. 
Acta physiologica Scandinavica 177, 329-336. 
 
Jumrussirikul, P., Dinerman, J., Dawson, T.M., Dawson, V.L., Ekelund, U., 
Georgakopoulos, D., Schramm, L.P., Calkins, H., Snyder, S.H., Hare, J.M., et al. 
(1998). Interaction between neuronal nitric oxide synthase and inhibitory G protein 
activity in heart rate regulation in conscious mice. The Journal of clinical investigation 
102, 1279-1285. 
 
Kardos, A., Taylor, D.J., Thompson, C., Styles, P., Hands, L., Collin, J., and Casadei, 
B. (2000). Sympathetic denervation of the upper limb improves forearm exercise 
performance and skeletal muscle bioenergetics. Circulation 101, 2716-2720. 
 
Kavdia, M., and Popel, A.S. (2004). Contribution of nNOS- and eNOS-derived NO to 
microvascular smooth muscle NO exposure. J Appl Physiol 97, 293-301. 
 
Kellogg, D.L., Jr., Liu, Y., Kosiba, I.F., and O'Donnell, D. (1999). Role of nitric oxide 
in the vascular effects of local warming of the skin in humans. J Appl Physiol 86, 
1185-1190. 
 
Kellogg, D.L., Jr., Zhao, J.L., and Wu, Y. (2008a). Endothelial nitric oxide synthase 
control mechanisms in the cutaneous vasculature of humans in vivo. American journal 




Kellogg, D.L., Jr., Zhao, J.L., and Wu, Y. (2008b). Neuronal nitric oxide synthase 
control mechanisms in the cutaneous vasculature of humans in vivo. The Journal of 
physiology 586, 847-857. 
 
Kellogg, D.L., Jr., Zhao, J.L., and Wu, Y. (2009). Roles of nitric oxide synthase 
isoforms in cutaneous vasodilation induced by local warming of the skin and whole 
body heat stress in humans. J Appl Physiol 107, 1438-1444. 
 
Kharbanda, R.K., and Deanfield, J.E. (2001). Functions of the healthy endothelium. 
Coronary artery disease 12, 485-491. 
 
Kiely, D.G., Lee, A.F., Struthers, A.D., and Lipworth, B.J. (1998). Nitric oxide: an 
important role in the maintenance of systemic and pulmonary vascular tone in man. 
British journal of clinical pharmacology 46, 263-266. 
 
Kiss, J.P., and Vizi, E.S. (2001). Nitric oxide: a novel link between synaptic and 
nonsynaptic transmission. Trends in neurosciences 24, 211-215. 
 
Kneale, B.J., Chowienczyk, P.J., Brett, S.E., Coltart, D.J., and Ritter, J.M. (2000). 
Gender differences in sensitivity to adrenergic agonists of forearm resistance 
vasculature. Journal of the American College of Cardiology 36, 1233-1238. 
 
Kobayashi, Y.M., Rader, E.P., Crawford, R.W., Iyengar, N.K., Thedens, D.R., 
Faulkner, J.A., Parikh, S.V., Weiss, R.M., Chamberlain, J.S., Moore, S.A., et al. 
210 
 
(2008). Sarcolemma-localized nNOS is required to maintain activity after mild 
exercise. Nature 456, 511-515. 
 
Kobzik, L., Reid, M.B., Bredt, D.S., and Stamler, J.S. (1994). Nitric oxide in skeletal 
muscle. Nature 372, 546-548. 
 
Komaru, T., Kanatsuka, H., and Shirato, K. (2000). Coronary microcirculation: 
physiology and pharmacology. Pharmacology & therapeutics 86, 217-261. 
 
Komers, R., Lindsley, J.N., Oyama, T.T., Allison, K.M., and Anderson, S. (2000). 
Role of neuronal nitric oxide synthase (NOS1) in the pathogenesis of renal 
hemodynamic changes in diabetes. American journal of physiology Renal physiology 
279, F573-583. 
 
Krantz, D.S., Kop, W.J., Santiago, H.T., and Gottdiener, J.S. (1996). Mental stress as a 
trigger of myocardial ischemia and infarction. Cardiology clinics 14, 271-287. 
 
Krantz, D.S., Santiago, H.T., Kop, W.J., Bairey Merz, C.N., Rozanski, A., and 
Gottdiener, J.S. (1999). Prognostic value of mental stress testing in coronary artery 
disease. The American journal of cardiology 84, 1292-1297. 
 
Kuo, L., Chilian, W.M., and Davis, M.J. (1991). Interaction of pressure- and flow-
induced responses in porcine coronary resistance vessels. The American journal of 




Lahera, V., Salom, M.G., Miranda-Guardiola, F., Moncada, S., and Romero, J.C. 
(1991). Effects of NG-nitro-L-arginine methyl ester on renal function and blood 
pressure. The American journal of physiology 261, F1033-1037. 
 
Lai, Y., Thomas, G.D., Yue, Y., Yang, H.T., Li, D., Long, C., Judge, L., Bostick, B., 
Chamberlain, J.S., Terjung, R.L., et al. (2009). Dystrophins carrying spectrin-like 
repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance 
in a mouse model of muscular dystrophy. The Journal of clinical investigation 119, 
624-635. 
 
Landmesser, U., Hornig, B., and Drexler, H. (2004). Endothelial function: a critical 
determinant in atherosclerosis? Circulation 109, II27-33. 
 
Lefroy, D.C., Crake, T., Uren, N.G., Davies, G.J., and Maseri, A. (1993). Effect of 
inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary 
blood flow in humans. Circulation 88, 43-54. 
 
Lepori, M., Sartori, C., Duplain, H., Nicod, P., and Scherrer, U. (2001). Interaction 
between cholinergic and nitrergic vasodilation: a novel mechanism of blood pressure 
control. Cardiovascular research 51, 767-772. 
 
Li, H., and Forstermann, U. (2000). Nitric oxide in the pathogenesis of vascular 




Liu, Y., Bubolz, A.H., Mendoza, S., Zhang, D.X., and Gutterman, D.D. (2011). H2O2 
is the transferrable factor mediating flow-induced dilation in human coronary 
arterioles. Circulation research 108, 566-573. 
 
Longhurst, J., Capone, R.J., Mason, D.T., and Zelis, R. (1974). Comparison of blood 
flow measured by plethysmograph and flowmeter during steady state forearm 
exercise. Circulation 49, 535-540. 
 
Ludmer, P.L., Selwyn, A.P., Shook, T.L., Wayne, R.R., Mudge, G.H., Alexander, 
R.W., and Ganz, P. (1986). Paradoxical vasoconstriction induced by acetylcholine in 
atherosclerotic coronary arteries. The New England journal of medicine 315, 1046-
1051. 
 
Lundberg, J.M. (1996). Pharmacology of cotransmission in the autonomic nervous 
system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino 
acids and nitric oxide. Pharmacological reviews 48, 113-178. 
 
Macho, P., Hintze, T.H., and Vatner, S.F. (1981). Regulation of large coronary arteries 
by increases in myocardial metabolic demands in conscious dogs. Circulation research 
49, 594-599. 
 
Majid, D.S., and Navar, L.G. (2001). Nitric oxide in the control of renal 




Majid, D.S., Williams, A., and Navar, L.G. (1993). Inhibition of nitric oxide synthesis 
attenuates pressure-induced natriuretic responses in anesthetized dogs. The American 
journal of physiology 264, F79-87. 
 
Mattei, J.P., Bendahan, D., and Cozzone, P. (2004). P-31 magnetic resonance 
spectroscopy. A tool for diagnostic purposes and pathophysiological insights in 
muscle diseases. Reumatismo 56, 9-14. 
 
Mattson, D.L., Roman, R.J., and Cowley, A.W., Jr. (1992). Role of nitric oxide in 
renal papillary blood flow and sodium excretion. Hypertension 19, 766-769. 
 
Meng, W., Ayata, C., Waeber, C., Huang, P.L., and Moskowitz, M.A. (1998). 
Neuronal NOS-cGMP-dependent ACh-induced relaxation in pial arterioles of 
endothelial NOS knockout mice. The American journal of physiology 274, H411-415. 
 
Merkus, D., Houweling, B., Zarbanoui, A., and Duncker, D.J. (2004). Interaction 
between prostanoids and nitric oxide in regulation of systemic, pulmonary, and 
coronary vascular tone in exercising swine. American journal of physiology Heart and 
circulatory physiology 286, H1114-1123. 
 
Michel, T., and Feron, O. (1997). Nitric oxide synthases: which, where, how, and 
why? The Journal of clinical investigation 100, 2146-2152. 
 
Miyauchi, T., and Masaki, T. (1999). Pathophysiology of endothelin in the 




Mohri, M., Egashira, K., Tagawa, T., Kuga, T., Tagawa, H., Harasawa, Y., 
Shimokawa, H., and Takeshita, A. (1997). Basal release of nitric oxide is decreased in 
the coronary circulation in patients with heart failure. Hypertension 30, 50-56. 
 
Mombouli, J.V., and Vanhoutte, P.M. (1999). Endothelial dysfunction: from 
physiology to therapy. Journal of molecular and cellular cardiology 31, 61-74. 
 
Moncada, S., and Higgs, A. (1993). The L-arginine-nitric oxide pathway. The New 
England journal of medicine 329, 2002-2012. 
 
Moncada, S., and Higgs, E.A. (2006). Nitric oxide and the vascular endothelium. 
Handbook of experimental pharmacology, 213-254. 
 
Mount, P.F., and Power, D.A. (2006). Nitric oxide in the kidney: functions and 
regulation of synthesis. Acta Physiol (Oxf) 187, 433-446. 
 
Musialek, P., Lei, M., Brown, H.F., Paterson, D.J., and Casadei, B. (1997). Nitric 
oxide can increase heart rate by stimulating the hyperpolarization-activated inward 
current, I(f). Circulation research 81, 60-68. 
 
Nabel, E.G., Selwyn, A.P., and Ganz, P. (1990a). Large coronary arteries in humans 
are responsive to changing blood flow: an endothelium-dependent mechanism that 





Nabel, E.G., Selwyn, A.P., and Ganz, P. (1990b). Paradoxical narrowing of 
atherosclerotic coronary arteries induced by increases in heart rate. Circulation 81, 
850-859. 
 
Nakane, M., Schmidt, H.H., Pollock, J.S., Forstermann, U., and Murad, F. (1993). 
Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. 
FEBS letters 316, 175-180. 
 
Narayanan, K., Spack, L., McMillan, K., Kilbourn, R.G., Hayward, M.A., Masters, 
B.S., and Griffith, O.W. (1995). S-alkyl-L-thiocitrullines. Potent stereoselective 
inhibitors of nitric oxide synthase with strong pressor activity in vivo. The Journal of 
biological chemistry 270, 11103-11110. 
 
Nelson, R.J., Demas, G.E., Huang, P.L., Fishman, M.C., Dawson, V.L., Dawson, 
T.M., and Snyder, S.H. (1995). Behavioural abnormalities in male mice lacking 
neuronal nitric oxide synthase. Nature 378, 383-386. 
 
O'Brien, E., Asmar, R., Beilin, L., Imai, Y., Mallion, J.M., Mancia, G., Mengden, T., 
Myers, M., Padfield, P., Palatini, P., et al. (2003). European Society of Hypertension 
recommendations for conventional, ambulatory and home blood pressure 
measurement. Journal of hypertension 21, 821-848. 
 
O'Dell, T.J., Hawkins, R.D., Kandel, E.R., and Arancio, O. (1991). Tests of the roles 
of two diffusible substances in long-term potentiation: evidence for nitric oxide as a 
216 
 
possible early retrograde messenger. Proceedings of the National Academy of 
Sciences of the United States of America 88, 11285-11289. 
 
Okamura, T., Yoshida, K., and Toda, N. (1995). Nitroxidergic innervation in dog and 
monkey renal arteries. Hypertension 25, 1090-1095. 
 
Oliver, J.J., Melville, V.P., and Webb, D.J. (2006). Effect of regular phosphodiesterase 
type 5 inhibition in hypertension. Hypertension 48, 622-627. 
 
Ollerstam, A., Pittner, J., Persson, A.E., and Thorup, C. (1997). Increased blood 
pressure in rats after long-term inhibition of the neuronal isoform of nitric oxide 
synthase. The Journal of clinical investigation 99, 2212-2218. 
 
Orshal, J.M., and Khalil, R.A. (2004). Gender, sex hormones, and vascular tone. 
American journal of physiology Regulatory, integrative and comparative physiology 
286, R233-249. 
 
Ortiz, P.A., and Garvin, J.L. (2002). Role of nitric oxide in the regulation of nephron 
transport. American journal of physiology Renal physiology 282, F777-784. 
 
Owlya, R., Vollenweider, L., Trueb, L., Sartori, C., Lepori, M., Nicod, P., and 
Scherrer, U. (1997). Cardiovascular and sympathetic effects of nitric oxide inhibition 




Pabla, R., and Curtis, M.J. (1995). Effects of NO modulation on cardiac arrhythmias in 
the rat isolated heart. Circulation research 77, 984-992. 
 
Pallone, T.L., and Mattson, D.L. (2002). Role of nitric oxide in regulation of the renal 
medulla in normal and hypertensive kidneys. Current opinion in nephrology and 
hypertension 11, 93-98. 
 
Palmer, R.M., Ferrige, A.G., and Moncada, S. (1987). Nitric oxide release accounts 
for the biological activity of endothelium-derived relaxing factor. Nature 327, 524-
526. 
 
Paulus, W.J., and Shah, A.M. (1999). NO and cardiac diastolic function. 
Cardiovascular research 43, 595-606. 
 
Percival, J.M., Anderson, K.N., Gregorevic, P., Chamberlain, J.S., and Froehner, S.C. 
(2008). Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS 
knockout mice. PloS one 3, e3387. 
 
Percival, J.M., Anderson, K.N., Huang, P., Adams, M.E., and Froehner, S.C. (2010). 
Golgi and sarcolemmal neuronal NOS differentially regulate contraction-induced 
fatigue and vasoconstriction in exercising mouse skeletal muscle. The Journal of 




Plochocka-Zulinska, D., and Krukoff, T.L. (1997). Increased gene expression of 
neuronal nitric oxide synthase in brain of adult spontaneously hypertensive rats. Brain 
research Molecular brain research 48, 291-297. 
 
Prendergast, B.D., Sagach, V.F., and Shah, A.M. (1997). Basal release of nitric oxide 
augments the Frank-Starling response in the isolated heart. Circulation 96, 1320-1329. 
 
Qadri, F., Arens, T., Schwarz, E.C., Hauser, W., Dendorfer, A., and Dominiak, P. 
(2003). Brain nitric oxide synthase activity in spontaneously hypertensive rats during 
the development of hypertension. Journal of hypertension 21, 1687-1694. 
 
Quyyumi, A.A., Dakak, N., Andrews, N.P., Gilligan, D.M., Panza, J.A., and Cannon, 
R.O., 3rd (1995a). Contribution of nitric oxide to metabolic coronary vasodilation in 
the human heart. Circulation 92, 320-326. 
 
Quyyumi, A.A., Dakak, N., Andrews, N.P., Husain, S., Arora, S., Gilligan, D.M., 
Panza, J.A., and Cannon, R.O., 3rd (1995b). Nitric oxide activity in the human 
coronary circulation. Impact of risk factors for coronary atherosclerosis. The Journal 
of clinical investigation 95, 1747-1755. 
 
Quyyumi, A.A., Mulcahy, D., Andrews, N.P., Husain, S., Panza, J.A., and Cannon, 
R.O., 3rd (1997). Coronary vascular nitric oxide activity in hypertension and 





Rand, M.J. (1992). Nitrergic transmission: nitric oxide as a mediator of non-
adrenergic, non-cholinergic neuro-effector transmission. Clinical and experimental 
pharmacology & physiology 19, 147-169. 
 
Rassaf, T., Poll, L.W., Brouzos, P., Lauer, T., Totzeck, M., Kleinbongard, P., Gharini, 
P., Andersen, K., Schulz, R., Heusch, G., et al. (2006). Positive effects of nitric oxide 
on left ventricular function in humans. European heart journal 27, 1699-1705. 
 
Rees, D.D., Palmer, R.M., and Moncada, S. (1989). Role of endothelium-derived nitric 
oxide in the regulation of blood pressure. Proceedings of the National Academy of 
Sciences of the United States of America 86, 3375-3378. 
 
Remensnyder, J.P., Mitchell, J.H., and Sarnoff, S.J. (1962). Functional sympatholysis 
during muscular activity. Observations on influence of carotid sinus on oxygen uptake. 
Circulation research 11, 370-380. 
 
Richter, E.A., Ruderman, N.B., and Galbo, H. (1982). Alpha and beta adrenergic 
effects on metabolism in contracting, perfused muscle. Acta physiologica 
Scandinavica 116, 215-222. 
 
Sander, M., Chavoshan, B., Harris, S.A., Iannaccone, S.T., Stull, J.T., Thomas, G.D., 
and Victor, R.G. (2000). Functional muscle ischemia in neuronal nitric oxide 
synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. 





Sartori, C., Lepori, M., and Scherrer, U. (2005). Interaction between nitric oxide and 
the cholinergic and sympathetic nervous system in cardiovascular control in humans. 
Pharmacology & therapeutics 106, 209-220. 
 
Schindler, C., Dobrev, D., Grossmann, M., Francke, K., Pittrow, D., and Kirch, W. 
(2004). Mechanisms of beta-adrenergic receptor-mediated venodilation in humans. 
Clinical pharmacology and therapeutics 75, 49-59. 
 
Schoder, H., Silverman, D.H., Campisi, R., Karpman, H., Phelps, M.E., Schelbert, 
H.R., and Czernin, J. (2000a). Effect of mental stress on myocardial blood flow and 
vasomotion in patients with coronary artery disease. Journal of nuclear medicine : 
official publication, Society of Nuclear Medicine 41, 11-16. 
 
Schoder, H., Silverman, D.H., Campisi, R., Sayre, J.W., Phelps, M.E., Schelbert, H.R., 
and Czernin, J. (2000b). Regulation of myocardial blood flow response to mental 
stress in healthy individuals. American journal of physiology Heart and circulatory 
physiology 278, H360-366. 
 
Schuman, E.M., and Madison, D.V. (1994). Nitric oxide and synaptic function. 
Annual review of neuroscience 17, 153-183. 
 
Sears, C.E., Bryant, S.M., Ashley, E.A., Lygate, C.A., Rakovic, S., Wallis, H.L., 
Neubauer, S., Terrar, D.A., and Casadei, B. (2003). Cardiac neuronal nitric oxide 
221 
 
synthase isoform regulates myocardial contraction and calcium handling. Circulation 
research 92, e52-59. 
 
Sears, C.E., Choate, J.K., and Paterson, D.J. (1998). Effect of nitric oxide synthase 
inhibition on the sympatho-vagal contol of heart rate. Journal of the autonomic 
nervous system 73, 63-73. 
 
Seddon, M., Melikian, N., Dworakowski, R., Shabeeh, H., Jiang, B., Byrne, J., 
Casadei, B., Chowienczyk, P., and Shah, A.M. (2009). Effects of neuronal nitric oxide 
synthase on human coronary artery diameter and blood flow in vivo. Circulation 119, 
2656-2662. 
 
Seddon, M., Shah, A.M., and Casadei, B. (2007). Cardiomyocytes as effectors of nitric 
oxide signalling. Cardiovascular research 75, 315-326. 
 
Seddon, M.D., Chowienczyk, P.J., Brett, S.E., Casadei, B., and Shah, A.M. (2008). 
Neuronal nitric oxide synthase regulates basal microvascular tone in humans in vivo. 
Circulation 117, 1991-1996. 
 
Shah, A.M., and MacCarthy, P.A. (2000). Paracrine and autocrine effects of nitric 
oxide on myocardial function. Pharmacology & therapeutics 86, 49-86. 
Shah, A.M., Vallance, P., and Harrison, D. (1999). NO in the cardiovascular system. 




Solomon, H., Man, J.W., and Jackson, G. (2003). Erectile dysfunction and the 
cardiovascular patient: endothelial dysfunction is the common denominator. Heart 89, 
251-253. 
 
Sorensen, K.E., Celermajer, D.S., Spiegelhalter, D.J., Georgakopoulos, D., Robinson, 
J., Thomas, O., and Deanfield, J.E. (1995). Non-invasive measurement of human 
endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 74, 
247-253. 
 
Stamler, J.S., Loh, E., Roddy, M.A., Currie, K.E., and Creager, M.A. (1994). Nitric 
oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. 
Circulation 89, 2035-2040. 
 
Straub, V., and Campbell, K.P. (1997). Muscular dystrophies and the dystrophin-
glycoprotein complex. Current opinion in neurology 10, 168-175. 
 
Sugeng, L., Mor-Avi, V., Weinert, L., Niel, J., Ebner, C., Steringer-Mascherbauer, R., 
Schmidt, F., Galuschky, C., Schummers, G., Lang, R.M., et al. (2006). Quantitative 
assessment of left ventricular size and function: side-by-side comparison of real-time 
three-dimensional echocardiography and computed tomography with magnetic 
resonance reference. Circulation 114, 654-661. 
 
Sundlof, G., and Wallin, B.G. (1978). Effect of lower body negative pressure on 




Taddei, S., Virdis, A., Ghiadoni, L., Sudano, I., Notari, M., and Salvetti, A. (1999). 
Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation 
of patients with essential hypertension. Circulation 100, 1680-1683. 
 
Thomas, G.D., Sander, M., Lau, K.S., Huang, P.L., Stull, J.T., and Victor, R.G. 
(1998). Impaired metabolic modulation of alpha-adrenergic vasoconstriction in 
dystrophin-deficient skeletal muscle. Proceedings of the National Academy of 
Sciences of the United States of America 95, 15090-15095. 
 
Thomas, G.D., and Victor, R.G. (1998). Nitric oxide mediates contraction-induced 
attenuation of sympathetic vasoconstriction in rat skeletal muscle. The Journal of 
physiology 506 ( Pt 3), 817-826. 
 
Toda, N., Ayajiki, K., and Okamura, T. (2009). Control of systemic and pulmonary 
blood pressure by nitric oxide formed through neuronal nitric oxide synthase. Journal 
of hypertension 27, 1929-1940. 
 
Toda, N., and Okamura, T. (1989). Endothelium-dependent and -independent 
responses to vasoactive substances of isolated human coronary arteries. The American 
journal of physiology 257, H988-995. 
 
Toda, N., and Okamura, T. (1990). Modification by L-NG-monomethyl arginine (L-
NMMA) of the response to nerve stimulation in isolated dog mesenteric and cerebral 




Toda, N., and Okamura, T. (1996). Nitroxidergic nerve: regulation of vascular tone 
and blood flow in the brain. Journal of hypertension 14, 423-434. 
 
Toda, N., and Okamura, T. (2003). The pharmacology of nitric oxide in the peripheral 
nervous system of blood vessels. Pharmacological reviews 55, 271-324. 
 
Toda, N., and Okamura, T. (2011). Modulation of renal blood flow and vascular tone 
by neuronal nitric oxide synthase-derived nitric oxide. Journal of vascular research 48, 
1-10. 
 
Tost, H., Hably, C., Lengyel, M., Gogl, A., Lendvai, A., and Bartha, J. (2000). Effect 
of nitric oxide synthase inhibition on renal circulation and excretory function in 
anaesthetized rats. Experimental physiology 85, 791-800. 
 
Tousoulis, D., Tentolouris, C., Crake, T., Toutouzas, P., and Davies, G. (1997). Basal 
and flow-mediated nitric oxide production by atheromatous coronary arteries. Journal 
of the American College of Cardiology 29, 1256-1262. 
 
Tschakovsky, M.E., Sujirattanawimol, K., Ruble, S.B., Valic, Z., and Joyner, M.J. 
(2002). Is sympathetic neural vasoconstriction blunted in the vascular bed of 
exercising human muscle? The Journal of physiology 541, 623-635. 
 
Tsui, J.C., Souza, D.S., Filbey, D., Karlsson, M.G., and Dashwood, M.R. (2002). 
Localization of nitric oxide synthase in saphenous vein grafts harvested with a novel 
225 
 
"no-touch" technique: potential role of nitric oxide contribution to improved early 
graft patency rates. J Vasc Surg 35, 356-362. 
 
Vallance, P., and Chan, N. (2001). Endothelial function and nitric oxide: clinical 
relevance. Heart 85, 342-350. 
 
Vallance, P., Collier, J., and Moncada, S. (1989). Effects of endothelium-derived nitric 
oxide on peripheral arteriolar tone in man. Lancet 2, 997-1000. 
 
Vallon, V., Traynor, T., Barajas, L., Huang, Y.G., Briggs, J.P., and Schnermann, J. 
(2001). Feedback control of glomerular vascular tone in neuronal nitric oxide synthase 
knockout mice. Journal of the American Society of Nephrology : JASN 12, 1599-
1606. 
 
Verma, S., and Anderson, T.J. (2002). Fundamentals of endothelial function for the 
clinical cardiologist. Circulation 105, 546-549. 
 
Vita, J.A., Treasure, C.B., Nabel, E.G., McLenachan, J.M., Fish, R.D., Yeung, A.C., 
Vekshtein, V.I., Selwyn, A.P., and Ganz, P. (1990). Coronary vasomotor response to 
acetylcholine relates to risk factors for coronary artery disease. Circulation 81, 491-
497. 
 
Wakefield, I.D., March, J.E., Kemp, P.A., Valentin, J.P., Bennett, T., and Gardiner, 
S.M. (2003). Comparative regional haemodynamic effects of the nitric oxide synthase 
226 
 
inhibitors, S-methyl-L-thiocitrulline and L-NAME, in conscious rats. British journal of 
pharmacology 139, 1235-1243. 
 
Walker, H.A., Jackson, G., Ritter, J.M., and Chowienczyk, P.J. (2001). Assessment of 
forearm vasodilator responses to acetylcholine and albuterol by strain gauge 
plethysmography: reproducibility and influence of strain gauge placement. British 
journal of clinical pharmacology 51, 225-229. 
 
Wang, Y., Liu, X.F., Cornish, K.G., Zucker, I.H., and Patel, K.P. (2005). Effects of 
nNOS antisense in the paraventricular nucleus on blood pressure and heart rate in rats 
with heart failure. American journal of physiology Heart and circulatory physiology 
288, H205-213. 
 
Webb, G.D., Lim, L.H., Oh, V.M., El Oakley, R., Lee, C.N., Wong, P.S., Aye, W.M., 
Chan, E.S., and Moore, P.K. (2006). Expression of neuronal nitric oxide synthase in 
the internal thoracic artery and saphenous vein. The Journal of thoracic and 
cardiovascular surgery 132, 1131-1136. 
 
Whitney, R.J. (1953). The measurement of volume changes in human limbs. The 
Journal of physiology 121, 1-27. 
 
Wilcox, C.S., and Welch, W.J. (1998). Macula densa nitric oxide synthase: expression, 




Wilkins, R., and Bradley, S. (1946). Changes in arterial and venous blood pressure and 
flow distal to a cuff inflated on the human arm. The American journal of physiology 
147, 260-269. 
 
Wilson, J.R., and Kapoor, S. (1993). Contribution of endothelium-derived relaxing 
factor to exercise-induced vasodilation in humans. J Appl Physiol 75, 2740-2744. 
 
Wray, D.W., Witman, M.A., Ives, S.J., McDaniel, J., Fjeldstad, A.S., Trinity, J.D., 
Conklin, J.D., Supiano, M.A., and Richardson, R.S. (2011). Progressive handgrip 
exercise: evidence of nitric oxide-dependent vasodilation and blood flow regulation in 
humans. American journal of physiology Heart and circulatory physiology 300, 
H1101-1107. 
 
Xu, K.Y., Huso, D.L., Dawson, T.M., Bredt, D.S., and Becker, L.C. (1999). Nitric 
oxide synthase in cardiac sarcoplasmic reticulum. Proceedings of the National 
Academy of Sciences of the United States of America 96, 657-662. 
 
Xu, L., Carter, E.P., Ohara, M., Martin, P.Y., Rogachev, B., Morris, K., 
Cadnapaphornchai, M., Knotek, M., and Schrier, R.W. (2000). Neuronal nitric oxide 
synthase and systemic vasodilation in rats with cirrhosis. American journal of 
physiology Renal physiology 279, F1110-1115. 
 
Yeung, A.C., Vekshtein, V.I., Krantz, D.S., Vita, J.A., Ryan, T.J., Jr., Ganz, P., and 
Selwyn, A.P. (1991). The effect of atherosclerosis on the vasomotor response of 
228 
 
coronary arteries to mental stress. The New England journal of medicine 325, 1551-
1556. 
 
Zanzinger, J. (1999). Role of nitric oxide in the neural control of cardiovascular 
function. Cardiovascular research 43, 639-649. 
 
Zeiher, A.M., Drexler, H., Wollschlager, H., and Just, H. (1991). Modulation of 
coronary vasomotor tone in humans. Progressive endothelial dysfunction with 
different early stages of coronary atherosclerosis. Circulation 83, 391-401. 
 
Zhou, L., and Zhu, D.Y. (2009). Neuronal nitric oxide synthase: structure, subcellular 
localization, regulation, and clinical implications. Nitric oxide : biology and chemistry 
/ official journal of the Nitric Oxide Society 20, 223-230. 
 
Zoccali, C. (2007). The endothelium as a target in renal diseases. Journal of 
nephrology 20 Suppl 12, S39-44. 
 
Zoller, R.P., Mark, A.L., Abboud, F.M., Schmid, P.G., and Heistad, D.D. (1972). The 
role of low pressure baroreceptors in reflex vasoconstrictor responses in man. The 
Journal of clinical investigation 51, 2967-2972. 
	  
 
